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CHAPTER 1 
INTRODUCTION 
1.1 Hypothalamus-pituitary-adrenal axis 
The hypothalamus-pituitary-adrenal (ΗΡΑ) axis is one of the major endocrine 
systems in mammals. It shares a similar structure with the hypothalamus-
pituitary-thyroid and the hypothalamus-pituitary-gonadal axis: hypothalamic 
releasing hormones stimulate the pituitary gland, which in turn releases 
hormones that influence the various target organs. 
1.1.1 Organization 
The ΗΡΑ axis consists of three components: hypothalamus, pituitary gland and 
adrenal glands. Activation of this system results in a cascade of subsequent 
events which are initiated by stimulation of the parvocellular neurons of the 
paraventricular nucleus of the hypothalamus (PVH). These neurosecretory cells 
project to the median eminence, which is located at the base of the third 
cerebroventricle. At this particular place nerve terminals originating from 
neurosecretory cells in the PVH make contact with blood vessels of the pituitary 
portal system. The nerve endings of these cells contain the releasing hormones 
corticotropin-releasing hormone (CRH) and arginine vasopressin (AVP), which 
are transported to the anterior lobe of the pituitary gland upon release into the 
portal blood. CRH and AVP stimulate the corticotropic cells of the anterior 
pituitary gland to produce and release adrenocorticotropic hormone (ACTH). 
ACTH is the intermediate hormone between the hypothalamus and the adrenal 
glands and stimulates the adrenal cortex to release glucocorticoids. In rodents 
the main glucocorticoid is corticosterone and in man Cortisol. Thus, increased 
plasma levels of ACTH and corticosterone are characteristics of the activated 
ΗΡΑ axis in rodents. Besides CRH, which is the most potent inducer of ACTH 
release by the pituitary gland, AVP and neurotransmitters as oxytocin, (norepi­
nephrine, angiotensin II, and cholecystokinin are also capable of inducing the 
release of ACTH [see for review 1]. The production of glucocorticoids is regulated 
in a negative feedback system: glucocorticoids inhibit their own production by 
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inhibiting the synthesis and release of ACTH at the level of the anterior pituitary 
and of CRH at the hypothalamic level [2,3]. One of the functions of glucocorti­
coids is to inhibit inflammatory processes [4]. 
1.1.2 Activation of the ΗΡΑ axis by stimulation of the immune system: 
immuno-neuroendocrinology 
A number of different stimuli, such as hemorrhage, hypoglycemia, and other 
physical and psychological stressors can activate the ΗΡΑ axis [see for reviews 
1,3]. In recent years, however, evidence has accumulated that the ΗΡΑ axis can 
also be activated by stimulation of the immune system. In 1975 Besedovsky and 
co-workers [5] were the first to show that serum corticosterone (В) levels were 
increased 2-3 fold in rats and mice at the time of the peak of the immune 
response to sheep or horse red blood cells. A decade later these researchers 
demonstrated a remarkable increase in blood levels of ACTH and В in mice 
inoculated with the Newcastle disease virus. Injection of the animals with 
supernatants derived from cocultures of Newcastle disease virus preparations 
and either human peripheral blood leukocytes or mouse spleen cells induced a 
similar response, indicating that these immune cells might be stimulated by the 
virus to produce one or more factors capable of influencing the ΗΡΑ axis [6]. 
There is now a considerable body of evidence that these factors belong to the 
cytokine family [see for review 7]. It has been proposed that interleukin-1 (IL-1) is 
an important trigger for the activation of the ΗΡΑ axis during stimulation of the 
immune system [8,9]. In recent years the concept has emerged that cytokines 
(particularly IL-1) and glucocorticoid hormones integrate an immuno-regulatory 
feedback circuit: during stimulation of the immune system, e.g. during infectious 
diseases, cytokines are released into the peripheral circulation, mediating an 
increase in plasma glucocorticoid levels. As a consequence immune cell 
functions and production of IL-1 and other cytokines will be suppressed, thereby 
protecting the organism against a harmful overshoot of immune reactions 
[4,8,10]. 
1.2 Cytokines 
Originally these polypeptides were named after the producing cells: monokines 
and lymphokines. Later on it appeared that not only monocytes and lymphocytes 
but also many other cells were capable of producing these peptides. Therefore 
these peptides are now referred to as cytokines. Many cytokines have been 
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characterized until now and this group of polypeptides is still increasing. The 
main groups of molecules classified as cytokines include interleukins (ILs; IL-1 to 
IL-15), interferons (cr, β and y), colony stimulating factors (CSFs; granulocyte 
[G]-, macrophage [M]- and granulocyte-macrophage [GM]-CSF), tumor necrosis 
factor (TNF), the transforming growth factor (TGF) family, erythropoietin, nerve 
growth factor (NGF), epidermal growth factor (EGF), fibroblast growth factors 
(FGFs), platelet-derived growth factor (PDGF), and insulin-like growth factors 
(IGFs) [see for reviews 11-13]. 
1.2.1. lnterleukin-1 
Historical perspectives 
In the early 1940s it was evidenced from the work of Menkin [14] that activated 
peritoneal exudate cells produce and release a soluble factor that caused acute 
inflammation after administration to rabbits. Several years later Beeson reported 
the isolation of a factor from polymorphonuclear leucocytes of rabbits which 
caused an increase of body temperature upon administration to rabbits [15]. This 
circulating factor was called endogenous pyrogen (EP) [see for review 16]. By 
1960 it became clear that EP accounted for the fever associated with most of the 
pyrogenic materials [see for reviews 17,18]. In the late 1960s, it was suggested 
that a host phagocyte product also mediated a number of components of the 
acute-phase response different from fever. This substance was called leucocytic 
endogenous mediator (LEM) and caused beside fever hypoferremia, hypo-
zincemia, hypercupremia, and granulocytosis. Furthermore, LEM induced the 
synthesis of acute phase proteins such as fibrinogen, haptoglobin, C-reactive 
protein and macroglobulins [19]. LEM was indistinguishable from EP. Experi­
mental work on the pathogenesis of immunologically mediated fever initiated the 
discovery of a soluble product which was produced by mononuclear phagocytes: 
lymphocyte-activating factor (LAF) [20,21]. Later on the importance of several 
other soluble products of mononuclear phagocytic cells in a number of in vitro 
models of immunoregulation has been described, e.g., В cell-activating factor 
(BAF) [22,23], thymocyte proliferation/differentiation factor (TPFHOF) [24,25] and 
helper-peak-1 (HP-1) [24]. Wood [26,27] demonstrated that BAF behaves iden­
tical to LAF. At the International Lymphokine Workshop held in Switzerland in 
1979 discussion was focused on the physical and physiological similarities 
between these factors. It was proposed that the term interleukin-1 (IL-1) be 
accepted to refer to the monokine previously described as LAF and also to 
include LEM, BAF and HP-1 [28]. 
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Characteristics 
In 1984 two forms of IL-1 have been cloned: one was cloned from the mouse 
macrophage cell line P388D, [29] and the other from human mononuclear cells 
[30]. Later on the murine-derived IL-1 was called IL-1 σ and the human-derived IL-
1 was called IL-1U. In addition to the description of the cDNA of the mouse IL-1a, 
the cDNA of human, rat and rabbit IL-Ισ has been isolated. IL-1 ß cDNA has also 
been isolated from the cow, rat, rabbit and mouse [see for review 31]. In spite of 
the fact that human IL-1 α and IL-1ß are not homologous proteins (they share 
only 26% homology at the amino acid level), they do share many of their 
biological activities [see for review 32]. In man IL-Ισ and IL-1ß are coded by two 
separate genes, both located on chromosome 2 [33]. Both subtypes of human IL-
1 are initially produced as 31 kDa precursor molecules (pro-IL-1) [34,35]. Pro-IL-1 
is subsequently cleaved, generating the mature IL-1. Mature human IL-Ισ 
consists of 159 amino acids (17.5 kDa, pi 5.3) and mature human IL-1ß of 153 
amino acids (17.3 kDa, pi 7.2) [see for reviews 36,37]. After production IL-Ισ 
remains mostly cell associated, whereas IL-1B is mainly released into the 
circulation [38]. The homology at the amino acid level between human and rat IL-
1σ is 58%, whereas the homology for IL-1 ß is 78% [39]. Many cell types, 
including lymphocytes, vascular cells, brain cells and skin cells have been 
reported to produce IL-1 [see for reviews 36,37]. However, cells of the monocyte-
macrophage lineage are the most important source of IL-1, because of their 
strategic location, their ability to synthesize large amounts of IL-1 and to process 
the IL-1 precursor more effectively than other cells [40]. 
Two different human IL-1 receptors (type I and II) have been identified [41] and 
cloned. Both receptors are transmembrane glycoproteins of the immunoglobulin 
superfamily [42-44] and are coded by separate genes located on chromosome 2. 
Type I IL-1 receptor, first cloned from Τ lymphocytes, has a molecular weight of 
about 80 kDa [42] and is primarily found on Τ cells, endothelial cells, keratino-
cytes, hepatocytes and on fibroblasts [45]. Type II IL-1 receptors, cloned from В 
lymphocytes, have a molecular weight of about 68 kDa [46] and are found on 
neutrophils, В cells and bone marrow cells [45]. It has been established that 
nearly all of the biological effects of IL-1 are mediated via the type I IL-1 receptor 
[47]. The function of the type II IL-1 receptor is unknown. Slack et al. [48] have 
clearly shown that type I and type II receptors are not two subunits of a multi­
mene IL-1 receptor complex but that they are capable of binding IL-1 indepen­
dently from each other. IL-1ß has been shown to have a greater affinity for the 
type II receptors, whereas IL-1o has a higher affinity for the type I receptors [49]. 
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It has recently been suggested, however, that the type II IL-1 receptor acts as a 
decoy target for IL-1. It can do so either as a membrane bound receptor or as a 
so-called "soluble" receptor which is generated after cleaving the extracellular 
part of the receptor from the cell surface [50,51]. In both cases the type II IL-1 
receptor would inhibit IL-1 action. 
IL-1 has multiple biological effects. In vitro IL-1 induces the proliferation and 
differentiation of cultured immune cells and in vivo it induces hematological, 
metabolic and immunological changes, fever and activation of the ΗΡΑ axis. For 
further details of the biology and characteristics of IL-1 and its receptors we refer 
to a number of review articles [16,31,32,36,37,40,43,52,53]. 
lnterleukin-1 receptor antagonist 
A third member of the IL-1 family was first reported in 1985 as IL-1 inhibitory 
bioactivity found in supernatants of human monocytes cultured on adherent 
immune complexes [54]. The cDNA encoding this IL-1 inhibitory protein was 
cloned by Eisenberg et al. [55], who also demonstrated that this protein was able 
to bind to the IL-1 receptors but had no agonistic activity. The generic term "IL-1 
inhibitor" was therefore replaced by the more specific term "IL-1 receptor 
antagonist" (IL-1ra) [56]. Human IL-1 га is a protein which consists of 152 amino 
acids. It has a molecular weight of about 17 kDa and a low structural homology 
with human IL-Ισ (18%) and human IL-1ß (26%) [39]. The IL-1ra gene has also 
been cloned from other species, such as the mouse [57], rat [39] and rabbit [58]. 
The homology at the amino acid level between murine, rat and human IL-1 га is 
between 75 and 90% [39]. IL-1ra blocks the activity of IL-1 both in vivo and in 
vitro by competitive inhibition of the binding of IL-1a and IL-1ß to their receptors. 
There are no in vitro data in which IL-1 га has failed to block the anticipated 
biological response to IL-1 [see for review 45]. Although IL-Ισ, IL-1ß and IL-1ra 
can be produced by the same cells, the production of IL-1 га and IL-1 β is 
differentially regulated. Serum, immunoglobulin G and GM-CSF are potent stimuli 
for the production of IL-1 га but not of IL-1 ß, moreover prevention of cell-cell 
contact of peripheral blood mononuclear cells in vitro reduced IL-1 ra but not IL-
1ß production [59]. 
1.2.2 Tumor necrosis factor-α 
Historical perspectives 
Already at the end of the 18th century physicians noted that, occasionally, 
cancer patients who went through a severe infection experienced shrinkage and 
13 
Introduction 
even elimination of their tumor. Around the turn of the century W.B. Coley even 
used bacteria-derived preparations for the treatment of cancer patients [60]. In 
1975, Carswell et al. [61] reported the presence of a protein in the serum of mice 
infected with Bacillus Calmette-Gué rin and subsequently injected with lipopoly-
saccharide, which caused a rapid necrosis and regression of an experimentally 
induced sarcoma in mice. They called that protein tumor necrosis factor or TNF. 
Subsequent reports linked a similar molecular weight protein, termed cachectin, 
to the development of tissue wasting in cachectic states. Beutler and co-workers 
demonstrated that tumor necrosis factor and cachectin were, in fact, the same 
protein [62-64]. 
Characteristics 
Two subtypes of tumor necrosis factor have been described: tumor necrosis 
factor-σ (TNFo) also known as cachectin and tumor necrosis factor-ß (TNFß) 
which is also known as lymphotoxin. The gene for human TNFo is found on the 
short arm of chromosome 6, in close proximity to the gene coding for TNFß [65]. 
The term TNF is now often used as synonym for TNFo. The human TNF cDNA 
gene has been cloned by Pennica and co-workers [66]. Subsequently, cloning of 
the TNF cDNA genes for pig, cow, cat, rabbit, rat, and mouse have been re-
ported [67-69]. Human TNF is produced as part of a 233 amino acid propeptide 
which undergoes proteolytic cleavage resulting in a circulating cytokine of 157 
amino acids with a molecular weight of about 17 kDa [70]. TNF is a well con-
served protein. The homology at the amino acid level between human, mouse 
and rabbit TNF is between 79 and 90% [70-72]. TNF is produced by monocytes 
and macrophages [73,74] as well as by polymorphonuclear neutrophils [75] and a 
number of other cell types [see for review 76]. 
TNF receptors are transmembrane proteins which are present on nearly all cell 
types, except for cells such as erythrocytes and resting Τ lymphocytes [77]. Two 
types of TNF receptors have been cloned: type I and type II receptors [78,79]. 
The type I receptor has a molecular weight of about 55 kDa and is referred to as 
TNF-R55 or TNF-RI; the type II receptor has a molecular weight of about 75 kDa 
and is referred to as TNF-R75 or TNF-RII. The gene for the human type I 
receptor is found on chromosome 12 and that for the human type II receptor on 
chromosome 1 [80,81]. 
The biological effects of TNF largely overlap those of IL-1 including Τ cell 
activation, induction of fever and of acute phase proteins [82]. For further details 
of the biology and characteristics of TNF and its receptors we refer to a number 
of review articles [76,82-84]. 
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1.2.3 lnterleukin-6 
Historical perspectives 
lnterleukin-б (IL-6) was already cloned before its major biological activities 
were discovered. The protein that we now call IL-6 was originally referred to by 
several different names, each reflecting a different activity of the protein. The 
original terms for IL-6 were interferon-ß2 (INFß-2) [85], 26K factor (26K) [86], 
hepatocyte stimulating factor (HSF) [87], B-cell stimulatory factor 2 (BSF-2) [88, 
89], interleukin-hybridoma/plasmacytoma growth factor (IL-HP1) [90,91], plasma-
cytoma growth factor (PCT-GF) [92], hybridoma growth factor (HGF) [93], and 
cytotoxic T-cell differentiation factor (CDF) [94]. In 1987 it turned out that all 
research groups that investigated the abovementioned factors had cloned or 
purified the same protein [see for review 95]. 
Characteristics 
The gene for human IL-6 has been located on chromosome 7 [96], cloned and 
sequenced [97,98]. IL-6 is initially produced as part of a propeptide of 212 amino 
acids including a signal sequence of 28 residues [89,97]. The gene for IL-6, has 
also been cloned from the rat and the mouse. At the amino acid level the 
homology between human and rat IL-6 is 58%, whereas the protein sequences 
between rat and murine IL-6 are 93% identical [99]. Like IL-1 and TNF, IL-6 is 
also produced by many different cell types, including fibroblasts [85], endothelial 
cells [100], T-cells [88,90], monocytes/macrophages [101] and mast cells [102, 
103]. 
The human IL-6 receptor has been cloned [104] and demonstrated to code for 
an 80 kDa protein. Binding studies revealed that this protein is a high affinity 
receptor which, however, has no signal transducing activity. Signal transduction 
is only accomplished after association of the 80 kDa IL-6 receptor with a 130 kDa 
signal transducing subunit, gp130 [105]. The gene for the human IL-6 receptor is 
found on chromosome 1 [106], whereas the gene for the gp130 subunit has two 
distinct chromosomal loci, one on chromosome 5 and one on chromosome 17 
[107]. Low affinity IL-6 receptors have also been described [104]. 
Like IL-1 and TNF, IL-6 is a pleiotropic cytokine exerting many different 
biological effects, such as activation of Τ and В cells, induction of acute-phase 
proteins and activation of the ΗΡΑ axis. For further details of the biology and 
characteristics of IL-6 and its receptors we refer to review papers [95,108-111]. 
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1.3 Outline of this thesis 
Bacterial infections are accompanied by activation of the immune system and 
an increased activity of the ΗΡΑ axis. There is compelling evidence that bacterial 
endotoxin is responsible for the stimulation of the immune system during such 
conditions. Activation of the immune system by endotoxin results in an increased 
production of the cytokines IL-1, TNF and IL-6 by cells of the immune system. It 
is also known that administration of endotoxin to rodents induces an increase in 
plasma levels of ACTH and B, which is characteristic for an activated ΗΡΑ axis, 
and it has been postulated that the cytokines IL-1, TNF and IL-6 are responsible 
for the stimulation of the ΗΡΑ axis commonly seen during infectious diseases. 
So, activation of the ΗΡΑ axis during infectious diseases might be mediated by 
the cytokines IL-1, TNF and IL-6, which are also thought to be important me­
diators of other biological effects of endotoxin including the induction of the acute 
phase response with fever and anorexia. This thesis deals with the question 
whether these cytokines, in particular IL-1, can indeed activate the ΗΡΑ axis in 
rats and, if so, by which mechanism. As it is unknown whether during (bacterial) 
infections plasma levels of these cytokines are only transiently increased or 
elevated for a prolonged period, we decided to study the effects of cytokines on 
the ΗΡΑ axis both during short-term and long-term cytokine administration. 
Chapters 2, 3 and 4 deal with short-term effects of IL-1, TNF and IL-6 on the 
activity of the ΗΡΑ axis in rats. In order to study the underlying mechanism of the 
stimulation of the ΗΡΑ axis by these cytokines both in vivo and in vitro studies 
were performed. Chapters 5, 6 and 7 focus on the effects of chronic infusion of 
IL-1 for 3 or 7 days on the activity of the ΗΡΑ axis in rats and on the mecha­
nisms by which chronically infused IL-1 activates the ΗΡΑ axis. Furthermore, the 
effects of continuously infused IL-1 on body weight, rectal temperature, and on 
food and fluid intake were studied. 
Although a number of studies have been published concerning the effect of 
acute administration of IL-1 on the activity of the ΗΡΑ axis only a few studies 
have been reported dealing with the stimulation of the ΗΡΑ axis by acute ad­
ministration of TNF and IL-6. Moreover, a study systematically comparing the 
effects of a single peripheral or central bolus injection of each of the three 
cytokines on the activity of the ΗΡΑ axis is lacking. Therefore the experiments 
described in chapter 2 were designed to systematically compare the effects of a 
single intravenous or intracerebroventricular bolus injection of IL-1, TNF or IL-6 
on the activity of the ΗΡΑ axis in rats (dose-response and time-course study). 
Furthermore, the role of endogenous CRH in the activation of the ΗΡΑ axis by 
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intravenous administration of these cytokines was investigated using a neutra­
lizing monoclonal antibody directed against CRH of the rat. Finally, it was studied 
whether stimulation of the ΗΡΑ axis by intravenous administration of TNF and IL-
6 is mediated by endogenous IL-1 release, using an IL-1 receptor antagonist. 
It is not fully understood at which level (hypothalamus, pituitary gland or 
adrenal gland) IL-1 activates the ΗΡΑ axis. In chapter 3 the question is ad­
dressed whether acute administration of IL-1 can induce activation of the ΗΡΑ 
axis at the level of the hypothalamus. The effects of a single intravenous bolus 
injection of IL-1 on the ΗΡΑ axis were evaluated by immunocytochemical double-
staining of the PVH for Fos-like immunoreactivity, a marker for activated neurons, 
and for CRH-like immunoreactivity. In addition to the experiments described in 
chapter 3, in chapter 4 a possible peripheral site of action (pituitary gland and/or 
adrenal gland) of cytokines in activating the ΗΡΑ axis is investigated. The in vitro 
release of pro-opiomelanocortin-derived ß-endorphin by the rat pituitary gland 
and of corticosterone by the rat adrenal gland in response to short-term exposure 
to IL-1o, IL-1ß, IL-2, IL-6 and TNF were studied using two supplementary in vitro 
systems: freshly isolated cell preparations and superfusion of tissue fragments. 
To mimic the setting of chronically elevated IL-1 production rats were 
continuously intraperitoneally infused with IL-1 for 7 days (chapter 5). In vivo as 
well as in vitro experiments were performed to investigate whether chronic 
infusion of IL-1 is capable of inducing long-term activation of the ΗΡΑ axis. 
Furthermore, the effects of continuous IL-1 infusion on body weight, rectal 
temperature, and on food and fluid intake were studied. 
Mechanisms by which chronically infused IL-1 activates the ΗΡΑ axis are 
investigated in the study described in chapter 6. First, it was investigated whether 
chronic central (intracerebroventricular) infusion of IL-1, like continuous intra­
peritoneal infusion of IL-1, is capable of inducing a sustained activation of the 
ΗΡΑ axis. Secondly, the involvement of the CRH system in the activation of the 
ΗΡΑ axis during continuous intraperitoneal infusion of IL-1 was examined by 
pretreatment of the rats with the same monoclonal anti-CRH antibody as used in 
chapter 2. Thirdly, it was investigated whether peripheral mechanisms, such as 
involvement of mediators released from IL-1-activated macrophages or a direct 
effect of IL-1 on В production by the adrenal glands, were involved in the 
activation of the ΗΡΑ axis during continuous intraperitoneal infusion of IL-1. 
Finally, it was studied whether high or low concentrations of circulating 
glucocorticoids were capable of modulating the effect of chronically infused IL-1 
on the activity of the ΗΡΑ axis. In addition, in all experiments described in this 
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chapter the effects of the different (pre)treatments of rats on body weight, rectal 
temperature, and on food and fluid intake were monitored. 
IL-1 and TNF share many of their biological activities. Additive or synergistic 
and, remarkably, also antagonistic effects of simultaneous administration of these 
cytokines have been described. In the light of these controversial data the ex­
periments described in chapter 7 focussed on the effects of continuous intra­
peritoneal infusion of rats with IL-1 and TNF for 3 days, separately or in combi­
nation, on the activity of the ΗΡΑ axis, body weight, rectal temperature, and on 
food and fluid intake. 
In the summary and conclusions section, the results presented in this thesis 
are discussed. 
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ABSTRACT 
We investigated the effects of intravenous (i.V.) and intracerebroventricular 
(i.c.v.) administration of increasing doses of recombinant human IL-1ß, TNFo and 
IL-6 on plasma corticosterone (В) levels in rats. Rats were equipped with a 
jugular cannula for repeated blood sampling and a subgroup of rats also received 
an i.c.v. implanted cannula. I.v. administration of IL-1Ü, TNFo or IL-6 and i.c.v. 
administration of IL-1ß and IL-6 induced a significant dose-dependent increase in 
plasma В levels, whereas i.c.v. injection of TNFo in doses up till 1000 ng/rat was 
not effective. Intravenous pretreatment of rats with anti-CRH antiserum had no 
significant overall effect on the plasma В response to i.v. administered IL-1 ß (500 
and 3000 ng/rat), whereas the plasma В responses to i.v. TNFa or IL-6 
administration (3000 ng/rat) were significantly reduced. Intravenous pretreatment 
of the animals with recombinant human IL-1 receptor antagonist (IL-1ra) 
significantly blocked the plasma В response to i.v. treatment with IL-1 ß, whereas 
the TNFa- and IL-6-induced increases in plasma В levels were not affected. Our 
data show that: 1] i.v. administration of IL-1 ß, TN Fa or IL-6 and i.c.v. 
administration of IL-1Ü or IL-6 dose-dependently stimulate the ΗΡΑ axis; 2] when 
given i.v. or i.c.v., IL-1U is more powerful than TNFo and IL-6 in activating the 
ΗΡΑ axis; 3] endogenous CRH is involved in the activation of the ΗΡΑ axis by 
acute i.v. administration of TNFa and IL-6. It is most likely that in case of i.v. 
treatment with IL-1 β a CRH-independent mechanism is involved. This study 
provides no arguments for the involvement of endogenous IL-1 in TNFo- or IL-6-
induced activation of the ΗΡΑ axis. 
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INTRODUCTION 
Activation of the immune system by microbial invasion or inflammatory pro­
cesses is characterized by increased production of the cytokines interleukin-1 (IL-
1), tumor necrosis factor-σ (TNFa) and interleukin-6 (IL-6) (1,2) and is ac­
companied by increased activity of the hypothalamic-pituitary-adrenal (ΗΡΑ) axis 
(3-5). It is widely accepted that there is a functional relationship between the 
immune system and the (neuro-) endocrine system (3,5). For instance, it has 
been demonstrated that intravenous (i.v.) or intracerebroventricular (i.c.v.) admini­
stration of IL-1 to rats in vivo can induce activation of the ΗΡΑ axis as manifested 
by increased plasma levels of adrenocorticotropic hormone (ACTH) and/or corti­
costerone (В) (6-10). There is increasing evidence that the hypothalamus is the 
main site of action of IL-1 to increase the activity of the ΗΡΑ axis, by stimulating 
corticotropin-releasing hormone (CRH) secreting neurons (6,11-13). Only a few 
studies have been published about the stimulation of the ΗΡΑ axis by peripheral 
or central administration of TNFa (14-16) or IL-6 (15,17-20) and the role of 
activation of hypothalamic CRH neurons in this stimulation is not fully understood 
(14,17,19). Furthermore, a study systematically comparing the effects (dose-
response and time-course relationships) of all three cytokines on the activity of 
the ΗΡΑ axis in response to a single peripheral (i.v.) or central (i.c.v.) bolus 
injection is lacking. Therefore we examined in the present study the dose- and 
time-related effects of i.v. and i.c.v. administration of IL-1, TNFa and IL-6 on 
plasma В levels in conscious, freely-moving rats. Furthermore, we investigated 
whether the endogenous CRH system is involved in the activation of the ΗΡΑ 
axis by i.v. administration of IL-1, TNFa and IL-6. Finally, we investigated by 
using an IL-1 receptor antagonist (IL-1 га) whether induction of endogenous IL-1 
is involved in the stimulation of the ΗΡΑ axis by TNFa and IL-6. 
MATERIALS AND METHODS 
Materials 
Recombinant human interleukin-1 ß (IL-1) used in studies 1 and 3 was kindly 
provided by Dr. D. Boraschi (Sciavo, Siena, Italy). The preparation has a specific 
activity of 109 U/mg protein on D10.G4.1 cells, corresponding to 105 U///g vs. the 
interim IL-1 ß reference reagent 86/552. For study 2, recombinant human inter-
leukin-1ß (batch RNB185 11/14-B; specific activity 2.5x107 U/mg protein in the 
LAF assay) from Glaxo (Glaxo 1MB, Geneva, Switzerland) was used. Recombi-
nant human tumor necrosis factor-σ (TNFa; lot К 9011 AX; specific activity 6x107 
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U/mg protein on murine L-M cells) was obtained from Genentech (San Francisco, 
CA), through the courtesy of Dr. G. Adolf, Ernst-Boehringer-Institut für Arznei-
mittelforschung (Vienna, Austria). According to the specifications of the suppliers 
of IL-1 and TNFa, endotoxin contamination was negligible (<1.2 ng/mg protein). 
Recombinant human interleukin-6 (IL-6; batch PPG9001; specific activity 5.2x107 
U/mg protein in the B13.29 assay) was obtained from Sandoz (Sandoz For-
schungsinstitut, Vienna, Austria). Endotoxin contamination was negligible (<0.4 
endotoxin units/mg protein). Recombinant human interleukin-1 receptor antago-
nist (IL-1ra; batch #008-91) was kindly provided by Dr. R.C. Thompson (Syner-
gen, Boulder, Colorado). All test materials were diluted to the desired concen-
tration in sterile, pyrogen-free saline just before use. All chemicals used were of 
analytical grade. 
Animals 
Male Wistar rats (Cpb:WU, 10-12 weeks old, 200-220 g) were obtained from 
the local breeding facility. The animals were individually housed in Plexiglass 
cages in an artificially lighted room (lights on at 0700 h; lights off at 1900 h). Rats 
were provided commercial rat chow (RMH-TM, Hope Farms, Woerden, The 
Netherlands) and tap water ad libitum. 
Experimental procedures 
To diminish the stress by the experimental procedures, the animals were 
handled daily by the experimentator, starting 3 days before cannulation. In addi-
tion, to become used to the blood sampling procedure, rats were daily connec-
ted to an extension cannula for at least 3 hours per day, starting 3 days prior to 
the experiment. For blood sampling, the external jugular vein was cannulated ac-
cording to the method described by Steffens (21), with some modifications as 
described earlier (22). 
For the experiments in which intracerebroventricular (i.c.v.) injections were 
given, rats were also provided with an i.c.v. cannula in the right lateral ventricle of 
the brain. The i.c.v. cannulation was done immediately after cannulation of the 
jugular vein, according to the method described by Brakkee and co-workers (23). 
Protocols 
All rats were allowed to recover from surgery for at least 1 week. Intravenous 
(i.v.) injections (300 //l/rat) were given in freely moving rats through the jugular 
cannula. Intracerebroventricular (i.c.v.) injections (3 //l/rat) were given in hand-
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held rats through the i.c.v. cannula with a 10 /#l microsyringe (Hamilton, Bonaduz, 
Switzerland). Three sets of experiments were performed: 
Study 1: In these experiments the effects of i.v. injection of saline, IL-1 (10, 50, 
100, 500 or 1000 ng/rat), TNFo (100, 500 or 1000 ng/rat) or IL-6 (1000, 3000 or 
5000 ng/rat) or of i.c.v. injection of saline, IL-1 (10, 100 or 1000 ng/rat), TNFo 
(10, 100 or 1000 ng/rat) or IL-6 (1000 or 5000 ng/rat) on plasma В levels were 
examined. 
Study 2: In these experiments the effects of i.v. treatment of rats with a monoclo­
nal antibody directed against rat CRH (PFU 83, batch 9301-B) (24) or normal rat 
IgG (NRI) prior to i.v. injection of IL-1, TNFa, IL-6 or saline, on plasma В levels 
were examined. The anti-CRH antibody or NRI were injected in a volume of 1 
ml/rat (30 nmol/ml) 90 min before IL-1 (500 or 3000 ng/rat), TNFo (3000 ng/rat), 
IL-6 (3000 ng/rat) or saline was administered. 
Study 3: In these experiments the effects of i.v. treatment of rats with IL-1ra or 
saline prior to i.v. injection of IL-1, TNFo, IL-6 or saline, on plasma В levels were 
examined. IL-1ra (3 mg/rat) or saline was given 15 min before the injection of 
cytokine (3000 ng/rat) or saline. 
Stood sampling 
Blood was collected from freely moving rats by means of a chronic jugular 
cannula according to the method described by Wiersma and Kastelijn (25). Blood 
sampling started between 1030 and 1130 h, which is 1 to 1.5 h after connection 
of the animals to the extension cannula. Blood samples (350 μ\) were taken 30 
min before, immediately before (t=0 min) and 15, 30, 60, 120 and 240 min after 
the i.v. or i.c.v. injection of cytokine or saline. To compensate for the volume loss, 
at all time points 350 μ\ pyrogen-free saline was injected intravenously after 
blood sampling except at t=0 min. Blood samples for measurement of plasma В 
levels were collected in tubes containing dry lithium-heparin additive (30 USP 
U/tube; Vacutainer, Becton Dickinson, Etten-Leur, The Netherlands). The 
samples were gently shaken and spun for 10 minutes at 1,500x g (4 °C). Plasma 
was separated and stored at -20 °C until assayed. 
Hormone measurements 
Plasma В was measured by radioimmunoassay as described by Sweep and 
co-workers (26). 
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Statistical analysis 
Data of study 1 were analyzed for a dose-response relationship by means of 
Spearman's rank correlation test between the logarithm of the area under the 
plasma В curve from 0-240 min (logAUC) and the dose of the cytokine. When a 
significant dose-response relationship was found, Dunnett's t-test was performed 
in order to determine which dose of the cytokine induced a significant increase of 
plasma В levels compared with the effect of saline treatment. Furthermore, the 
effects of 1000 ng of each cytokine on plasma В levels were compared by 
Tukey's t-test. In the studies 2 and 3 the logAUC's were determined and 
Dunnett's t-test was used to determine whether pretreatment with anti-CRH 
antiserum or IL-1ra significantly affected basal plasma В levels or the cytokine-
induced increases of plasma В levels. Effects are considered to be significant if 
p<0.05. 
RESULTS 
Effects of IL-1, TNFa and IL-6 on plasma В levels 
The effects of acute i.v. and i.c.v. administration of saline or increasing doses 
of IL-1, TNFa, or IL-6 on plasma В levels are shown in Figure 1. Intravenous 
administration of each cytokine induced a significant dose-dependent increase in 
plasma В levels (IL-1: p<0.0005; TNFa: p<0.05; IL-6: p<0.05). Dunnett's t-test 
revealed that 500 ng and 1000 ng of IL-1, 1000 ng of TNFa and 5000 ng of IL-6 
induced a significant increase in plasma В levels compared with the levels of 
saline treated rats. Maximal В levels were reached at 30 min after i.v. injection of 
IL-1 (except for the highest dose) and TNFa, and at 60 min after the injection of 
IL-6. At t=120 min plasma В levels had returned to control values. The plasma В 
response to i.v. injection of 1000 ng of IL-1 was significantly higher than those of 
1000 ng of TNFa and 1000 ng of IL-6 (both p<0.05). There was no significant 
difference between the plasma В response to i.v. administration of 1000 ng of 
TNFa and 1000 ng of IL-6. 
The procedure of the i.c.v. injection itself induced a small effect, as evidenced 
by an increase in plasma В levels 15 and 30 min after the injection of saline. In 
contrast with i.v. administration of IL-1, rats became visibly ill after i.c.v. 
administration of IL-1. The symptoms (piloerection, crouched posture) were most 
pronounced at 120 min after the injection. At t=240 min the animals were 
recovering except for those injected with the highest dose of IL-1. Saline, TNFa 
and IL-6 injected animals did not develop these symptoms. Intracerebroventricu-
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Fig. 1. Effects of ¡.v. {upper panels) or i.e.v. {lower panels) bolus injection of recombinant human 
IL-1B (/eft panels), TNFo {middle panels) or IL-6 {right panels) on plasma В levels in rats. Data 
are expressed as the mean + S.E.M. N=4-8 for cytokine treated rats and n=11-14 for saline 
treated rats. The arrow indicates the time of injection, о : saline; о : 10 ng; л : 50 ng; • : 100 ng; 
• : 500 ng; • : 1000 ng; Δ : 3000 ng; ν : 5000 ng. *: p<0.05 (Dunnett's t-test). 
lar administration of increasing doses of IL-1 or IL-6 induced a significant (IL-1: 
p<0.0005 and IL-6: p<0.005) dose-dependent increase in plasma В levels, which 
peaked at 120 min after injection of IL-1 and at 60 min after injection of IL-6. At 
t=240 min after i.c.v. IL-1 administration plasma В levels were still elevated. 
Dunnett's t-test revealed that plasma В levels were significantly increased in case 
of IL-1 at all doses tested and in case of IL-6 at a dose of 5000 ng/rat, as 
compared to control levels. The plasma В response to i.c.v. administration of 
1000 ng of IL-1 was significantly higher than that to i.c.v. administration of 1000 
ng of IL-6. Intracerebroventricular administration of TNFo in doses of 10, 100 or 
1000 ng/rat did not affect plasma В levels. 
31 
Acute stimulation of the ΗΡΑ axis by cytokines in vivo 
TNF ( 3 0 0 0 ng) 
T__ I 
/τ ,-' 
I—-— 1 
о 
IL-6 (3000 ng) 
-30 О 30 60 120 
time (mm) 
2 4 0 -30 О 30 6 0 120 
| time (mm) 
Fig. 2. Effects of ι ν bolus injections of rats with recombinant human IL-Ш (left upper panel· 500 
ng/rat, /eft lower panel 3000 ng/rat), TNFe (nght upper panel 3000 ng/rat) or IL-6 {right lower 
panel 3000 ng/rat) after pretreatment (ι ν ) of these rats with 30 nmol normal rat IgG (NRI) or 
anti-CRH antiserum per animal at t= -90 mm, on plasma В levels Data are expressed as the 
mean + SEM of 5-8 rats The arrow indicates the time of the second injection (cytokine/sahne) о 
pretreatment with NRI followed by saline, · pretreatment with anti-CRH followed by saline, Δ 
pretreatment with NRI followed by 500 ng IL-1, • pretreatment with anti-CRH followed by 500 
ng IL-1, α pretreatment with NRI followed by 3000 ng cytokine, • pretreatment with anti-CRH 
followed by 3000 ng cytokine 
Effect of anti-CRH antibody on the plasma В response to saline, IL-1, TN Fa and 
IL-6 
Figure 2 shows the effects of i.v. pretreatment of rats with an anti-CRH 
antibody or NRI on the plasma В response to i.v. administered saline, IL-1 (500 
or 3000 ng/rat), TNFo and IL-6 (both 3000 ng/rat). Intravenous pretreatment of 
the animals with NRI, followed by i.v. injection of saline, had no effect on plasma 
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В levels. Repeated blood sampling did not induce a significant clearance of the 
anti-CRH antibody from the circulation as can be deduced from the unaltered and 
ow plasma В levels throughout the period of blood sampling in rats injected i.v. 
with saline following i.v. pretreatment with anti-CRH antiserum. Compared with 
.v. pretreatment with NRI, i.v. pretreatment with anti-CRH antiserum significantly 
decreased basal plasma В levels. Intravenous injection of both doses of IL-1, as 
well as 3000 ng of TNFa or of IL-6 following i.v. pretreatment with NRI induced a 
significant increase in plasma В levels compared with i.v. injection of saline in 
rats pretreated with NRI. With respect to i.v. injected IL-1 no significant overall 
Dlockade of the plasma В response to both doses of IL-1 by i.v. pretreatment with 
anti-CRH antiserum could be demonstrated, although it seemed that the res-
Donse of plasma В was blocked at t=15 min. Dunnett's t-test revealed that i.v. 
aretreatment of rats with anti-CRH antiserum did induce a significant overall 
Dlockade of the plasma В response to i.v. administered TNFa and IL-6 
administration. 
Effect of IL-1га on the plasma В response to saline, IL-1, TNFa and IL-6 
Figure 3 shows the effects of i.v. pretreatment of rats with IL-1 ra or saline on 
¡he plasma В response to i.v. administered saline, IL-1, TNFa or IL-6. 
ntravenous pretreatment of the animals with IL-1ra had no significant effect on 
sasal plasma В levels compared with saline pretreatment. All three cytokines, 
njected i.v. at a dose of 3000 ng/rat induced a significant increase in plasma В 
evels reaching maximal levels at t=60 min in case of IL-1 and IL-6 and at t=30 
Tiin in case of TNFa. Dunnett's t-test revealed that IL-1ra significantly blocked the 
L-1-induced increase in plasma В levels, whereas the TNFa- and IL-6-induced 
ncreases in plasma В levels were not significantly affected by pretreatment of 
tie animals with IL-1ra. 
DISCUSSION 
The present study shows that, with decreasing potency, intravenously 
administered IL-1, TNFa and IL-6 dose-dependently induce activation of the ΗΡΑ 
axis. This result is in agreement with literature data (6,8-11). Our study differs 
тот other studies on activation of the ΗΡΑ axis by cytokines in the fact that 
tiree cytokines were systematically compared and in the use of multiple 
Dbservations during a number of hours instead of single point observations 
shortly after administration of the cytokine. 
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Fig. 3. Effects of ι ν bolus injections of rats with recombinant human IL-Ш (upper panel), TNFe 
(middle panel) or IL-6 (lowerpanel) after pretreatment ( ιν) of these rats with 3 mg IL-1ra per rat 
or saline at t= -15 mm, on plasma В levels Data are presented as the mean + S Ε M of 6-7 rats 
The arrow indicates the time of the second injection (cytokine/sahne) о pretreatment with saline 
followed by saline, · pretreatment with IL-1ra followed by saline, π pretreatment with saline 
followed by 3000 ng cytokine, • pretreatment with IL-1ra followed by 3000 ng cytokine 
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When given intracerebroventricularly, considerably lower doses of IL-1 were 
needed to activate the ΗΡΑ axis compared with i.v. administration, which Is in 
agreement with earlier studies (8,9). The effects of i.v. and i.c.v. administration of 
IL-6 were comparable, whereas TNFa after i.c.v. administration failed to activate 
the ΗΡΑ axis in doses up to 1000 ng. These observations suggest that the site of 
action of i.c.v. administered IL-1 in stimulating the ΗΡΑ axis is located in the 
central nervous system. In this context it is noteworthy that i.c.v. administration of 
IL-1 leads to behavioral changes and sickness, whereas i.c.v. administration of 
IL-6 and TNFa did not. 
Immunoneutralization of CRH significantly reduced the increases of plasma В 
levels induced by intravenous administration of TNFo or IL-6. Thus, CRH is con­
sidered to play an intermediate role in the activation of the ΗΡΑ axis by these 
cytokines. It has to be noted, however, that in our study and also In the study of 
Bernardini and co-workers (14) the plasma В response to TNFo was indeed sig­
nificantly reduced though not completely abolished by pretreatment with anti-CRH 
antiserum. Pretreatment of rats with an anti-CRH antibody caused no significant 
overall blockade of the IL-1-induced activation of the ΗΡΑ axis, although it 
seemed that the plasma В response to either doses of IL-1 was blocked at t=15 
min. This agrees with data of Sapolsky et al. (11), who found a complete 
blockade of the IL-1-induced plasma В response at t=10 min by pretreatment of 
the rats with an anti-CRH antibody. Our data contrast with those of others 
(6,10,27), who did claim an overall blockade in short-term experiments. 
There are a number of possible explanations for the failure of the anti-CRH 
antibody to induce a complete blockade of the IL-1-induced plasma В response. 
First, it may be that the amount of the anti-CRH antibody we used was in­
sufficient to fully neutralize all of the secreted CRH. Secondly, IL-1 might directly 
stimulate the pituitary and/or adrenal gland to release ACTH and В respectively. 
Thirdly, factors structurally distinct from CRH might be involved in the activation 
of the ΗΡΑ axis by IL-1. An insufficient amount of neutralizing anti-CRH antibody 
is not likely, as the dose used in our study has been shown to block the increase 
in plasma ACTH levels induced by ether-stress (24). A direct effect of IL-1 on the 
pituitary and/or adrenal gland is also unlikely as in vitro studies have demon­
strated that IL-1 had no effect on hormone release by isolated rat anterior 
pituitary cells and adrenal cells following short-term incubation (6,11,16,28-30). 
With respect to factors structurally different from CRH, in vivo studies using 
postembedding electron microscopic immunocytochemistry (31) and push-pull 
perfusion (32) demonstrated the release of hypothalamic vasopressin in addition 
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to CRH following acute administration of IL-1. Furthermore, Loxley and co­
workers (33) showed vasopressin release from rat hypothalami in vitro in 
response to IL-1. Thus besides CRH, a vasopressinergic mechanism might be in­
volved in the IL-1-induced activation of the ΗΡΑ axis. In this respect a recent 
study (34) showing that destruction of the hypothalamic paraventricular nucleus 
only partially attenuated the activation of the ΗΡΑ axis induced by administration 
of IL-1, suggesting that in addition to releasing factors of paraventricular origin 
also non-paraventricular factors may be involved in IL-1-induced activation of the 
ΗΡΑ axis, is also of interest. 
The fact that TNFo, when administered i.v. in a dose of 1000 ng/rat, activates 
the ΗΡΑ axis whereas i.c.v. administration of the same dose is not effective, 
suggests that i.c.v. administered TNFo is not able to reach the (hypothalamic) 
centers responsible for the activation of the ΗΡΑ axis or that intravenously 
administered TNFo either stimulates the pituitary and/or adrenal gland directly to 
release ACTH and В respectively or that it exerts its effect via induction of 
endogenous IL-1 secretion (35). Other researchers have demonstrated that TNFo 
has no direct stimulating effect on ACTH (16) and В (28) release by the pituitary 
and adrenal gland respectively. Regarding cytokine-induced endogenous IL-1 
secretion, we investigated the effects of i.v. injected IL-1, TNFo or IL-6 on the 
activity of the ΗΡΑ axis after pretreatment of these rats with a recombinant 
human IL-1 receptor antagonist (IL-1ra). Pretreatment of rats with IL-1 ra 
completely blocked the IL-1-induced activation of the ΗΡΑ axis. These results are 
in agreement with data of Matta et al. (36). Pretreatment of rats with IL-1 ra did 
not affect the TNFo- and IL-6-induced stimulation of the adrenal gland, which 
argues against a role for endogenous IL-1 in the stimulation of the ΗΡΑ axis by 
TNFo and IL-6. Interestingly, Bluthé et al. (37) demonstrated that TNFo-induced 
behavioral effects in mice are fully antagonized by pre-treatment of the mice with 
IL-1ra, whereas Everaerdt and co-workers (38) showed a protective effect of IL-
1ra against TNFo-induced lethality in mice. These results suggest that the effects 
of exogenously administered TNFo on behaviour and lethality but not on 
activation of the ΗΡΑ axis are mediated by the induction of endogenous IL-1. 
In summary, the present study shows: 1] i.v. administration of IL-1, TNFo or IL-
6 and i.c.v. administration of IL-1 or IL-6 dose-dependently stimulate the ΗΡΑ 
axis; 2] when given i.v. or i.c.v., IL-1 is more powerful than TNFo and IL-6 in 
activating the ΗΡΑ axis; 3] endogenous CRH is involved in the activation of the 
ΗΡΑ axis by acute administration of TNFo and IL-6. It is most likely that in case 
of IL-1 a CRH-independent mechanism is involved. This study provides no argu­
ments for the involvement of endogenous IL-1 in TNFo- or IL-6-induced activation 
of the ΗΡΑ axis. 
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ABSTRACT 
It has been shown that acute administration of recombinant human interleukin 1ß 
(IL-1) to rats elicits an activation of the pituitary-adrenal axis. In the present study 
we investigated ¡mmunohistochemically the expression of Fos-like-immunoreactivity 
(Fos-LI) in the hypothalamus of rats following intravenous injection of IL-1. One, 2 
and 4 h after IL-1 or physiological saline injections, rats were killed and perfused, 
and the brain processed for Fos-immunohistochemistry. Dense populations of 
neurons containing Fos-LI-positive nuclei were found in the paraventricular 
hypothalamic nuclei (PVH) of IL-1-treated rats. In particular, the dorsal medial 
parvocellular part, but also some of the other parvocellular subdivisions contained 
many Fos-LI neurons. Maximal induction of staining was found at a dose of 5 
//g/rat after 1 or 2 h survival, while immunostaining had decreased to almost 
control levels after 4 h. No Fos-LI was found in the PVH of control animals. Double 
immunocytochemical staining for Fos and corticotropin-releasing hormone (CRH) 
revealed that Fos-LI was predominantly present in parvocellular CRH-containing 
neurons of the PVH. The finding that peripherally injected IL-1 induces Fos-LI in 
hypothalamic CRH neurons strengthens the hypothesis that these neurons are part 
of the circuitry mediating IL-1-induced activation of the pituitary-adrenal axis. 
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INTRODUCTION 
The proto-oncogene c-fos codes for a 380 amino acid nuclear phosphoprotein 
(Fos) that forms a heterodimer complex with the protein product of c-jun and 
interacts with DNA to regulate transcription from specific target genes 
(12,21,22,28). Concerning its function, Fos has been proposed to act as a third 
messenger to transform extracellular signals into intracellular genetic action 
(21,22,30). The c-fos gene is transiently activated in a variety of cell types. In the 
brain, different levels of Fos-like-immunoreactivity (Fos-LI) may be detectable in 
neuronal nuclei and various types of stimulation lead to a rapid and transient 
increase in c-fos-mRNA and Fos-LI in distinct neuronal populations. In the rat, for 
instance, adrenalectomy, hypertonic saline injections and water deprivation result 
in the consistent appearance of Fos-LI within magnocellular and parvocellular 
neurons of the paraventricular (PVH) and supraoptic (SON) nucleus of the 
hypothalamus (11,16,25,29). Double immunostaining procedures reveal that Fos-LI 
can be located in neurons containing corticotropin-releasing hormone (CRH), 
vasopressin, oxytocin or gonadotropin-releasing hormone (GnRH) (11,17,23, 
personal observation). Since physiological relevant stimuli induce c-fos expression 
in appropriate regions in the brain and basal expression of c-fos is relatively low in 
most areas of the central nervous system, it has been suggested that Fos-LI can 
be used as a specific marker for mapping activated neurons at the single cell level 
(25). 
Stimulation of the immune system as induced by infection is associated with an 
activation of the pituitary-adrenal axis. There is increasing evidence that increased 
production of interleukin-1 (IL-1), a polypeptide produced by activated 
macrophages and monocytes, is at least partially responsible for this effect (5). In 
the rat, peripheral administration of IL-1 caused marked elevations of plasma 
adrenocorticotropic hormone (ACTH) and corticosterone (В) concentrations 
(7,15,24). Although the mechanism that mediates IL-1-induced ACTH release still 
remains to be elucidated, there is increasing consensus that in acute experiments 
the main site of action of IL-1 is not at the pituitary level but on CRH-secreting 
neurons in the hypothalamus (6,18,19,27). Direct evidence for the effect of IL-1 on 
hypothalamic CRH neurons is rather limited and mainly based on the observed 
effects on the pituitary-adrenal axis. In a recent study, it has been suggested that 
peripheral IL-1 may exert its stimulatory effect mainly at the level of nerve 
terminals in the median eminence, without immediate activation of the PVH 
perikarya (23). 
The present study was designed to obtain evidence that systemically injected IL-
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1 can induce an activation of hypothalamic CRH neurons, using the expression of 
the c-fos gene as a marker of cellular activity. 
MATERIALS AND METHODS 
Recombinant human interleukin-1ß (IL-1) was kindly provided by Dr. D. Boraschi 
(Sciavo, Siena, Italy). The preparation has a specific activity of 109 U/mg protein on 
D10.G4.1 cells, corresponding to 105 U///g vs. the interim IL-1B reference reagent 
86/552. According to the specifications of the suppliers, endotoxin contamination 
was negligible (<1.2 ng lipopolysaccharides/mg IL-1). 
Male albino Wistar rats (Cpb:WU, 200-220 g), obtained from the local breeding 
facility, were individually housed in Plexiglass cages in an artificially lighted room 
(lights on at 07.00h; lights off at 19.00h), and provided with pelleted rat chow 
(RMH-TM, Hope Farms, Woerden, The Netherlands) and tap water ad libitum. 
Rats were cannulated according to the method of Steffens (31), as described 
earlier (32). 
Rats were intravenously injected with 1, 3 or 5 //g IL-1/rat diluted in 300 μ\ sterile 
physiological saline, and were killed by perfusion 1, 2 or 4 h after injection. Control 
rats were injected with the same volume of sterile physiological saline. Each group 
consisted of two to three rats. To diminish the stress caused by the experimental 
procedure the animals were handled daily by the experimenter starting 1 week 
before cannulation. On the observation day, the cap closing the cannula was 
replaced by a long polyethylene tubing and the heparin-polyvinylpyrrolidone 
solution in the internal cannula was replaced by a heparin solution. After 90 min to 
recover from the handling, the animal was ready for blood sampling and i.v. 
injection. 
Because of the circadian rhythm of hormone release, blood was withdrawn from 
the animals between 10.00 and 12.00 h. At the time of injections, the animals were 
usually sleeping or at rest. Blood samples for ACTH and corticosterone 
determinations were collected immediately before injection and perfusion. Blood 
was collected in prechilled tubes containing dry lithium-heparin additive (30 USP 
units/tube, Vacutainer, Becton Dickinson, Etten-Leur, The Netherlands). Samples 
were gently shaken and spun for 10 min at 1500 g (4°C). Plasma was separated 
and stored at -20°C until assayed. Plasma ACTH and corticosterone levels were 
determined by radioimmunoassay as described by Sweep et al. (32). 
Immediately after the last blood collection, rats were injected intravenously with 
sodium pentobarbital (55 mg/kg body weight) and perfused transcardially with 
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phosphate-buffered saline (PBS, 0.1 M, pH 7.5) for 5 min followed by 400 ml of 
ice-cold 2% paraformaldehyde in PBS within 30 min. Thereafter the rats were left 
undisturbed for 2 h at 4°C. Brains were then removed and left overnight at 4°C in 
the above fixative. The next day a frontal slice of the brain containing the 
hypothalamus was removed and 75 yum thick coronal sections of this tissue were 
cut with a Vibratome and sections were collected in 0.1 M-PBS (pH 7.3) at room 
temperature. Sections were collected so as to generate two parallel series through 
the rostral-caudal extent of the hypothalamus. One series of sections was 
processed for Fos-LI immunocytochemistry, while the other series was stained with 
cresyl violet. Briefly, free-floating sections were soaked in a mixture of 0.1 M-PBS 
(pH 7.3) containing 5% normal rabbit serum, 0.5% Triton X-100 and 0.1% bovine 
serum albumin (solution A) at room temperature for at least 1 h to remove fixative 
and to block non-specific binding sites. Next, the tissue sections were incubated 
overnight at room temperature on a slow shaker with sheep anti-Fos (c-fos OA-11-
823, Cambridge Research Biochemicals, Northwich, England) diluted 1:3000 in 
solution A. The sections were washed three times (20 min per wash) in PBS (0.1 
M, pH 7.3) and subsequently incubated for 90 min in rabbit anti-sheep 
immunoglobulin (Nordic, Tilburg, The Netherlands, diluted 1:100 in solution A) at 
room temperature. After three further rinses in PBS, the sections were transferred 
to vials containing sheep peroxidase anti-peroxidase (Nordic; diluted 1:600 in PBS) 
and were incubated for 90 min at room temperature. The Fos antibody peroxidase 
complex was visualized by 3,3' diaminobenzidine tetrahydrochloride (DAB) 
staining. The tissues were first rinsed three times in PBS and placed for 10 min in 
a chromogen solution consisting of 0.02% DAB and 0.03% Ni-ammonium sulfate in 
0.05 M-Tris buffer (pH 7.6), and then incubated for 5 min in chromogen solution 
containing hydrogen peroxide (10 μ\ of a 30% solution per 100 ml of reaction 
solution). For double immune staining, a number of tissue sections were washed 
three times in PBS, 0.1 M, pH 7.3, to stop the DAB staining reaction for Fos, 
rinsed in solution В (0.1 M-PBS, pH 7.3, containing 5% normal goat serum, 0.5% 
Triton-X-100 and 0.1% BSA) for 60 min and then incubated in a rabbit-anti-CRH 
solution (kindly provided by Prof. F. Tilders, Free University of Amsterdam, The 
Netherlands; dilution 1:1000 in solution B) overnight at 4°C. After rinsing three 
times 20 min in PBS, the tissue was incubated in goat-anti-rabbit-serum (Nordic) 
diluted 1:100 in solution В at room temperature for 90 min. After rinsing three times 
20 min in PBS, the sections were incubated in rabbit peroxidase anti-peroxidase 
(Dakopatts, Denmark), diluted 1:600 in PBS for 90 min at room temperature. After 
rinsing three times 20 min in PBS, the CRH-antibody-peroxidase-complex was 
45 
IL-1 and FOS-LI in the РУН 
visualized by DAB-staining without Ni-ammonium sulfate for 30 min. The presence 
of Fos-LI was evident as a black reaction product in cell nuclei, whereas CRH 
immunoreactivity within the cell cytoplasm was stained brown. Following staining, 
the tissue sections were rinsed three times in PBS and mounted on gelatin/chrome 
alum-coated glass slides, dried overnight, cleared in zylene, embedded with 
Entellan (Merck, Darmstadt, Germany) and coverslipped. All incubations were 
performed at room temperature. For control purposes, other series of brain 
sections were prepared for Fos-LI after experiments involving intraperitoneal 
injections of hypertonic salt solution (NaCI, 1.5 M, 1 ml/100 g bodt weight, 90 min 
survival time) and for CRH immunoreactivity in an animal that had been 
adrenalectomized 2 weeks before. 
RESULTS 
The distribution of Fos-LI neurons in the rostral hypothalamus, including the PVH 
and the SON, was markedly different from the patterns induced by either 
intravenous physiological saline injections (Fig. 1A) or intraperitoneal hypertonic 
saline (Fig. 1B) injections. After isotonic saline injections, the number of Fos-LI 
neurons is very small, and only a few scattered Fos-LI neurons can be observed in 
the hypothalamus (Fig. 1A). On the other hand, intraperitoneal injection of a 
hypertonic salt solution consistently induced a strong pattern of Fos-LI in the SON 
(not shown), and in the PVH (Fig. 1B). The most darkly staining cell nuclei were 
observed in the magnocellular part of the PVH, with numerous more weakly 
staining cell nuclei in the parvocellular parts of the PVH. The effects of intravenous 
IL-1 injections were markedly different. IL-1-induced Fos-LI was not observed in 
the SON. Within the PVH, Fos-LI was mainly observed outside the magnocellular 
parts (Fig. 1C,D) in different parvocellular subdivisions. The highest densities of 
Fos-LI nuclei were observed in the dorsal medial parvocellular part of the PVH. In 
a series of pilot-experiments, we had observed that this IL-1-induced Fos-LI 
pattern can be observed clearly at 1 h, is optimal at least 2 h and had almost 
returned to control levels at 4 h after the intravenous injection of IL-1. In addition, 
the IL-1-induced Fos response was clearly dose dependent. 1 //g IL-1 per rat 
induced a Fos pattern not much different from the isotonic saline injections. 3 //g 
IL-1 induced a clear pattern of Fos-LI after 2 h (Fig. 1С). However the number of 
labelled cell nuclei was consistently smaller and the intensity of Fos-LI staining 
was lower, when compared with the effects of injections with 5//g IL-1 (Fig. 1D). 
These differences correspond with the observed dose-dependent increases in 
plasma concentrations of ACTH and corticosterone (Table 1). 
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Fig. 1. Paraventricular hypothalamic nucleus (PVH) of the rat (same magnification, in Α-F). (A) Intravenous 
infusion of physiological saline does not result in Fos-LI in the PVH, after 2 h. (B) Numerous Fos-LI nuclei 
induced by intraperitoneal loading with hypertonic salt. Magnocellular neurons are strongly activated, as visible 
in the large number of very dark nuclei in the ventrolateral part of the PVH Numerous parvocellular nuclei are 
activated as well, but their Fos-LI tends to be weaker (90 min). (С and D) Fos-LI in the PVH after i.v. injection 
of 3 /yg IL-1 (2 h) and after 5 μ$ IL-1 (2 h) respectively. Comparison of (C) and (D) shows that the number of 
Fos-LI nuclei increases with the increased doses of IL-1. Comparison of (C) and (D) with (B) shows that most 
Fos-LI nuclei are observed in the parvocellular part of the PVH, especially its dorsal medial subdivision, while 
the magnocellular part contains only a few activated neurons after i.v. IL-1 injection. (E) Distribution of CRH-
containing neurons in the PVH of a male rat, adrenalectomized 2 weeks earlier. (F) Results of the double-
staining experiments. After an i.v injection of 5 //g IL-1, numerous Fos-LI nuclei are visible (·) after 2 h. In 
addition, a number of CRH-containing neurons become detectable (A) and by far the majority of these CRH 
neurons are double labeled (O) The figure shows data from a single section after double immunostaining. The 
neurons expressing either or both Fos-LI and CRH-LI were mapped by camera lucida tracing. 
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ТаЫ 1. Plasma levels of ACTH and corticosterone immediately before and 2 h after ι ν injections 
of physiological saline, 1, 3 and 5 j/g IL-1 There were one or two rats per group Values 
for individual rats are given 
Injection 
Saline 
1 //g IL-1 
3 //g IL-1 
5 //g IL-1 
ACTH 
Before 
injection 
91 
66 
<10 
36 
<10 
113 
<10 
(Da/ml) 
2h after 
injection 
82 
49 
<10 
95 
123 
363 
224 
Corticosterone 
Before 
injection 
40 
23 
2Θ 
37 
8 
47 
15 
ι fnmol/L) 
2h after 
injection 
54 
63 
160 
489 
935 
1195 
1152 
The distribution of the Fos-LI neurons in the PVH was remarkably similar to the 
distribution of the CRH containing neurons in the PVH (Fig. 1E). Since CRH 
neurons are hardly detectable immunocytochemically under normal circumstances, 
their distribution in the PVH is shown after adrenalectomy, (Fig. 1E). The 
intravenous IL-1 injections of the present series of experiments (5 //g; 2 or 4 h 
before sacrifice), apparently improved CRH immunoreactivity in the PVH, making 
the neurons detectable, under high magnification, by their light yellow-brown 
staining. Since Fos-reactivity was already strongly reduced after 4 h, we have 
chosen the 5 μ^ IL-1, 2 h survival scheme for the double immunostaining 
experiments. These results are shown in Fig. 1F, and indicate that CRH could be 
detected in many (44%) of the Fos-LI neurons. Of the total number of detectable 
CRH neurons at this level of the PVH, 90% contained a Fos-LI-positive nucleus. 
DISCUSSION 
The Fos-method has been applied successfully in many different physiological 
and behavioral situations. Despite the fact that the emerging patterns of Fos-LI can 
be rather complicated, or that negative findings may occur as a result of either 
inhibitory connections in the neuronal circuits, or the activation of other messenger 
systems in the cells that do not induce Fos-LI, the method is apparently able to 
bridge gaps between anatomical, physiological, pharmacological, endocrinological 
and behavioral findings (12,21,22,30). 
The results of our study are consistent with the view that the CRH-containing 
neurons in the PVH are involved in the activation of the pituitary-adrenal axis by 
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intravenous injections of IL-1ß. Stimulation of the immune system, for example by 
an infection, induces an increased production of IL-1 by macrophages and mono-
cytes (5,8,10,13) and this increased production of IL-1 may be responsible for the 
elevation of plasma ACTH and corticosterone levels (7,24,27). The evidence ob-
tained so far indicates that IL-1 effects are not the result of a direct action of IL-1 
upon the ACTH-containing cells of the pituitary, but that different parts of the 
central nervous system are involved (6,24,27). IL-1 seems to have access to the 
brain (2,3), and IL-1 receptors are widely distributed, with especially high densities 
in the hippocampal formation (1,33). The occurrence of IL-1-containing neurons 
and fibers has been described in the human and rat brain (9,20). 
The effects of circulating IL-1 on the hypothalamic-pituitary-adrenal (ΗΡΑ) axis 
probably occur via an entrance involving the Organum vasculosum of the lamina 
terminalis (OVLT) (14,19). With the presumable involvement of prostaglandins, 
medial preoptic neurons are activated that may stimulate the CRH-containing 
neurons in the PVH (19). Indeed, a number Fos-LI neurons were observed in the 
medial preoptic region. On the other hand, ascending catecholaminergic projec­
tions may play an important role in the activation of CRH neurons in the PVH (35). 
In the present study, we observed the activation of neurons in the PVH after i.v. 
administration of IL-1, with a distribution strongly similar to the distribution of the 
CRH-containing neurons. The application of a double-immunostaining procedure 
revealed that the CRH-containing neurons became partially visible, by a weak 
immunostaining, as a result of the IL-1 injection 2 h earlier. In addition, 90% of 
these weakly stained CRH neurons contained nuclei with Fos-LI. The higher dose 
of IL-1 ß (5 //g/rat) induced the strongest response after about 2 h. These results 
agree with the findings of Ju et al. (17), who showed that intracerebroventricular 
(i.c.v.) injections of IL-1o resulted in an activation of CRH neurons in the PVH. 
Since they used essentially the same techniques as we did in the present study, it 
is interesting to see that several differences appear to be present in the effects of 
i.v. versus i.c.v. applications of IL-1. First, larger doses of IL-1 were needed with 
the systemic IL-1 administration. Secondly, and surprisingly, the Fos-LI staining 
was optimal 4-5 h after i.c.v.-injection, while in our study, i.v. injections gave 
optimal results after 1 to 2 h, and Fos-LI staining almost returned to control levels 
after 4 h survival time. Thirdly, the IL-1-induced CRH immunostaining is obviously 
stronger after a 4 h i.c.v. than after a 2 h i.v. survival time. Apart from these 
differences, the study by Ju et al. (17) and the present report are in good 
agreement. 
In a recent study, Rivest ef al. (23) compared the effects of central versus 
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peripheral IL-1 β injections on c-fos expression in the brain. For the peripheral 
injections, they used the dose of 1//g, and, in agreement with our findings, the 
effect on c-fos expression in the PVH was negligible. In the present study, 
however, we show that larger doses of IL-1 (3 and 5//g) are able to induce Fos-LI 
in the PVH, and especially in the CRH-containing neurons. Therefore we conclude 
that peripheral IL-1, in sufficiently high doses, may exert direct or indirect effects 
on the central nervous system, and that these effects are not necessarily limited to 
the CRH terminals in the median eminence. Since our rats were handled 
chronically prior to administration of IL-1 or saline, we cannot exclude effects of 
this handling on the IL-1-induced Fos expression, although we would expect that 
handling results mainly in lower levels of Fos expression under non-stimulated 
conditions. 
Our data are consistent with other experimental findings suggesting the coupling 
between IL-1 and the activity of the ΗΡΑ axis. Intravenously administered IL-1 
induces increased electrical activity of CRH- but not of vasopressin-containing 
neurons in the PVH (26). It has been observed that intravenously administered IL-1 
or an intracerebral infusion of IL-1 near the PVH induces an increased release of 
CRH in the median eminence (4,34). This activation of the ΗΡΑ axis is virtually 
eliminated after immunoneutralization of CRH (6,27). 
In conclusion the CRH neurons of the PVH appear to play a key role in the 
effects of IL-1 upon the ΗΡΑ axis. The findings of the present study, showing Fos-
LI activation in CRH-containing neurons of the PVH after intravenous IL-1 
injections, strongly support this role. 
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ABSTRACT 
We investigated the effects of recombinant human IL-Ισ ,-1ß, -2, -6 and TNF 
on the in vitro secretion of ß-endorphin-immunoreactivity (ßE-IR) by the rat 
anterior and neurointermediate lobes (AL and NIL, respectively) and of В by the 
rat adrenal gland. Isolated AL and NIL cells were incubated for 2 h with cytokines 
(1 pg/ml - 1 //g/ml), CRH (5-1010 M) or with cytokines in combination with CRH 
(AL cells), isolated adrenal cells were incubated for 2 h with cytokines, ACTH (25 
pg/ml) or with cytokines in combination with ACTH. Furthermore, AL, NIL and 
adrenal tissue fragments were superfused for 30 or 60 min with cytokines (10 
and/or 100 ng/ml). Incubation of AL, NIL and adrenal cells and superfusion of 
these tissues with cytokines had no significant effect on ßE-IR and В release. 
However, there are some exceptions: incubation of AL cells with IL-2 increased 
CRH-induced ßE-IR release, incubation of NIL cells with IL-2 induced an in-
crease of basal ßE-IR release, ACTH-induced В secretion was reduced after co-
incubation of adrenal cells with TNF and after prolonged (6 h) superFusion of 
adrenal tissue with TNF, and finally, prolonged (6 h) superfusion of adrenal 
fragments with IL-1ß increased basal В release. Taken together, these data sug­
gest that the acute activation of the pituitary-adrenal axis of rats by admini­
stration of cytokines (at least IL-1, IL-6 and TNF) in vivo is not mediated by a 
direct action of these cytokines at the level of the pituitary and/or adrenal gland. 
54 
Chapter 4 
INTRODUCTION 
The concept that there ¡s a functional relationship between the immune system 
and the (neuro-) endocrine system is now widely accepted. It has been 
postulated that cytokines - polypeptides synthesized and released by cells of the 
immune system - may function as messengers of the immune system to activate 
the pituitary-adrenal axis (PA-axis) (1). There is ample evidence that in rodents, 
after intravenous or intracerebroventricular bolus injection of interleukin-1 (IL-1), 
plasma levels of adrenocorticotropic hormone (ACTH) and corticosterone (В) rise 
within 10-30 minutes (2,3). Besides IL-1 also interleukin-2 (IL-2), interleukin-6 (IL-
6) and tumor necrosis factor-σ (TNF) have been reported to stimulate the activity 
of the ΡΑ-axis when injected into laboratory animals or humans (4-6). There is 
increasing consensus that the central nervous system is the main site of action of 
IL-1 in activating the PA-axis (7-9). Whether IL-1 can directly stimulate ACTH and 
ß-endorphin (ßE) secretion by the anterior lobe (AL) of the pituitary gland and/or 
В secretion by the adrenal gland is controversial (3,7,8,10-28). Data concerning 
direct effects of IL-2 and TNF on hormone release by the AL in vitro are also 
conflicting. Positive effects of IL-2 on ACTH release by cultured murine AtT-20 
cells (29) and of TNF on ACTH release by rat anterior pituitary cells or tissue 
(30) have been described. However, other researchers found no effect of IL-2 on 
ACTH release by cultured AtT-20 cells (14) and of TNF on ACTH release by rat 
AL cells in vitro (6,16,31,32). Regarding the effects of IL-6, positive effects on 
ACTH release by rat anterior pituitary tissue (33) or on murine AtT-20 cells (14) 
have been described. With respect to the effects of IL-2, IL-6 and TNF on В 
release by adrenal cells in vitro only few data are available (22,24,34,35), 
whereas there are no data at all concerning direct effects of IL-1 and other 
cytokines on hormone release by the intermediate lobe of the pituitary gland. 
In the light of these controversial data, we systematically investigated in the 
present study the effects of a number of cytokines (IL-1o, IL-1ß, IL-2, IL-6 and 
TNF) in a broad range of concentrations, on the secretion of ß-endorphin-
immunoreactivity (ßE-IR) by the AL and the NIL of the rat pituitary gland and on 
the secretion of В by the rat adrenal gland. We used two supplementary in vitro 
methods: static incubation of freshly prepared cell suspensions and superfusion 
of the tissues. 
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MATERIALS AND METHODS 
Test materials 
Human adrenocorticotropic hormone ,_39 (ACTH) was obtained from the National 
Institute for Biological Standards and Control (NIBSC, Potters Bar, UK; MRC 
standard 74/555). Rat corticotropin-releasing hormone (CRH) was obtained from 
Byk (Zwanenburg, The Netherlands) and isoproterenol (isoprenalini sulfas) was 
obtained from OPG (Utrecht, The Netherlands). Dopamine HCl was obtained 
from Sigma Chemical Company (St. Louis, MO). Recombinant human interleukin-
1σ (IL-1o; specific activity (S.A.) 3-108 U/mg protein, endotoxin contamination 
(E.C.) <1 endotoxin unit/mg protein) was a generous gift of Dr. P. Lomedico 
(Hoffman-La Roche, Nutley, NJ), recombinant human interleukin-1ß (IL-1ß; S.A. 
2.5-107 U/mg protein, E.C. <1.2 ng/mg protein) was kindly provided by Dr. A. 
Shaw (Biogen, Geneva, Switzerland), recombinant human tumor necrosis factor-
а (TNF; S.A. 6-107 U/mg protein, E.C. <1 endotoxin unit/mg protein) was 
obtained from Boehringer (Ingelheim, Germany), recombinant human interleukin-
2 (IL-2; S.A. 1.5-106 U/mg protein, E.C. <7 endotoxin units/mg protein) was 
kindly provided by Dr. A. Galazka (Glaxo, Geneva, Switzerland) and recombinant 
human interleukin-6 (IL-6; S.A. 106 U/mg protein, E.C. <1.2 ng/mg protein) was 
generously donated by Dr. L. Aarden (Central Laboratory of the Blood 
Transfusion Service of The Netherlands Red Cross, Amsterdam, The 
Netherlands). All chemicals used were of analytical grade. 
Animals 
Male albino Wistar rats (Cpb:WU) weighing 180-240 g were obtained from the 
local breeding facility on the day before the experiment. The animals were then 
housed overnight, 4 to a cage, in a room adjacent to the animal home in which 
the decapitations were to be performed. In all experiments the rats were killed by 
decapitation between 0930 and 1030 h. 
Cell suspension experiments 
Pituitary cells. Immediately after decapitation the skull was opened, the brain 
taken out and the pituitary quickly removed from the cranium. The anterior lobe 
(AL) and the neurointermediate lobe (NIL) were carefully separated from each 
other and the AL was cut in about 8-10 pieces. AL and NIL tissues were 
separately placed in a flask filled with 10 ml Earle's Balanced Salt Solution 
(EBSS, 116 mM NaCI, 5.36 mM KCl, 1.15 mM NaH2P04 ·2Η20, 0.81 mM 
MgS04-7H20, 26 mM NaHC03, 1.79 mM CaCI2-2H20 and 5.0 mM glucose H20) 
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containing benzylpenicillin (15 //g/ml; Sigma), streptomycin (25 //g/ml; Merck, 
Darmstadt, Germany), ascorbic acid (30 //g/ml; Merck) and 0.25% (w/v) trypsin 
(type II; Sigma). The cells were dispersed at 37 °C by mild mechanical agitation 
in a shaking waterbath. During dispersion the cells were gassed with carbogen 
(95% 0 2 and 5% C02). After 20 min of incubation the supernatant was decanted 
into a 10 ml plastic centrifuge tube and retained at room temperature. A further 
10 ml of the EBSS/trypsin solution was added to the pituitary fragments. A total 
of 3x20 min cell harvests were collected. The supernatants were pooled and 
centrifuged at room temperature for 40 min (200x g). The pellet, consisting of 
isolated cells, was resuspended and diluted in EBSS buffer containing bovine 
serum albumin (BSA, 0.25% (w/v); OHRD 20/21, Hoechst-Behring, Marburg, 
Germany), ascorbic acid (30 //g/ml), the antibiotics, aprotinine (100 KIE/ml; Bayer 
AG, Leverkusen, Germany), bacitracin (100//g/ml; Sigma) and lima bean trypsin 
inhibitor (66 //g/ml; type l-S1f Sigma) (EBSS*) to a concentration of about 50,000 
cells per 800 //I medium. Cell suspensions were preincubated for 90 min at 37 
°C, and subsequently 200 //I of EBSS+ solution containing CRH (5-10"10 M), 
cytokine (IL-Ισ, IL-1B, IL-2, IL-6, or TNF; 1 pg/ml - 1 //g/ml) or CRH in 
combination with cytokines, was added. Incubation was continued for another 
120 min. NIL cells were only incubated with cytokines (IL-Ισ, IL-1B, IL-2, IL-6, or 
TNF; 1 pg/ml - 1 //g/ml). Incubation was terminated by cooling on ice and the 
supernatant was subsequently collected by centrifugation (15 min, ЮООх g) and 
the medium assayed for ßE-IR within 24 h. 
Adrenal cells. Rat adrenal cells were isolated and incubated according to a 
method extensively described by Goverde et al. (36). Isolated rat adrenal cells 
were incubated for 2 h with different peptides (ACTH 25 pg/ml; cytokines 1 
pg/ml - 1 //g/ml; ACTH and cytokines) dissolved in Krebs-Ringer-Bicarbonate 
buffer containing 0.2% glucose, 0.5% BSA and 7.65 mM Ca2+ (KRBGACa). 
Incubation was stopped by cooling on ice and all samples were stored at 4 °C. 
Corticosterone production was measured the next day. 
Cell viability. After preparing the cell suspensions, cell viability was tested by 
mixing an aliquot of the cell suspension with an equal volume of trypan blue 
(BDH, 0.1% (w/v) in 0.9% NaCI). In all experiments, more than 95% of the cells 
excluded the dye. Responsiveness of the cells was tested by incubation of AL 
cells with CRH (5-10-10 M), NIL cells with dopamine (10"6 M) and adrenal cells 
with ACTH (25 pg/ml). 
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Superfusion experiments 
Pituitary tissue. Dissected ALs (quartered) and NILs (intact) were transferred 
to a superfusion apparatus (2 ALs or 2 NILs per chamber). The tissues were 
superfused continuously with carbogenated KRB-buffer (118 mM NaCI, 4.85 mM 
KCl, 1.15 mM KH2PO<, 1.15 mM MgSCy7H20, 25 mM NaHC03, and 1.25 mM 
CaCI2-2H20) supplemented with BSA (0.5%; Sigma fraction V), ascorbic acid 
(0.1 mM) and glucose (11.1 mM) (medium). The flow rate was kept constant at 
0.1 ml/rnin using a Gilson Minipuls 3 peristaltic pump (Meyvis, Bergen Op Zoom, 
The Netherlands). The temperature of the superfusion chambers and media was 
kept constant at 37 °C. In these experiments, the tissues were first superfused 
with medium for 180 min to allow the release of ßE-IR to reach a rather stable 
level. Thereafter superfusion was continued for 240 min and fractions (fr.) were 
collected in ice-chilled tubes every 10 min. Pituitary tissues were superfused 
twice for 30 min (1s l pulse: fr. 7-9, 2nd pulse: fr. 17-19) with medium containing 
cytokines (IL-1a, IL-1B, IL-2, IL-6 or TNF; 1st pulse: 10 ng/ml; 2nd pulse: 100 
ng/ml), CRH (ALs; 1st pulse: 5-10"10 M; 2nd pulse: 5-10'9 M) or isoproterenol 
(NILs; 1st pulse: 10"7 M; 2nd pulse: 10"6 M). 100 μ\ aliquots of the supervisâtes 
were taken for determination of ßE-IR. 
Adrenal tissue. Dissected adrenals were freed of fat, cut in about 16 pieces 
and transferred to a superfusion apparatus (1 adrenal/chamber). The adrenal 
tissue was first superfused for 30 min with medium to allow the release of В to 
reach a rather stable level. From then on 15 min fractions were collected in ice-
chilled tubes for 5.5 h. During this period the adrenal tissue was superfused for 1 
h (fr. 11-14) with medium containing cytokines (IL-Ισ, IL-1ß, IL-2, IL-6 or TNF; 
100 ng/ml) or ACTH (125 pg/ml). In order to investigate whether prolonged 
exposure of adrenal tissue to cytokines had any effect on basal or ACTH-induced 
В release, rat adrenal tissues were superfused in other experiments for 6 h with 
medium containing 100 ng/ml of IL-1ß, IL-2 or TNF and later for 30 min with 250 
pg/ml ACTH. Control tissues were superfused continuously with medium alone. 
During these prolonged adrenal superfusion experiments medium was 
supplemented with benzylpenicillin (100 //g/ml), streptomycin (100 pg/ml), 
aprotinine (20 KIE/ml) and bacitracin (30 pg/ml) (medium*). The flow rate was 
kept constant at 2 ml/h, В release was allowed to reach rather stable levels for 2 
h and fractions were collected every 2 h for 28 h. Adrenal tissue was superfused 
for 6 h (fr. 4-6) with medium* alone or with medium* containing 100 ng/ml of IL-
1ß, IL-2 or TNF. After 28 h of superfusion the responsiveness of the adrenal 
tissue was tested by superfusion for 30 min with medium* containing 250 pg/ml 
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ACTH. From then on 30 min fractions were collected for 3.5 h. Total superfusate 
fractions were taken for В determination. 
Hormone measurement 
ß-endorphin-like-immunoreactivity (ßE-IR) was measured by radioimmuno-
assay (RIA) as described by Sweep et al. (37), using an antiserum kindly 
provided by Dr. V.M. Wiegant, Rudolf Magnus Institute (Utrecht, The 
Netherlands). В was measured fluorometrically, as described by Goverde et al. 
(36). 
Calculations and statistical analysis 
Cell suspension experiments. ßE-IR and В release is expressed as 
percentage of basal hormone release by AL and NIL cells incubated with EBSS* 
solution (control) respectively by adrenal cells incubated with KRBGACa buffer 
(control). In case of incubation of adrenal cells with cytokines in combination with 
ACTH (25 pg/ml), В release is expressed as percentage of the release during 
incubation of cells with ACTH only. Data were statistically analyzed for a dose-
response relationship using a linear regression model. This model uses the 
logarithm of the dose of the used peptide. 
% release = σ, + o2(CRH) + o3(log cytokine) + o„(CRH) -(log cytokine) 
Here α
λ
 is an estimate of the effect of incubation of AL or NIL cells with EBSS* 
solution respectively incubation of adrenal cells with KRBGACa buffer or an 
estimate of the effect of incubation of adrenal cells with 25 pg/ml ACTH only. σ2 
is an estimate of the effect of incubation of AL cells with CRH alone. σ3 is an 
estimate of the dose-response relationship for the effects of incubation of AL, NIL 
or adrenal cells with cytokines only or for the effects of incubation of adrenal cells 
with cytokines in combination with ACTH. σ4 is an estimate of the dose-response 
relationship for the effects of incubation of AL cells with cytokines in combination 
with CRH. Testing for a significant dose-response implies testing whether the 
corresponding a's are equal to zero. By way of precaution, differences are 
considered to be statistically significant if p<0.01. 
Superfusion experiments. The spontaneous rate of release of ßE-IR and В 
was not identical for the different AL, NIL or adrenal tissues within the same 
experiments. To compare results between the superfusion chambers, the total 
amount of drug-induced ßE-IR (AL and NIL: fr. 7-13 and fr. 17-23) or В (adrenal: 
fr. 12-21; prolonged adrenal superfusion: fr. 15-20 (28.5-31 h)) release was 
summed and expressed as percentage of the calculated basal release. The area 
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under the line linking the means of the ßE-IR or В content of the two fractions 
immediately preceding (ßE-IR (AL and NIL): 1st pulse: fr. 5-6, 2nd pulse: fr. 15-16; 
В (adrenal): fr. 10-11; В (prolonged adrenal superfusion): 2nd pulse: fr. 13-14 (26-
28 h)) and the first one or two fractions in which stabilization of the release to 
basal levels had occurred (ßE-IR (AL and NIL): 1st pulse: fr. 14-15, 2nd pulse: fr. 
24; В (adrenal): fr. 22; В (prolonged adrenal superfusion): 2nd pulse: fr. 21 (31.5 
h)) was taken as basal release. Data concerning differences between the drug-
induced hormone release and the computed basal release were statistically 
analyzed by a paired t-test after logarithmic transformation of the doses. By way 
of precaution, differences are considered to be statistically significant if p<0.01. 
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Flg. 1. Release of ßE-IR from isolated rat AL cells in vitro incubated with IL-1a, IL-1ß, IL-2, IL-6 
or TNF (1 pg/ml - 1 //g/ml; open bars) or with these cytokines in combination with 5-10"10 M CRH 
(closed bars). After 2 h of incubation AL cells and medium were separated. ßE-IR content in the 
medium was measured by a specific RIA. ßE-IR release is expressed as percentage (mean + 
SEM; n=8) of hormone release by the control group. ND = not determined. ***: IL-2 induced a 
dose-dependent increase of CRH-induced ßE-IR release (p<0.0001). 
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RESULTS 
Cell suspension experiments 
AL cells. Figure 1 shows the effects of incubation of freshly isolated AL cells 
with IL-Ισ, IL-1ß, IL-2, IL-6 or TNF alone, or with these cytokines in combination 
with CRH on the release of ßE-IR in vitro. In all experiments incubation of AL 
cells with 5-10"10 M CRH induced a significant (p<0.001) increase in ßE-IR 
release (+114 ± 8%; n=38) as compared to ßE-IR release by cells incubated with 
EBSS* (1.5 ± 0.1 ng/2 h; n=40). Incubation of cells with each of the cytokines (1 
pg/ml - 1 //g/ml) alone had no significant effect on ßE-IR release. Incubation of 
cells with IL-Ισ, -1ß, -6 or TNF in combination with CRH had no significant effect 
on ßE-IR release, whereas incubation of cells with IL-2 in combination with CRH 
induced a significant (p<0.0001) dose-dependent increase in ßE-IR secretion as 
compared to the release by cells incubated with CRH alone. 
NIL cells. The effects of incubation of freshly isolated NIL cells with IL-Ισ, IL-
1ß, IL-2, IL-6 or TNF in concentrations of 1 pg/ml - 1 //g/ml on ßE-IR release are 
listed in Table 1. Incubation of NIL cells wit2h dopamine (10"8 M) induced a 
significant (p<0.01) reduction of ßE-IR release (-43 ± 5%; n=12) as compared to 
hormone release by cells incubated with buffer alone (3.0 ± 0.2 ng/2 h; data not 
shown). Incubation of cells with increasing doses of IL-1o, IL-1ß or IL-6 had no 
significant effect on ßE-IR release. Although ßE-IR release by NIL cells in 
response to incubation with TNF at a dose of 10 pg/ml was markedly increased, 
TNF had no significant overall effect on ßE-IR release. Incubation with IL-2, 
however, induced a statistically significant (p<0.001) dose-dependent increase in 
ßE-IR release. 
Adrenal cells. Table 2 lists the effects of incubation of freshly isolated adrenal 
cells with IL-1a, IL-1ß, IL-2, IL-6 or TNF alone or with these cytokines in 
combination with ACTH on corticosterone release. Incubation of cells with 25 
pg/ml ACTH induced a strong increase in В release (+1672 ± 71%; n=53) as 
compared to В release by the control group (6.1 ± 0.4 ng/2 h, n=39; data not 
shown). Incubation of adrenal cells with cytokines (1 pg/ml - 1 //g/ml) alone had 
no significant effect on В release. Incubation of cells with IL-1or, IL-1B, IL-2 or IL-
6 in combination with ACTH had no significant effect on В release as compared 
to the release induced by ACTH alone, whereas TNF induced a significant 
(p<0.01) dose-dependent decrease of the ACTH-induced stimulation of В 
secretion by rat adrenal cells as compared to the stimulation of В secretion by 
ACTH alone. 
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В from superfused rat adrenal tissue in vitro Tissue was superfused for 60 mm (fr 11-14, black 
bar) with medium containing ΙΙ_-1σ (·), IL-1B (о), IL-2 (•), IL-6 (o), TNF (ν) (100 ng/ml) or ACTH 
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63 
Cytokines and in väro ßE-IR and В release 
Superfusion experiments 
AL tissue. Figure 2 (upper panel) shows the effects of superfusion of AL 
fragments with IL-Ισ, IL-1Ü, IL-2, IL-6, TNF or CRH on ßE-IR release. 
Superfusion of ALs for 30 min with medium containing CRH (5-10'10 M 
respectively 5-10"9 M) induced a rapid, sustained, and significant (p<0.001) dose-
dependent increase in the amount of ßE-IR in the superfusates. Upon removal of 
CRH from the medium, the concentration of ßE-IR in the superfusates rapidly 
decreased and returned to basal levels. Superfusion of AL tissue with medium 
containing cytokine (1st pulse: 10 ng/ml, 2nd pulse: 100 ng/ml) had no significant 
effect on ßE-IR release. 
NIL tissue. Superfusion of NILs for 30 min with medium containing the fi-
ad renoceptor agonist isoproterenol (10'7 M respectively 10"6 M) induced a 
significant (p<0.01) dose-dependent increase of ßE-IR release (181 pulse: +62 ± 
15%, 2nd pulse: +122 ± 36%; data not shown). Table 3 shows that superfusion of 
NILs for 30 min with 10 respectively 100 ng/ml of IL-1a, IL-1B, IL-2, IL-6 or TNF 
had no significant effect on ßE-IR release. 
Table 3. Effects of superfusion of NILs with cytokines on the release of ßE-IR* 
% RE-IR RELEASE 
fr 7-13 fr 17-23 
IL-1flf 93 5 ± 1 6 95 5 ± 1 2 
IL-1B 92 5 ± 2 9 99 4 ± 1 9 
IL-2 90 8 ± 2 3 106 8 ± 2 9 
IL-6 103 5 ± 2 4 969 ± 1 9 
TNF 97 6 ± 3 4 89 4 ± 5 0 
'ßE-IR release is expressed as percentage (mean ± SEM, n=4) of the computed basal release as 
described in materials and methods Cytokines were added to the medium during pulse 1 (10 
ng/ml) and pulse 2 (100 ng/ml) 
Adrenal tissue. The effects of superfusion of adrenal tissue with IL-1o, IL-1ß, 
IL-2, IL-6, TNF or ACTH on В release are shown in Figure 2 (lower panel). В 
content in the superfusates was found to be increased (+195 ± 5% vs. basal 
release) after superfusion of adrenal tissue for 60 min with medium containing 
125 pg/ml ACTH. Superfusion of adrenal tissue for 1 h with each of the cytokines 
in a dose of 100 ng/ml, had no effect on В release. Prolonged superfusion (6 h) 
of adrenal tissue with cytokines did not induce an immediate increase in В 
release, therefore total В release was calculated from 8-24 h by summation of 
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the В content of each of the fractions, and subsequently compared to the total В 
release (8-24 h) after superfusion of adrenal tissue with medium alone. Figure 3 
(upper panel) shows that superfusion of adrenal tissue for 6 h with IL-1B resulted 
in a significantly higher (p<0.01) В release as compared to the release by the 
control tissues. IL-2 and TNF had no significant effect on basal В release. 
Superfusion of these adrenals was continued, and Figure 3 (lower panel) shows 
that exposure of the tissues for 30 min to 250 pg/ml ACTH induced a significant 
(all p<0.001 vs. basal release) increase in В release. Superfusion of adrenal 
tissue with IL-1B or IL-2 prior to ACTH had no effect on ACTH-induced В release 
16 h later, whereas superfusion with TNF resulted in a reduced (-28.6 ± 10.3%; 
0.01<p<0.05) response of this tissue to ACTH as compared to ACTH-induced В 
release by tissue prior superfused with only medium. 
DISCUSSION 
The present study shows that short-term (2 h) incubation of rat AL cells with 
recombinant human (rh) IL-Ισ or IL-1 β in concentrations up to 1 //g/ml did not 
significantly modify basal ßE-IR secretion. A review of the effects of rhlL-1 on 
ACTH and/or ßE release by the rat anterior pituitary in vitro is given in Table 4. 
Our results are in agreement with those in two other studies, which demonstrated 
that IL-1 has no effect on ACTH release by cultured rat AL cells after an 
incubation period of 2-3 h (7,8). In contrast with the lack of a stimulatory effect 
during short-term incubation, it seems that IL-1 stimulates ACTH or ßE secretion 
by rat AL cells or mouse anterior pituitary tumor cells (AtT-20 cells) during 
incubation for a more prolonged time (4-8 h for rat AL cells (12,16) and 23-24 h 
(10,13,14,17) for murine AtT-20 cells). In our study IL-1 did not modulate CRH-
induced ßE-IR release by AL cells, which is in agreement with data from 
Berkenbosch et al. (8). 
We showed that IL-2, IL-6 and TNF were unable to modify basal ßE-IR release 
by rat AL cells during a 2 h incubation period. Other researchers have 
demonstrated that rhlL-2 (29) and rhlL-6 (14) increase basal ACTH release by 
murine AtT-20 cells, but only after 24 h of incubation. With regard to TNF our 
results are in agreement with the results of other studies (6,31). Even during a 
more prolonged incubation period (24 h), it seems that rhTNF is still not capable 
of modifying basal ACTH release by rat AL cells (16,32). We found that IL-2 
induced a small, but significant and dose-dependent increase in CRH-induced 
ßE-IR release by AL cells, whereas IL-6 and TNF had no such a modulatory 
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Cytokines and in vitro ßE-IR and В release 
effect. Concerning IL-2 and IL-6 no comparable data are available in literature. 
With respect to TNF, our results are in line with those of Sharp et al. (6) Gaillard 
et al. (32) demonstrated an inhibitory effect of TNF on CRH-induced ACTH 
release by rat AL cells, but only after prolonged (8-24 h) and not after short-term 
(2 h) incubation. 
In our study incubation of NIL cells with IL-2 for 2 h induced a small but 
significant and dose-dependent increase in UE secretion, whereas the other 
cytokines tested were not effective in this respect. There are no data in literature 
regarding effects of cytokines on BE secretion by the NIL of the rat pituitary 
gland. Very recently, Stepien et al. (38) demonstrated that IL-1ß stimulated 
proliferation of rat intermediate lobe cells. 
In the present study short-term (2 h) incubation of isolated adrenal cells with IL-
1σ, IL-1B, IL-2, IL-6 or TNF in concentrations up to 1 //g/ml had no effect on 
basal В release. Table 4 reviews the effects of rhlL-1 on В release by rat adrenal 
cells or tissue in vitro. Our results with respect to IL-1 are in agreement with the 
results of other studies (26,27). However, one of these studies did demonstrate a 
stimulatory effect of IL-1 on В secretion by rat adrenal slices after short-term 
incubation (90 min) and the authors suggested that the mechanism underlying 
the direct stimulatory effect of IL-1B on the adrenal gland may involve the 
activation of an intraadrenal CRH-ACTH system (26). Other investigators (22-25) 
showed that IL-1 dose-dependently increased В release by rat adrenal cells after 
24 h of incubation. Some of these researchers found evidence for an adrenergic 
(23,25) or a prostaglandin-dependent (24) mechanism by which IL-1 stimulated 
the adrenal cells to release B. Our results concerning TNF are in line with those 
of Brennan et al. (35), who found no effect of rhTNF on basal secretion of В by 
adrenal cells during short-term (90 min) incubation. Regarding IL-2, only 
prolonged (24 h) incubation experiments have been performed (24). In that study 
it was found that rhlL-2 had no effect on В release by rat adrenal cells, whereas 
rat IL-2 increased В release. With respect to rhlL-6 a stimulatory effect on В 
secretion by freshly isolated (22,34) or cultured (24) rat adrenal cells has been 
demonstrated after 24 h of incubation, though not after 3 or 12 h (22,34). In our 
study, IL-1 had no modulatory effect on ACTH-induced В release, which is in 
agreement with the results of a study performed by Andreis et al. (26). We 
demonstrated in this study that neither IL-2 nor IL-6 had any modulatory effect on 
ACTH-induced В secretion. Other researchers have demonstrated that rhlL-2 
(24) and rhlL-6 (34) increased ACTH-induced В release by rat adrenal cells after 
24 h of incubation. In the present study it is shown that TNF dose-dependently 
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decreased ACTH-induced В secretion during 2 h of incubation. Such an inhibitory 
effect was also demonstrated by Brennan et al. (35). 
Since paracrine effects can be missed in a cell suspension system, the present 
study also describes the effects of superfusion of AL, NIL and adrenal tissue with 
cytokines on the release of ßE-IR and B. We demonstrated that superfusion of 
rat AL or NIL tissue with 10 respectively 100 ng/ml of IL-Ισ, IL-1 β, IL-2, IL-6 or 
TNF for 30 min had no significant effect on the secretion of ßE-IR. There are no 
other reports on effects of cytokines on the secretion of ßE-IR by the NIL using 
the superfusion technique. With respect to the AL, our results concerning IL-1 are 
in line with those of Parsadaniantz et al. (19), who showed that neither rhlL-Ισ 
nor rhlL-1ß was able to modify basal or CRH-induced ACTH and BE release after 
50 min of perfusion of rat anterior pituitary tissue, and are in contrast with those 
of Beach et al. (11), who demonstrated that perfusion of rat anterior pituitary 
tissue with IL-1 for 20 min induced a dose-dependent increase in ACTH release. 
With respect to IL-6 and TNF, our results are conflicting with those of other 
investigators, who found a stimulatory effect of rhlL-6 (33) and rhTNF (30) on 
ACTH release by rat anterior pituitary tissue during 2 h of incubation. However, 
these researchers performed static incubation experiments using 
hemi(anterior)pituitaries. 
In our experiments, superfusion of rat adrenal tissue with IL-Ισ, IL-1 ß, IL-2, IL-
6, or TNF for 60 min had no effect on basal В release. Our in vitro results are in 
line with in vivo data by Gwosdow et al. (3), who demonstrated that plasma В 
levels were not increased after administration of IL-1 ß to hypophysectomized 
rats, implying that the cytokine had no detectable direct effect on the adrenal 
gland. On the contrary, Roh et al. (21) found that acute administration of IL-1B 
into the renal artery of dissected and perfused rat adrenal glands increased 
adrenocortical activity as measured by increased output of B. It has to be noted, 
however, that these authors demonstrated stimulation of В secretion after a bolus 
injection in the renal artery of a high dose (3.5 μq) of IL-1. In our study prolonged 
superfusion of adrenal tissue for 6 h with medium containing IL-1 significantly 
increased В secretion as compared to superfusion of adrenal tissue with only 
medium, whereas IL-2 and TNF were not effective in this respect. ACTH-induced 
В release was not significantly affected after prolonged superfusion of adrenal 
tissue with IL-1 or IL-2. Prolonged superfusion with TNF, however, seems to 
inhibit ACTH-induced В release. This result is in agreement with the data on 
simultaneous incubation of isolated rat adrenal cells with both TNF and ACTH 
(this study). In this respect, it is of interest that Keri et al. (39) demonstrated that 
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plasma from patients with septic shock contains (a) factor(s) which attenuate the 
responsiveness of adrenocortical cells to ACTH and that Mathison et al. (40,41) 
observed that lipopolysaccharide (LPS)-stimulated macrophages release a 
product that suppresses the steroidogenic response of adrenocortical cells to 
ACTH. We now know that one of the substances, produced and secreted by 
macrophages in response to LPS, is TNF (42). So the observations of Keri et al. 
(39) and Mathison et al. (40,41) might be mediated by TNF. 
In summary, the present study shows: 1) prolonged superfusion (6 h) of rat 
adrenal tissue with IL-1 increased basal В secretion; 2) short-term (2 h) 
incubation with IL-2 increased CRH-stimulated ßE secretion by AL cells and 
basal ßE secretion by NIL cells; 3) short-term (2 h) incubation of adrenal cells 
with TNF inhibited ACTH-induced В release and prolonged (6 h) superfusion of 
adrenal tissue with TNF also reduced ACTH-induced В release; 4) in all other 
experiments IL-Ισ, IL-1ß, IL-2, IL-6 and TNF did not modify basal or CRH-
induced secretion of ßE and basal or ACTH-induced secretion of B. It has to be 
stressed, however, that the effects of cytokines on hormone secretion by the 
pituitary or adrenal gland were small and only found during incubation with high 
doses of cytokines and/or prolonged incubation. Our data make it unlikely that 
the acute elevation of plasma ACTH and В levels, seen after bolus injections of 
these cytokines in vivo, are mediated by a direct action of these cytokines on the 
pituitary and/or adrenal gland. 
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ABSTRACT 
It has been shown that acute administration of interleukin-1 (IL-1) to rats elicits a 
transitory increase in plasma ACTH and corticosterone (В) levels. To investigate the 
effects of chronic administration of IL-1 on plasma ACTH and В levels, in the 
present study rats were equipped with Alzet osmotic minipumps loaded with either 
IL-1 (delivery rate 0.5, 2.0 or 4.0 //g/24 h, ip, for 1 week) or with saline. At the end 
of the treatment the rats were decapitated, the adrenals weighed, and the in vitro 
release of ß-endorphin (ßE) by the anterior pituitary and that of В by the adrenal 
gland were measured. Continuous administration of 2.0 and 4.0 //g IL-1/24 h 
resulted in a persistent increase in plasma ACTH and В concentrations compared 
to the levels in saline-infused rats, with peak levels on the first day of administration. 
In addition, adrenal weights of IL-1 rats were significantly higher than those of saline 
rats. The 4.0 μο, IL-1/day in vivo treatment induced an increase in spontaneous in 
vitro secretion of ßE and B, while the in vitro response of the pituitary (to CRF) and 
the adrenal (to ACTH) of animals treated in vivo with IL-1 were significantly 
diminished. IL-1 at a dose of 0.5 //g failed to affect plasma ACTH and В values, 
adrenal weight and in vitro ßE and В secretion. Chronic infusion of rats with 4.0 //g 
IL-1/day induced prolonged fever, whereas at lower doses of IL-1 (2.0 and 0.5 μg), 
temperatures were elevated only the first 2 days of infusion. IL-1 at a dose of 2.0 
and 4.0 //g/day induced a suppression of body weight gain the first 2 days of the 
treatment period compared to saline treatment. Plasma norepinephrine and/or 
epinephrine concentrations were raised only on day 1 of the 2.0- and 4.0-//g IL-1 
experiments. Thus, the observed effects of IL-1 on the hypothalamo-pituitary-adrenal 
axis probably do not result merely from stress induced by the treatment. Taken 
together, our data show the potential of IL-1 to induce a dose-dependent and long 
term activation of the pituitary-adrenal axis. 
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INTRODUCTION 
Substantial evidence has now accumulated that there is a functional relationship 
between the immune and the (neuro)endocrine system, lnterleukin-1 (IL-1), a 
pleiotropic polypeptide synthesized and released predominantly by macrophages, 
acts as a primary mediator of the acute phase response to microbial invasion and 
physical stressors (1, 2). In addition to its role in the coordination of host defense 
mechanisms, IL-1 is thought to serve as a trigger for the activity of the hypothalamo-
pituitary-adrenal (ΗΡΑ) axis, which is chronically stimulated under these conditions 
(3-5). 
Evidence for this idea is primarily based on in vivo experiments in laboratory 
animals. It has been shown that acute administration of IL-1 activates the ΗΡΑ axis 
in mice and rats, as manifested by increased levels of ACTH and/or corticosterone 
(В) in plasma (3, 6-8). Whether IL-1 can directly act at the pituitary and/or adrenal 
level to release ACTH and B, respectively, is still controversial. Strong evidence 
exists that the brain is the primary site of action, and that IL-1, either directly or 
indirectly, acts at the level of the hypothalamus by stimulation of the release of CRF 
(6, 7, 9-12). In these studies IL-1 was administered as a single bolus injection in 
relatively high doses, and plasma levels of ACTH and/or В were followed for only 
a few hours. IL-1 has been shown to induce fever (13), to inhibit food intake (14-16) 
and, in high doses, to be toxic to the animal (17). Little or no attention has been 
given in studies on effects of IL-1 on the ΗΡΑ axis to the question whether these 
effects resulted from a direct action of IL-1 on the ΗΡΑ axis or were secondary to 
stress effects induced by IL-1 administration. 
Increased levels of IL-1, and in particular of IL-6 and tumor necrosis factor have 
been measured in biological fluids of patients suffering from infection or inflam­
matory diseases (18-20). In the present study we investigated whether IL-1 is 
capable of mediating long term changes in ΗΡΑ-activity. To mimic the setting of 
chronically elevated IL-1 production that is thought to occur during some infectious 
diseases, we implanted osmotic minipumps in rats in order to infuse low doses of 
0.5, 2.0 and 4.0 //g IL-1/day continuously during a period of 1 week. ACTH and В 
levels were measured in blood samples, which were daily withdrawn by means of 
a chronic jugular cannula. In addition, we investigated the in vitro secretion of ß-
endorphin and corticosterone from pituitary and adrenal glands of rats chronically 
infused with IL-1 or saline in vivo. To detect stress effects, particular attention was 
given to the effects of chronic administration of IL-1 on body temperature and food 
consumption and on plasma levels of the stress hormones PRL, norepinephrine 
(NE) and epinephrine (E). In the present longitudinal study we show that continuous 
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infusion of rats with low doses of IL-1 elicits a long term activation of the ΗΡΑ axis, 
and it is evidenced that these effects of IL-1 are not simply secondary to stress 
effects induced by IL-1 administration. 
MATERIALS AND METHODS 
Test materials 
Recombinant human interleukin-1ß (rhlL-1ß) was kindly provided by Dr. D. 
Boraschi (Sciavo, Siena, Italy). The preparation has a specific activity of 10s U/mg 
protein on D10.G4.1 cells, corresponding to 105 U///g vs. the interim IL-1 ß reference 
reagent 86/552. According to the specifications of the suppliers, endotoxin 
contamination was negligible (<1.2 ng LPS/mg IL-1). rhlL-1ß was diluted in sterile 
pyrogen-free saline. 
Animals 
Male albino Wistar rats (Cpb:WU) were obtained from the local breeding facility. 
They were individually housed in Plexiglass cages in an artificially lighted room 
(lights on at 0700 h; lights off at 1900 h). Rats were provided commercial rat chow 
(RMH-TM, Hope Farms, Woerden, The Netherlands) and tap water ad libitum. At the 
start of the experiments rats were 10 weeks old and weighed 200-220 g. 
In vivo experimental procedures 
In order to diminish the stress caused by the experimental procedures, the 
animals were handled daily by the experimentator, starting 1 week before can-
nulation. Body weight was measured daily at 0800 h, and food and water intake was 
estimated by weighing the residual food and water for individual cages. Body 
temperature was measured serially twice a day between 0830-0900 h and between 
1300-1430 h in conscious hand-held rats by insertion of a thermal probe into the 
rectum. The probe was connected to a digital temperature monitor (Digital DT100, 
Elbatron, Kerkdriel, The Netherlands). The mean daily temperature for each rat was 
determined by averaging the morning and afternoon rectal temperatures. 
Blood was collected from freely moving rats by means of a chronic cannula. Rats 
were cannulated according to the method described by Steffens (21) with some 
minor modifications. Briefly, under pentobarbital (60 mg/kg BW, ip; Apharma, 
Arnhem, The Netherlands)-atropine (0.125 mg/kg, im; Pharmachemie, Haarlem, The 
Netherlands) anaesthesia, a Silastic cannula (id, 0.5 mm; od, 0.94 mm: Down 
Corning Corp., Midland, Ml) was inserted into the right external jugular vein and 
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passed down to the atrium. The distal end of the cannula was tunneled sc and 
exteriorized through a stab wound in the skin on the head, where it was connected 
to a hooked stainless steel tube. This assembly was anchored to the skull with three 
stainless steel screws and acrylic cement. During cannulation, rats were con­
tinuously exposed to a gasflow of O2-N20 (each 500 ml/min). The cannula was filled 
with a 0.9% NaCI solution containing heparin (500 Ill/ml; Organon Teknika, Oss, 
The Netherlands) and polyvinylpyrrolidone (1 g/ml; Merck, Darmstadt, Germany). 
Seven to 9 days following cannulation, rats were equipped with osmotic mini-
pumps (1 //l/h, model 2001 Alzet Corp., Palo Alto, CA), which were loaded with rhlL-
1 dissolved in sterile pyrogen-free physiological saline or with saline alone and 
equilibrated, immersed in saline, for 3-4 h at 37 °C according to the instructions of 
the manufacturer. The pumps were implanted ip in ether-anesthetized animals 
(1400-1600 h). Three separate experiments, each including 14 animals, were 
performed, in which one group of rats (n=7) was continuously infused at a rate of 
0.5, 2.0 or 4.0 /ig IL-1/day/rat. In each experiment a control group (n=7) receiving 
0.9% pyrogen-free saline-filled osmotic pumps was included. The indwelling cannula 
and the osmotic pumps were tolerated well by the animals, with no signs of 
discomfort or infection. 
At the end of the experiments, the pumps filled with IL-1 were found to be 
encapsulated by a firm layer of granulation tissue, with deposition of collagen and 
abundant fibroblasts and capillaries. Pumps delivering the higher doses of IL-1 (4.0 
and 2.0 //g IL-1/day) were more encapsulated than those delivering 0.5 //g/day. 
Saline-loaded pumps were not encapsulated. Mrosovsky et al. (22) elegantly 
showed that encapsulation of the pumps does not block the release of IL-1 into the 
peritoneal cavity and that IL-1 under these circumstances remains bioactive for at 
least 1 week. 
Blood sampling. 
Blood was collected once a day for 8 days starting on the morning before 
implantation of the pumps (day 0 up to day 7), as described by Wiersma and 
Castelijn (23) with some minor modifications. Because of the circadian variation in 
hormone release, blood was withdrawn daily from the animals between 1000 and 
1200 h. Blood samples (2.0 ml) for ACTH, B, PRL, E, and NE determinations were 
collected in prechilled tubes containing dry lithium-heparin additive (30 USP 
units/tube; Vacutainer, Becton Dickinson, Etten-Leur, The Netherlands). Blood 
samples were gently shaken and spun for 10 min at 1,500 χ g (4 °C). Plasma was 
separated, and red blood cells were resuspended in sterile physiological saline (1.5 
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ml) and returned to each rat. For PRL determination, plasma (80 μ\) was diluted with 
160 μ\ PBS, and for catecholamine determination, plasma was stored in tubes 
containing 0.24 M EGTA (Merck) and 0.2 M glutathione (Sigma, St. Louis, MO). 
Plasma samples were aliquoted and stored at -20 °C until assayed. 
In vitro experimental procedures 
Rats were decapitated 8 days after implantation of the pumps. Immediately after 
decapitation (1000-1030 h) the brain was removed, the pituitary gland was taken 
out, and the anterior lobe (AL) was carefully separated from the neurointermediate 
lobe. The adrenals were removed and placed together with the ALs in a tissue 
holder containing ice-cold carbogenated superfusion medium. 
Superfusion. 
After dissection, the adrenals were freed of fat, weighed, cut in about 16 pieces 
and transferred to a superfusion apparatus (2 adrenals of 1 animal/chamber). ALs 
were quartered and also transferred to the apparatus (1 AL/chamber). The tissues 
were superfused continuously with carbogenated Krebs-Ringer bicarbonate buffer 
(118 mM NaCI, 4.85 mM KCl, 1.15 mM KH2PO«, 1.15 mM MgSO,-7H20, 25 mM 
NaHC03, and 1.25 mM CaCI2-2H20) supplemented with BSA (Sigma fraction V; 
0.5%), ascorbic acid (0.1 mM) and glucose (11.1 mM; superfusion medium). The 
flow rate was kept constant at 0.1 ml/min using a Gilson Minipuls 3 peristaltic pump 
(Meyvis, Bergen op Zoom, The Netherlands). The temperature of the superfusion 
chambers and media was kept constant at 37 °C. In all experiments, the tissues 
were first superfused for 45 min to allow the release of BE immunoreactivity (ßE-IR) 
and В to reach a rather stable level. From then on, fractions (15 min, 1.5 ml) were 
collected in ice-chilled tubes, and superfusion was continued for 165 min without 
further experimental manipulations. After this period, the ALs were exposed for 30 
min (fractions 12-13) to medium containing 10"9 M rat CRF (Byk, Zwanenburg, The 
Netherlands), and the adrenals for 60 min (fractions 12-15) to medium containing 
250 pg/ml ACTH (MRC 74/555). Thereafter, superfusion was continued for another 
120 (ALs) or 90 (adrenals) min with the initial medium. One hundred-microliter 
aliquots of the AL superfusate fractions were taken for direct RIA of ßE-IR, whereas 
the total adrenal superfusate fractions (1.5 ml) were taken for В determination. 
Calculations. 
The spontaneous rate of release of ßE-IR and В was not identical for the different 
ALs or adrenals within the same experiment. To compare results between the 
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superfusion chambers, the total amount of drug-induced ßE-IR (fractions 12-17) or 
В (fractions 13-19) release was summated and expressed as percentage of the 
calculated basal release. The area under the line linking the means of the ßE-IR or 
В content of the two fractions immediately preceding (ßE-IR, fractions 10-11; B, 
fractions 11-12) and the first two fractions in which stabilization of the release to 
basal levels had occurred (ßE-IR, fractions 18-19; B, fractions 20-21) was taken as 
basal release. 
Hormone extraction and measurement 
ACTH. Extraction from anterior pituitaries.Tbe ACTH content of the anterior 
pituitary was investigated in a separate fourth experiment. Anterior pituitaries of rats 
were rapidly dissected on the seventh day of continuous infusion with 2.0 //g IL-
1/day or saline. Anterior pituitaries were frozen in liquid nitrogen and stored at -20 
°C. These tissues were heated for 10 min in 1.0 N acetic acid (1:10, wt/vol) in a 
boiling waterbath and subsequently cooled on ice. Then, the tissues were 
homogenized by sonification and centrifuged at 20,000 χ g for 20 min at 4 °C. The 
supernatants were evaporated to dryness, and the residues were dissolved in 1 ml 
PBS containing 0.25% BSA and 0.2% sodium azide. Insoluble material was removed 
by centrifugation, and the supernatants stored at -20 °C. 
Extraction from plasma. For measurement of ACTH in rat plasma, 50-//I aliquots 
of plasma sample to each of which 250 μ\ ACTH-free human plasma (pooled from 
20 healthy volunteers after suppression of ACTH secretion by dexamethasone) had 
been added was used. ACTH was extracted and concentrated from tissue extracts 
and plasma by the addition of 25 mg Vycor glass powder (325 mesh; Corning Glass 
Works, Corning, NY) in 250 μ\ bidistilled water. The mixture was inverted end over 
end for 30 min at 4 С After centrifugation (2,000 χ g; 10 min; 4 °C), the super­
natants were discarded. The pellets were washed with 2 ml of bidistilled water and 
2 ml 1 N HCl, respectively. ACTH was eluted from the glass pellet by rotation (30 
min at 4 °C) with 1 ml of a mixture of acetone and bidistilled water (50:50, vol/vol). 
After centrifugation, the acetone fractions were decanted and evaporated to dryness, 
and the residues were reconstituted in 125 μ\ of a solution containing 0.9% NaCI 
and 0.25% BSA (ORHD 20/21, Behring, Marburg, Germany), pH 3.5, at 4 °C for 60 
min to ensure maximal reuptake of the hormone. After centrifugation for 45 min at 
30,000 χ g, a 100-//I aliquot was taken from this solution for estimation of the ACTH 
content by RIA. Standard curves were prepared by spiking ACTH-free plasma with 
ACTH (MRC 74/555). The standard samples were subjected to the same extraction 
procedure as the unknowns in order to compensate for procedural losses. The 
recovery was approximately 70%. All samples were extracted in triplicate. 
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RIA. ACTH-IR in the supernatants was measured by RIA, using a commercial 
ACTH antibody (IgG Corp., Nashville, TN). ACTH-1-39 was used as standard and 
[125l] ACTH-1-39 as tracer. The ACTH RIA was performed as follows. On hundred-
microliters of rabbit ACTH antiserum [final dilution, 1:30,000 in ACTH RIA buffer 
(phosphate buffer containing 13 mM EDTA, 0.02% sodium azide, 0.25% BSA 
(ORHD 20/21, Behring), 0.1% Triton X-100 and 250 kallikrein inhibitory units 
aprotonine (Bayer, Leverkusen, Germany)/ml] was added to 100 μ\ supernatant 
(sample or standard). The mixture was preincubated for 3 days at 4 eC with 
antiserum. Then, tracer ( * 7,000 dpm/100 μ\) was added, and incubation was 
continued for another day. Bound and free ACTH were separated by a second 
antibody system. One hundred microliters of a separation reagent [10% (vol/vol) 
sheep antirabbit immunoglobulin G and 0.01% (wt/vol) rabbit immunoglobulin G 
(Sigma)] were added to each tube and incubated for 20 min at room temperature. 
The antibody complex was precipitated by addition of 1 ml 7.5% polyethylene glycol 
6000 (Merck). The sensitivity of the assay system was 10-15 pg/ml, and the within-
and between-assay coefficients of variation of the extraction and RIA procedure 
were 9.1% and 15.3%, respectively. 
B. Plasma В was measured by RIA after extraction using an antiserum from our 
own laboratory (S-05 230676) raised in sheep against a B-21-hemisuccinate-BSA 
conjugate. The following cross-reactivities (expressed as percentage on a mass 
basis) were obtained: desoxy-B, 28.6%; cortisone, 0.2%; Cortisol, 0.8%; 
desoxycortisol, 0.3%; testosterone, 3.8%; and progesterone, 22.5%. To each plasma 
sample (50 μ\), 100 μ\ 0.1 N NaOH, 100 μ\ В tracer [[1σ,2σ-Ν-3Η]Β; Amersham 
International PLC, Amersham, Aylesbury, Buckinghamshire, United Kingdom; 10,000 
dpm in 0.2% ethylene glycol (Merck) -water (EGW)] and 500 μ\ bidistilled water were 
added. Extraction was carried out using 7.5 ml dichloromethane (Baker, Deventer, 
The Netherlands). The water phase was discarded, and the dichloromethane phase 
was evaporated. The residue was dissolved in 2 ml 0.2% EGW, and the 
concentration of В in the eluate was measured by RIA. Briefly, aliquots of 100, 200 
or 300 μ\ eluate were transferred to test tubes, the volume was made up to 300 μ\ 
with 0.2% EGW and mixed with 200 μ\ of an antiserum dilution (final dilution, 
1:100,000) and 100 pi В tracer (10,000 dpm/tube). Antiserum and tracer were 
diluted in 0.05 M borate buffer (pH 8.0) containing 0.1% human K-g'°bulin 
(Beriglobin S, Behring, Marburg, Germany). Aliquots of 300//I eluate were taken for 
recovery. Amounts of 0-5,000 fmol/tube В (Steraloids Inc., Wilton, NH) diluted in 
0.2% EGW were used for obtaining a standard curve. After incubation overnight at 
4 °C, the suspension was mixed with 150 //I dextran-coated charcoal suspension 
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and left at 4 °C for 5 min. After centrifugation the supernatants were decanted into 
counting vials, and 4 ml Aqualuma (Lumac LSC, Olen, Belgium) was used as 
counting solution for radioactivity measurements. The sensitivity of the assay was 
25-45 fmol/tube. The within- and between-assay coefficients of variation were 10.0% 
and 16.7%, respectively. 
В produced by adrenal glands in vitro was measured fluorometrically, as 
described by Goverde et al. (24). 
PRL. Plasma PRL levels were measured directly by RIA, using reagents [purified 
ratPRL(AFP-10505B) foriodination; rabbit antirat PRL antiserum (AFP-131581580), 
and rat PRL reference preparation (AFP-4459B)] obtained from the NIDDK through 
the courtesy of Dr. Raiti of the National Hormone and Pituitary Program, University 
of Maryland School of Medicine. The RIA was performed in essence as described 
by Wiersma (25). The sensitivity of the assay was 160 pg/ml, and the within-assay 
coefficient of variation was 4.4%. All necessary comparisons between test and 
control animals were made within one assay run. Data are expressed as picograms 
of PRL per ml plasma. 
Catecholamines. Plasma catecholamines (E and NE) were determined by using 
HPLC followed by fluorescence detection, as described in detail by van der Hoorn 
étal. (26). Catecholamines were concentrated from plasma by liquid-liquid extraction 
and derivatized with the fluorescent agent 1,2-diphenylethylenediamine before 
chromatography. The instrumentation for the chromatography consisted of a 610 
Fluid unit pump, a WISP 710 В autoinjector and a 470 scanning fluorescence 
detector, all from Waters Associates (Etten-Leur, The Netherlands). All separations 
were performed on a Nova-Pak C18 column. Calculations were made on a NEC 
Powermate SX plus computer using the Baseline 815 program (Waters Associates). 
BE. The RIA procedure was performed essentially as described by Sweep et al. 
(27), using an antiserum kindly provided by Dr. V.M. Wiegant, Rudolf Magnus 
Institute (Utrecht, The Netherlands). 
Chemicals 
All chemicals used were of analytical grade. 
Statistical analysis 
All data are presented as mean ± SE of five to seven rats. Comparisons between 
IL-1 and saline groups were made by analysis of variance with repeated 
measurements to analyze the effects of the treatment course. To get a fair picture 
of the effect of continuous IL-1 treatment, analysis of repeated measures was 
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performed from day 2-7, as on the first day changes occurred in ACTH, B, and 
catecholamine levels in plasma, and in body temperature, food consumption, and 
body weight, which in most instances surpass the changes seen from day 2-7. 
When analysis of variance revealed a statistically significant difference, comparison 
of the individual groups at specific time points was further evaluated by Student's 
f test as were the effects of IL-1 on the first day of treatment. For single 
comparisons between IL-1 and saline groups, Student's f test was used. 
RESULTS 
Infusion of IL-1 ß at a dose of 4.0 //g/day induced clear signs of physical 
discomfort to the animals, including piloerection and decreased physical activity, 
starting a few hours following implantation of the pumps. This visually observed 
uneasiness gradually diminished during the first day of the treatment period and had 
disappeared at the end of day 1. Infusion with a dose of 2.0 //g IL-1/day also 
induced signs of discomfort, which were less pronounced than those induced by the 
4.0 //g IL-1 dose. Treatment of rats with 0.5 μα, IL-1/day or physiological saline did 
not perceptibly distress the animals. 
Effects of IL-1 on plasma ACTH and B, and on pituitary ACTH content and adrenal 
weight 
Using osmotic minipumps, rats were continuously infused for 7 days with 0.5, 2.0 
or 4.0 μα, IL-1/day or with physiological saline, and plasma levels of ACTH and В 
were monitored for 8 days, starting on the morning before implantation of the 
pumps. Plasma ACTH and В values in animals implanted with saline-filled osmotic 
pumps varied between 15-51 pg/ml and 24-50 nmol/liter, respectively. Under the 
present conditions, the operation and infusion procedures, as such, virtually did not 
alter plasma ACTH and В levels, as demonstrated by the stable hormone levels in 
saline-treated rats. 
Administration of 0.5 //g IL-1/day did not affect plasma ACTH and В levels (Fig. 
1). Infusion of 2.0//g IL-1/day induced a significant increase in plasma ACTH and 
В levels compared to saline-treated controls. Repeated measures analysis revealed 
a significant treatment effect on plasma ACTH (day 2-7; P<0.0005) and В (day 2-7; 
P<0.05) in IL-1-infused rats compared to saline-treated controls. The maximal effect 
[ACTH. +184 ± 38% (PO.005); B, +2114 ± 381% (PO.0005)] was observed on day 
1 of the treatment. Plasma levels had declined on day 2, but sustained elevations 
of ACTH and В levels were found up to day 6. Post-hoc analysis of individual groups 
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by means of Student's f test showed a significant increase in plasma levels of ACTH 
on days 1,3,4, 5, and 6 and of В on days 1 and 6 compared to saline-treated 
controls. When IL-1 was infused at a rate of 4.0 //g/day, a more pronounced effect 
on plasma ACTH (repeated measures analysis from days 2-7; P<0.0005) and В 
(days 2-7; P<0.005) levels was observed. Peak levels on day 1 were about 6.2 
(ACTH; P<0.0005) and 17.5 (B; P<0.0005) times higher than those in control rats. 
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Fig. 1. Effects of continuous infusion for 1 week of different doses of IL-1 (0.5, 2.0 and 4.0 //g IL-
1/day; · ) or physiological saline (o) in rats on the concentrations of ACTH (/eft panels) and В (right 
panels) in plasma. Osmotic minipumps were implanted between 1400-1600 h on day 0 (arrow). Data 
are expressed as mean ± SE of five to seven rats. Asterisks mark statistically significant differences 
between IL-1 and saline-treated rats. *, P<0.05; **, P<0.005; ***, P<0.0005 (by Student's f test). 
Significant elevations of plasma ACTH levels were found from day 1 up to day 7, 
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and significant elevations of В occurred on days 1, 2, 4, and 5. 
The effects of continuous treatment of rats with IL-1 on the ACTH content of the 
anterior pituitary (2.0-//g IL-1 experiment) and the weight of the adrenal glands (0.5-, 
2.0- and 4.0-//g IL-1/day experiments) were also studied. The ALs of rats treated for 
1 week with 2.0 //g IL-1/day contained significantly more immunoreactive ACTH than 
those of saline-treated rats (IL-1 vs. saline, 436 ± 45 vs. 291 ± 30 ng; P<0.05). 
Chronic administration of 2.0 and 4.0 //g IL-1 induced significant increases in total 
adrenal weight [summated weight of both adrenals of each rat, 2.0 //g IL-1 vs. 
saline, 46.6 ± 1.4 mg vs. 40.1 ± 1.6 mg (P<0.05); 4.0 //g IL-1 vs. saline, 48.7 ± 1.9 
mg vs. 44.0 ± 0.6 mg (P<0.05)]. IL-1 at a dose of 0.5 //g/day failed to affect adrenal 
weight. 
Effects of IL-1 treatment on in vitro ßE-IR and В release (Fig. 2) 
After decapitation and dissection, ALs and adrenals were transferred to a 
superfusion apparatus, and the effects of chronic treatment of rats with IL-1 on the 
in vitro release of ßE-IR and B, respectively, were studied. ßE-IR release was taken 
as an index for the secretory activity of pituitary corticotrophs. Figure 2 shows the 
pattern of spontaneous and CRF/ACTH-induced release of ßE-IR and B. The rate 
of release into the medium generally ranged from 350-1500 pg ßE-IR/AL-15 min 
and 35-120 ng B/2 adrenals-15 min. Superfusion of ALs for 30 min with medium 
containing CRF (10'9 M) and of adrenals for 60 min with 250 pg/ml ACTH induced 
a rapid sustained increase in the amount of ßE-IR and В found in the superfusates. 
The effects of CRF and ACTH on ßE-IR and В release, respectively, are expressed 
for each superfusion cell as a percentage of the computed basal release and listed 
in Table 1. Chronic treatment of rats with 4.0 μ§ IL-1/day significantly increased the 
spontaneous rate of secretion of ßE-IR (P<0.05) and В (P<0.05), which were 
determined from the concentrations of these hormones in the first 11 superfusion 
fractions collected compared to treatment with saline (Fig. 2 and Table 1). On the 
other hand, the CRF-induced ßE-IR and the ACTH-induced В release from tissue 
of IL-1 (4.0 /yg/day)-treated rats were significantly depressed (both P<0.05) 
compared to the responses of these tissues in saline rats. Treatment with 2.0 and 
0.5 μο, IL-1/day did not affect basal secretory rate of the anterior pituitary or the 
adrenal gland, whereas a tendency to a reduced response of the pituitary and 
adrenal glands to CRF and ACTH, respectively, was observed (Fig. 2). However, 
these differences did not reach statistical significance (Table 1). 
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Fig. 2. Release of (ΙΕ-IR from rat ALs (/eft panels) of pituitaries or of В from adrenal glands (right 
panels) superfused in vitro. ALs and adrenals from rats chronically treated with IL-1 (·) or saline (o) 
in vivo were superfused for 165 min with medium (fractions 1-11). Subsequently, the ALs were super-
fused for 30 min (fractions 12-13) with medium containing CRF (10 9 M), and the adrenals for60 min 
(fractions 12-15) with medium containing 250 pg/ml ACTH. Thereafter, superfusion was continued 
with initial medium. Each value represents the mean ± SE of six rats. *, Statistically significant 
difference from control (P<0.05, by Student's f test). 
Plasma prolactin and catecholamine levels 
To examine whether IL-1-induced ACTH and В release in vivo is due to a stress 
effect of the IL infusion, plasma PRL and catecholamine concentrations, well known 
parameters for stress effects, were determined during continuous IL-1 admini­
stration. Basal plasma PRL levels in saline- and IL-1-treated rats varied between 
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Table 1. Effects of in vivo treatment of rats with IL-1 or saline on basal and CRF/ACTH-induced HE­
IR and В release in vitro. 
Spontaneous release* Stimulation of release (%)" 
ßE-IR (ng) B(ng) ßE-IR tí 
saline 8.49 ± 1.56 757 ± 133 443 ± 69 401 ± 49 
IL-1 (0.5 /ig) 9.69 ± 3.26 536 ± 92 425 ± 80 362 ± 35 
saline 10.59 ± 1.46 745 ± 6 4 463 ± 54 553 ± 75 
IL-1 (2.0 //g) 13.43 ± 1.64 647 ± 78 302 ± 55 434 ± 57 
saline 7.25 ± 0.80 584 ± 2 9 840 ± 166 485 ± 117 
IL-1 (4.0//g) 27.78 ± 6.24c 951 ± 126c 324 ± 73c 186 ± 15' 
" Total content of ßE-IR and В in the first 11 superfusion fractions collected. 
b
 Stimulation of ßE-IR/B release induced by CRF and ACTH, respectively, is expressed as a 
percentage of calculated basal release, as described in the text. 
c
 P<0.05 vs. control. 
1140-2460 pg/ml. Chronic infusion with IL-1 did not significantly affect PRL levels 
(data not shown). Due to sample shortage, plasma E and NE could only be 
measured in the 2.0- and 4.0-pg IL-1/day experiments, with the exception of basal 
levels in the latter (Table 2). One day after the start of the 2.0-//g IL-1/day infusion, 
plasma E and NE levels were significantly higher than those in the saline animals 
(P<0.0005 and P<0.05, respectively). In the 4.0-//g experiment only NE levels were 
significantly higher on day 1 (P<0.0005). The data in Table 2 allow to conclude that 
chronic IL-1 infusion led to a short-lasting increase in circulating catecholamine 
levels on the first day of treatment only. 
Rectal temperature changes (Fig. 3) 
Rectal temperature levels of rats on the morning of the day of implantation of the 
pumps (day 0) varied between 37.1-37.8 С and did not differ significantly between 
the treatment groups. In addition, saline-treated rats maintained a virtually constant 
mean daily rectal temperature throughout the experimental period. Infusion of IL-1 
produced a brisk increase in rectal temperature in rats (Fig. 3). Temperature peaked 
1 day after implantation of pumps infusing IL-1 at rates of 0.5 and 2.0 //g/day, and 
temperature had returned to the values found in saline-infused control rats on day 
3. From then on, values of IL-1-treated rats were not different from those in the 
saline group. The mean maximal increase in temperature induced by the 2.0-¿/g IL-
1/day dose (+1.7 °C) was significantly greater (P<0.05) than that induced by the lower 
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Table 2. Effects of chronic infusion of rats with IL-1 or saline on plasma E and NE concentrations 
(picograms per ml) 
E 
NE 
E 
NE 
saline 
IL-1 2 /ig 
salme 
IL-1 2 #ig 
salme 
IL-1 4 /#g 
salme 
IL-1 4 цд 
0 
34 ± 9 
21 ± 7 
182 ±24 
133 ±12 
1 
9 ± 2 
62 ± 10" 
165 ± 36 
323 ± 51" 
31 ± 13 
51 ± 8 
136 ± 25 
368 ± 17" 
2 
17 ± 5 
34 ± 8 
202 ±36 
260 ±52 
38 ± 9 
67 ±27 
134 ±24 
201 ±36 
Day 
3 
17 ± 1 
28 ± 7 
151 ±13 
97 ±24 
20 ± 4 
19 ± 9 
123 ±18 
54 ±12 
4 
20 ± 5 
20 ±11 
106 ±17 
50 ±23 
19 ± 4 
24 ± 6 
88 ± 4 
97 ±43 
5 
16 ± 1 
19 ± 3 
191 ±70 
121 ±39 
32 ± 6 
28 ± 2 
72 ±18 
96 ±33 
6 
28 ± 14 
19 ± 5 
244 ± 73 
125 ± 55 
16 ± 4 
11 ± 3 
49 ± 14 
76 ± 36 
Analysis of variance from days 2-6 revealed no statistically significant differences for either E 
or NE levels between rats infused with IL-1 or saline (P>0 10) 
" P<0 05 vs control (by Student's f test) 
" P<0 0005 vs control (by Student's f test) 
dose (+0 9 °C) At a dose of 4 0 //g IL-1/day, rectal temperature also peaked at day 
1 (+1 3 °C), and then gradually declined but remained elevated throughout the 
experimental period (analysis of variance, days 2-7, P<0 05) Post-hoc analysis of 
the individual groups in this experiment revealed that rectal temperatures were 
significantly elevated on days 1, 2, 3, 4, and 7 
Suppression of food intake and daily body weight change (Fig 4) 
The effect of administration of IL-1 on food consumption and daily body weight 
change was monitored for 9 days and is shown in Figure 4 There was a transient 
slight reduction in food consumption in saline-treated rats 1 day after implantation 
of the osmotic pumps This decrease is likely due to the anesthesia on the day of 
operation Chronic treatment of rats with 0 5 //g IL-1/day did not significantly affect 
daily food consumption Analysis of repeated measures (days 2-7) revealed a 
depressive effect of the higher doses of IL-1 (2 0 //g IL-1, P<0 05, 4 0 /#g IL-1, 
P<0 0005) on food intake One day after implantation of the pumps, the decrease 
in food intake was maximal [2 0 //g IL-1, -7 2 ± 1 6 g (vs saline, P<0 05), 4 0 //g IL-
1, -8 2 ± 0 9 g, (P<0 0005)] and values remained significantly lower in these animals 
than in their saline-treated controls until day 3 (2 0 //g) and day 5 (4 0 //g), 
respectively There was only a small (0 5 //g IL-1, -3 4 ± 1 8 g, 2 0 //g IL-1, -7 1 ± 
1 9 g) or no (4 0 //g IL-1) decrease in body weight on the first day of saline infusion 
(Fig 4) A statistically significant reduction in body weight gain of animals infused 
87 
Chronic stimulation of the ΗΡΑ axis by IL-1 infusion 
з 
37 
~P^t 
°I 2 3 4 5 6 day 
2 0 мд ILI 
day 
Ö 40 
4 0 ug IL1 
Fig. 3. Effects of chronic administration of IL-1 (0 5, 2 0 and 4 0 pg/day, ·) on rectal temperature 
compared with values during saline infusion (o) Each point represents the mean ± SE of five to 
seven rats By analysis of vanance, days 2-7 0 5 μ$ IL-1/day, P<0 05, 2 0 //g IL-1/day, P>0 10, 4 0 
//g/day, P<0 05) Statistically significant differences *, P<0 05, **, P<0 005, ***, PO0005 (by 
Student's t test) 
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fig. 4. The effect of continuous infusion of IL-1 (·) or saline (o) for 7 days on food intake and daily 
body weight change of rats. The daily body weight change for each rat was calculated by subtraction 
of the daily measured body weights on subsequent days. Statistically significant differences: *, 
P<0.05; **, P<0.005; ***, P<0.0005 (by Student's ( test). 
with 0.5 //g IL-1/day was found on day 1 (-6.3 ± 1.6 g; vs. saline, P<0.05). 
Thereafter, IL-1 treatment did not notably affect the change in body weight of the 
animals compared to saline infusion. Continuous infusion of 2.0 and 4.0 //g IL-1/day 
produced a more distinct weight loss in rats. Weight loss was already maximal on 
the first day of infusion [(2.0 //g IL-1/day, -15.2 ± 1.3 g (vs. saline, PO.0005); 4.0 
pg IL-1/day, -11.8 ± 3.6 g (vs. saline, P<0.005)]. The daily body weight change of 
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IL-1 -treated rats reached approximately initial levels by the third day. Thereafter, the 
rate of body weight increase was virtually the same for both IL-1- and saline-treated 
groups of animals. 
Chronic infusion of IL-1 at a dose of 0.5, 2.0 and 4.0 //g/day into rats had no 
effect on total daily fluid intake (data not shown). 
DISCUSSION 
The present study demonstrates that continuous ip infusion of rats with rather low 
doses of IL-1 (2.0 and 4.0 //g/day) induces a dose-dependent and sustained in­
crease in plasma ACTH levels. IL-1 at a dose of 0.5 //g/day was not active. To­
gether with the increased ACTH content of the anterior pituitary, this effect reflects 
in vivo increased biosynthesis of ACTH induced by IL-1. IL-1, indeed, has been 
reported to increase ACTH biosynthesis in corticotroph cells, possibly at the 
transcriptional stage (28-30). The changes in plasma ACTH levels are parallelled by 
those in B; the maximal effect of the IL-1 treatment occurrs on day 1, and hormone 
levels remain on a less elevated plateau level from days 2-6. On day 7, plasma 
ACTH (2.0-//g experiment) or В (2.0- and 4.0-//g experiments) levels had returned 
to control values, whereas plasma ACTH in the 4.0-//g IL-1 experiment was still 
elevated on this day. The increase in plasma В levels was parallelled by an 
enlargement of the adrenal glands (11-16%), which is a well-known consequence 
of chronic activation of the ΗΡΑ axis. 
There are two other in vivo studies on the effects of chronic treatment of rats with 
IL-1 on the activity of the ΗΡΑ axis (31,32). In those studies ACTH and gluco­
corticoid levels were determined at the end of the treatment period in plasma of 
decapitated rats. In the present study the effects of continuous infusion of rats with 
IL-1 on ACTH and В levels in plasma, collected by means of a chronic jugular 
cannula, were monitored daily for 1 week. In our study, unlike in the above-
mentioned studies, plasma PRL, E and NE levels were followed together with body 
temperature and food intake to detect aspecific secondary stress effects. Gaillard 
et al. (31), showed in a preliminary report that ACTH levels in plasma of rats 
chronically treated for 1 week with 5.0 μα, IL-1/day and decapitated at the end of the 
infusion period had not changed, whereas the mean adrenal weight and pituitary 
ACTH content were significantly increased in IL-1 rats. Naito et al. (32), in a cross-
sectional study, showed that repetitive administration of 1.0 /#g IL-1 twice a day for 
periods up to 10 days induces an increase in the ACTH content of the anterior 
pituitary as early as day 3, whereas the wet weight of the adrenal glands had not 
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increased significantly in rats until day 10 of the treatment period. Plasma ACTH 
concentrations measured 2-4 h after the last bolus injection were significantly higher 
after 1, 3, 7 and 10 days of treatment with IL-1 compared with those in saline-
treated rats. 
In our study chronic treatment of rats with 4.0 //g IL-1/day resulted in an increase 
in the spontaneous in vitro release of BE from the anterior pituitary and of В from 
the adrenals, whereas no significant effects were observed using lower doses of IL-
1. As ACTH and ßE are generally secreted simultaneously (33), one may assume 
that the secretion of ACTH had also increased. Remarkably, 1 day before 
decapitation, plasma levels were only slightly, although significantly (ACTH), or not 
at all (B) elevated compared to values in saline control rats. Thus, although a firm 
increase in the in vitro secretory activity of the pituitary and adrenal glands was 
observed, this was only paralleled by a small increase in plasma levels of ACTH. 
One should bear in mind, however, that in vitro these tissues are devoid of any 
humoral or neuronal regulatory input signal and, thus, might exhibit a secretory 
pattern that is probably distinct from that in vivo. It is difficult to understand why the 
in vitro hormonal responses of the pituitary and adrenal glands of chronically IL-1-
treated rats to CRF and ACTH, respectively, were diminished. A depletion of 
releasable ACTH stores in the pituitary by a higher spontaneous release of ACTH 
is not likely, as pituitary ACTH levels were significantly increased in IL-1 rats. 
Alternatively, it might be that long term activation of the ΗΡΑ axis in vivo leads to 
desensitization of pituitary and adrenal tissues to secretogogues. Continuous 
intracerebroventricular infusion of CRF in rats for 52 days, however, has been 
reported to cause a persistent increase in plasma ACTH levels (34), indicating that 
a significant desensitization to the effect of CRF in the anterior pituitary did not 
occur. Likewise, Rebuffat ef a/. (35) recently showed that chronic treatment of rats 
bearing adrenocortical autotransplants for 2 weeks with ACTH does not affect the 
in vitro responsiveness of these transplants to ACTH. Therefore, the possibility 
should be considered that the reduced sensitivity of the pituitary and adrenal glands 
in vitro resulted from direct effects of IL-1 on these glands. 
From our study it cannot be concluded whether the observed increase in plasma 
hormone levels resulted from direct effects of IL-1 on corticotroph and/or 
adrenocortical cells or via an action on the central nervous system. There is 
compelling evidence indicating that acute administration of IL-1 stimulates plasma 
ACTH and В levels, primarily through an action on the brain. This effect involves, 
directly or through catecholamine (36) or prostaglandin (10, 37) release, the 
secretion of CRF from neurosecretory cells in the hypothalamic paraventricular 
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nucleus (6, 7, 9, 12). Naito et al. (32) showed that chronic administration of IL-1 
induces an increase in the levels of CRF in the hypothalamus, which suggests that 
during these conditions the brain is a site of neuroendocrine action of IL-1. It is still 
a matter of debate, however, whether IL-1 can act directly on corticotroph and 
adrenocortical cells to stimulate hormone release. Although IL-1 does not alter 
ACTH (6, 9, 29) or В (38, 39) release from cultured anterior pituitary or 
adrenocortical cells during short term (<4-8 h) incubation, prolonged (>12 h) 
treatment of these cells with IL-1 is reported to induce a dose-dependent increase 
in ACTH (29, 30, 40, 41) and В (38, 39, 42) secretion. It cannot be excluded, 
therefore, that such a delayed action of IL-1 contributes to enhanced ACTH and В 
levels during long term treatment in vivo. It may be that chronic IL-1 treatment 
activates the ΗΡΑ axis via two mechanisms of action: 1) a rapid indirect effect, 
which increases plasma ACTH and В through activation of the hypothalamic CRF 
neurons, and 2) a delayed effect, which results from a direct stimulation of pituitary 
and/or adrenal cells. 
Catecholamines released from the sympathetic adrenomedullary system upon 
stress may contribute to increased plasma levels of ACTH (43). Rivier et al. (8) 
showed that acute administration of IL-1 to rats induces a dose-related increase in 
plasma levels of ACTH, B, E, and NE. We determined plasma levels of NE and E 
during chronic infusion with IL-1. Two and 4.0 //g IL-1/day induced significant 
increases in plasma NE and/or E concentrations only on the first day of infusion, 
whereas a prolonged increase in plasma ACTH levels was found. Thus, although 
chronic IL-1 administration induces a transient increase in plasma catecholamine 
levels, activation of pituitary adrenergic receptors by circulating catecholamines is 
unlikely to be a mechanism by which IL-1 stimulates sustained ACTH secretion. As 
peripheral administration of IL-1 has been shown to change the activity of central 
noradrenergic neurons (36, 44), and NE and E are secreted locally within the 
median eminence in response to IL-1 (45), we cannot exclude that modulation of the 
central catecholaminergic system contributes to the action of IL-1 on ACTH levels. 
As far as PRL is concerned, it has been demonstrated that acute administration of 
IL-1 to rats does not affect the plasma concentration of this hormone (7, 10, 46). In 
the present study we showed that chronic administration of IL-1 also does not affect 
plasma PRL concentrations. 
Another activity of IL-1 is the capacity to elevate body temperature. The effects 
of IL-1 as an endogenous mediator of endotoxin-induced fever are well documented 
(13). In the present study we confirm that chronic administration of IL-1 induces 
dose-dependent fever in rats. Although the 2.0-//g dose produced a significant 
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higher peak the first day of infusion than the 4.0-//g dose, the latter produced a rise 
in temperature that lasted longer, until the end of the experiment. It is clear from the 
present study and a number of acute studies using subpyrogenic doses of IL-1 (3), 
non-pyrogenic IL-1 analogues (47), and injections of IL-1 in the preoptic area (48) 
that stimulation of ACTH secretion after IL-1 administration does not simply depend 
on fever production. 
The demonstration that IL-1 suppresses food intake and body weight gain is in 
good agreement with previous reports (14, 49-51). No effects of IL-1 were found on 
water intake, indicating that the observed weight loss is not simply caused by altered 
fluid intake. The effect of IL-1 on body weight change was maintained during the first 
2 days of infusion and had been lost on day 3 of treatment. An elegant study by 
Mrosovsky et al. (22) clearly demonstrated that recovery of body weight and food 
intake is not due to failure of the osmotic pumps or hindrance of the release of IL-1 
into the peritoneal cavity, and that osmotic pumps are effectively delivering bioactive 
IL-1 for at least 1 week. These researchers suggested that tolerance to the anorectic 
effect of IL-1 develops within a few days. 
It is not clear whether the anorectic effects of IL-1 are mediated through effects 
on the brain. Intracerebroventricular injections of IL-1 do not affect food intake (15), 
supporting a peripheral site of action. However, IL-1 specifically suppresses 
electrical activity of glucose-sensitive neurons in the hypothalamus (16), and 
intracerebroventricular injection of anti-CRF antiserum before ip IL-1 administration 
reduces feeding suppression (51). This suggests that CRF secretion should at least 
partially be involved in the effect of IL-1 on food intake. 
We have shown that continuous ip infusion of rats with IL-1 induces a dose-
dependent and sustained activation of the pituitary-adrenal axis. On only the first day 
of infusion with 2.0 and 4.0 //g IL-1 were rats ill and plasma catecholamine levels 
elevated. Daily body weight gain was temporarily reduced, but had returned to 
control values on day 3. Therefore, it is not likely that the effects on the ΗΡΑ axis 
can be solely explained by the illness-inducing effects of IL-1, as these effects were 
only observed during the first days, whereas plasma ACTH and В levels were 
elevated throughout the treatment period. It is also not likely that the activation of 
the ΗΡΑ axis is simply secondary to changes in body temperature, as in the 2.0-//g 
IL-1 experiment temperature was only elevated during the first 2 days of treatment, 
whereas plasma ACTH and В levels were persistently increased. 
Acute infection and inflammation are accompanied by a sustained activation of the 
ΗΡΑ axis, an increase in body temperature, and a decrease in food intake. It is 
assumed that IL-1 is, directly or indirectly, an important mediator of these changes. 
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Our study shows that continuous administration of IL-1 to rats elicits enhanced 
activity of the ΗΡΑ axis and that it is unlikely that this stimulation can be simply 
explained by stress effects induced by IL-1 treatment. 
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ABSTRACT 
We have studied mechanisms which could be involved in the sustained 
activation of the hypothalamus-pituitary-adrenal (ΗΡΑ) axis during continuous 
infusion of rats with recombinant human interleukin-1ß (IL-1). First, we in-
vestigated the effects of 3 days of intracerebroventricular (icv) infusion of rats 
with IL-1 on plasma adrenocorticotropin (ACTH) and corticosterone (В) levels. 
Thereafter, changes in plasma ACTH and В levels were followed in rats 
intraperitoneally (ip) infused with IL-1 after immunoneutralization of corticotropin-
releasing hormone (CRH), hypophysectomy (HPX), macrophage depletion using 
CI2MDP-containing liposomes, adrenalectomy (ADX) and dexamethasone (DEX) 
administration, respectively, lev infusion of IL-1, even in doses as low as 0.1 
//g/day, induced significant increases in plasma ACTH and В levels. HPX- and 
ADX-rats died within 18 h after starting the IL-1 infusion (0.5 //g/day). 
Immunoneutralization of CRH significantly decreased and macrophage depletion 
significantly increased the stimulation of the ΗΡΑ axis by IL-1 (4.0 //g/day). 
Administration of high doses of DEX completely abolished the stimulation of the 
ΗΡΑ axis by IL-1 (2.0 //g/day). The present study demonstrates that lower doses 
of IL-1 were able to activate the ΗΡΑ axis when infused icv compared with ip. 
Regarding stimulation of the ΗΡΑ axis by chronic ip infusion of IL-1 the present 
study 1] provides evidence that the CRH system is involved; 2] provides no 
evidence for a direct stimulatory effect of IL-1 on the release of В by the adrenal 
gland which is of sufficient magnitude to resist the stress of chronic ip IL-1 
infusion; 3] shows that endogenous macrophage-derived mediators, induced by 
ip IL-1 infusion, express an overall inhibitory rather than a stimulatory effect on 
the activity of the ΗΡΑ axis; 4] demonstrates that exogenous administration of 
DEX blocks the effect of IL-1, which fits well in the concept of an ¡mmuno-
regulatory feedback between IL-1 and glucocorticoids. 
98 
Chapter 6 
INTRODUCTION 
There is increasing evidence that bidirectional communication between the 
immune system and the neuroendocrine system enables an organism to respond 
appropriately to disturbances of its homeostasis by infection and inflammation 
(1,2). During these circumstances activation of the hypothalamus-pituitary-adrenal 
axis (ΗΡΑ axis) is of utmost importance and interleukin-1 (IL-1), a polypeptide 
mainly produced by macrophages, is thought to be a mediator of this activation 
(1-3). Increased levels of IL-1 have been measured in biological fluids of patients 
suffering from some infectious or inflammatory diseases (4,5), most probably 
indicating chronically elevated IL-1 production during these circumstances. In this 
context we have previously shown that continuous intra-peritoneal (ip) infusion of 
rats with IL-1 (2 and 4 //g/day) for 7 days induced sustained activation of the 
ΗΡΑ axis, an increase in rectal temperature and a decrease in food intake (6). 
In the present study we have extended our earlier observations on chronic IL-1 
infusion in rats and we investigated some potential mechanisms which could be 
involved in the activation of the ΗΡΑ axis during 3 days of continuous infusion 
with IL-1. First, we investigated whether, like chronic ip administration of IL-1, 
chronic central infusion of IL-1 is also able to activate the ΗΡΑ axis. Therefore 
we infused IL-1 for 3 days into the cerebroventricular system in doses lower than 
in our ip infusion studies (6). Secondly, we investigated the involvement of the 
corticotropin-releasing hormone (CRH) system in the activation of the ΗΡΑ axis 
during continuous ip infusion of IL-1 by pretreatment of the rats with a 
monoclonal anti-CRH antibody. Thirdly, we investigated whether peripheral 
mechanisms, such as release of mediators from IL-1-activated macrophages or a 
direct effect of IL-1 on corticosterone (В) production by the adrenal glands, are 
involved in the activation of the ΗΡΑ axis during continuous ip infusion of IL-1. 
Therefore we chronically infused IL-1 ip in macrophage-depleted rats and in 
hypophysectomized rats. Finally, we examined whether high or low concentra­
tions of circulating glucocorticoids are capable of modulating the effects of 
continuously infused IL-1. For this purpose IL-1 was infused ip in rats treated with 
high doses of the synthetic glucocorticoid dexamethasone and in adrenal-
ectomized rats. Plasma ACTH and В levels were measured in blood samples 
which were withdrawn daily by means of a chronic jugular cannula. In addition, 
we examined in all experiments the effects of the different (pre)treatments of rats 
on rectal temperature, body weight change, and on food and fluid intake. 
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MATERIALS AND METHODS 
Materials 
Recombinant human interleukin-1ß (IL-1) was obtained from Glaxo (Glaxo 1MB, 
Geneva, Switzerland). The IL-1 preparation used in experiments 2, 4 and 5 
(batch RNB 18511/14-B) has a specific activity of 2.5x107 U/mg protein and the 
IL-1 preparation used in experiments 1, 3 and 6 (batch RNB 00488/14) has a 
specific activity of 1.2x107 U/mg protein. According to the specifications of the 
supplier, endotoxin contamination was negligible (<1.2 ng/mg protein as detected 
in the limulus amoebocyte lysate assay). Dexamethasone (DEX) was obtained 
from Organon, Oss, The Netherlands. IL-1 was diluted to the desired concentra-
tion in pyrogen-free saline just before use. All chemicals used were of analytical 
grade. 
Animals 
Male Wistar rats (Cpb:WU, 10-12 weeks old, weight 210-230 g in experiments 
2-6 and 260-280 g in experiment 1) were obtained from the local breeding facility. 
The animals were individually housed in Plexiglass cages in an artificially lighted 
room (lights on at 0700 h; lights off at 1900 h). Rats were provided commercial 
rat chow (RMH-TM, Hope Farms, Woerden, The Netherlands) and tap water ad 
libitum. Hypophysectomized and sham-hypophysectomized rats (experiment 3) 
were provided with 5% glucose in their drinking solution whereas adrenal-
ectomized and sham-adrenalectomized rats (experiment 6) were provided with a 
0.9% NaCI drinking solution. 
Experimental procedures 
To diminish the stress by the experimental procedures the animals were 
handled daily by the experimentator, starting 1 week before cannulation. Blood 
was collected from conscious, freely moving rats by means of a chronic jugular 
cannula. Rats were cannulated according to the method described by Steffens 
(7) with some modifications as described earlier (8). For continuous intra-
cerebroventricular (icv) infusion of IL-1, a stainless steel cannula (Brain Infusion 
Kit, Alzet Corp., Palo Alto, CA) was stereotactically implanted in the right cerebral 
ventricle of the brain immediately following jugular cannulation (coordinates 
according to the Paxinos and Watson atlas (9): 8.2 mm anterior from the 
interaural line; 1.4 mm lateral to the antero-posterior suture; 4.5 mm ventral from 
the surface of the skull). Adrenalectomy (ADX) or sham-ADX was performed 
using the dorsal approach under halothane (ICI Pharmaceuticals, Macclesfield, 
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UK)-02-N20 anaesthesia between 0930-1130 h, 4 days after (annulation of the 
jugular vein. Hypophysectomy (HPX) or sham-HPX was done by the para-
pharyngeal approach (10) immediately prior to cannulation of the jugular vein. 
Four to eleven days after jugular vein cannulation rats were equipped with 
osmotic minipumps (1.0 //l/h for 3 days, model 1003D, Alzet Corp., Palo Alto, 
CA), which were loaded with either pyrogen-free saline or saline containing IL-1. 
After loading, the pumps were equilibrated, immersed in saline at 37 °C for 3-4 h 
according to the instructions of the manufacturer. The pumps were implanted 
intraperitoneally (ip) under halothane-02-N20 anaesthesia between 1430 and 
1630 h (experiment 2-6). In experiment 1 the osmotic minipumps were implanted 
subcutaneously in the neck and connected to the icv cannula via a polyethylene 
tube which was also filled with saline or IL-1 solution. 
Protocols 
Experiment 1: In this experiment we studied the effects of continuous icv 
infusion of saline or IL-1. The osmotic minipumps were implanted 10-11 days 
after jugular cannulation and implantation of the icv cannula. Localization of the 
icv cannula was checked at the end of the experiment according to the method of 
Brakkee et al. (11). There were three groups: saline, 0.1 //g IL-1/day and 0.5 //g 
IL-1/day. 
Experiment 2: In this experiment it was studied whether pretreatment of rats 
with a monoclonal antibody directed against rat CRH (PFU 83, batch 9102-A) 
(12) or normal rat IgG (NRI) modulated the effects of continuous ip infusion of 
saline or 4.0 //g IL-1/day. The anti-CRH antibody or NRI were injected 
intravenously (iv) in a volume of 1.0 ml/rat (100 nmol/ml) 2.5-3 h prior to 
implantation of the minipumps (day 0), 7 days after jugular cannulation. There 
were four groups: NRI/saline, NRI/IL-1, anti-CRH/saline and anti-CRH/IL-1. 
Experiment 3: In this experiment the effects of continuous ip infusion of 0.5 //g 
IL-1/day were examined in HPX or sham-HPX rats. (Sham-)HPX was performed 
immediately before jugular cannulation, 4 days prior to implantation of the 
minipumps (day 0). At the end of the experiment rats were decapitated and it 
was checked macroscopically whether the pituitary gland was completely 
removed. There were two groups: sham-HPX/IL-1 and HPX/IL-1. 
Experiment 4: In this experiment the effects of continuous ip infusion of saline 
or 4.0 //g IL-1/day were studied in macrophage-depleted or control rats. Depletion 
of splenic, liver and peritoneal macrophages (13,14) was achieved by injecting 
rats twice (between 0900-1000 h [iv and ip] and 1130-1230 h [iv and ip]) with 
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liposomes encapsulating dichloromethylene diphosphonate (CI2MDP) 2 days prior 
to implantation of the minipumps (day 0). 0.8 ml of a suspension of CI2MDP-
containing liposomes was injected iv via the tail vein and 0.2 ml of this 
suspension was injected ip. Control rats received injections with saline. In this 
experiment minipumps were implanted 7-8 days after jugular cannulation. There 
were four groups: saline/saline, saline/IL-1, CI2MDP-liposomes/saline and 
CI2MDP-liposomes/IL-1. 
Experiment 5: The effects of continuous ip infusion of 2.0 //g IL-1/day in rats 
(pre)treated with DEX or saline were investigated. Rats were injected 
subcutaneously twice a day for 4 days (day -1 up to and including day 2) with 
DEX (600 //g/0.5 ml) or saline (0.5 ml) between 1300-1430 h and 2230-2330 h. 
The osmotic minipumps were implanted 7-8 days after jugular cannulation (day 
0). There were two groups: saline/IL-1 and DEX/IL-1. 
Experiment 6: In this experiment the effects of continuous ip infusion of 0.5 //g 
IL-1/day were examined in ADX or sham-ADX rats. (sham-)ADX was performed 
4 days prior to implantation of the minipumps (day 0), which were implanted 7-8 
days after jugular cannulation. At the end of the experiment rats were decapitated 
and it was checked macroscopically whether both adrenal glands were 
completely removed. There were two groups: sham-ADX/IL-1 and ADX/IL-1. 
In all experiments rectal temperature was measured twice a day between 
0815-0915 h and between 1230-1430 h in conscious hand-held rats by insertion 
of a thermal probe into the rectum. The mean daily rectal temperature for each 
rat was determined by averaging the morning and afternoon rectal temperatures. 
Body weight was measured daily at about the same time (0815-0915 h) and daily 
body weight change was calculated by subtracting the values measured on 
subsequent days. Food and water intake was estimated daily between 0815 and 
0900 h by weighing the residual food pellets and water for individual cages. At 
the end of the experiments 1-5 (day 3) rats were killed by decapitation, the 
adrenals removed, freed of fat and weighed. Total adrenal weight is expressed 
as the summed weight of both adrenals. 
In all experiments, blood was collected once a day (between 1000 and 1200 h) 
from freely moving rats for 5 days, starting one day before implantation of the 
minipumps (day -1 up to and including day 3). Blood samples (1.8 ml) for 
measurement of plasma ACTH and В levels, were collected on ice in tubes 
containing EDTA [45 μ\ of a 10% (wt/vol) solution in saline]. The samples were 
gently shaken and spun for 10 minutes at 1,500x g (4 °C). Plasma was 
separated and red blood cells resuspended in sterile physiological saline (1.3 ml) 
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and returned to each rat. Plasma samples were stored at -20 °C in aliquote of 
250 μ\ to which 60 KIE aprotinine (Bayer AG, Leverkusen, Germany) was added. 
Hormone measurements 
Plasma ACTH and В values were measured by radioimmunoassay as 
described by Sweep et al. (6). 
Statistical analysis 
In the statistical analysis first the areas under the curves (AUC) were 
calculated. These were corrected for pretreatment values by subtracting the 
pretreatment value on day 0 from the treatment values on each day (day 1-3). 
Data of experiment 1 were analyzed for a dose-response relationship by using a 
one-way ANOVA of the AUC and the dose of IL-1. When a significant dose-
response relationship was found, Dunnett's t-test was performed in order to 
determine which dose of IL-1 induced a significant effect compared with the 
effect of saline infusion. In the experiments 2 and 4 the AUC's were analyzed by 
Dunnett's t-test to determine whether pretreatment of rats with anti-CRH 
antiserum or CI2MDP-liposomes significantly affected basal or IL-1 stimulated 
plasma ACTH and В levels. Data of experiment 5 (AUC's) were also analyzed by 
Dunnett's t-test. Differences are considered to be significant if p<0.05. 
RESULTS 
Infusion (both peripheral and central) of IL-1 induced clear signs of physical 
discomfort to the animals, including piloerection and decreased physical activity, 
starting a few hours after implantation of the pumps. This visually observed 
uneasiness gradually diminished during the first day of infusion and disappeared 
on day 2. 
Effects of intracerebroventricular infusion of rats with IL-1 
Figure 1 shows the effects of 3 days continuous icv infusion of saline or IL-1 
(100 and 500 ng IL-1/day) on plasma levels of ACTH and B, rectal temperature, 
daily body weight change and on food and fluid intake. Continuous infusion of 
500 ng IL-1/day induced a significant increase in plasma ACTH levels. Due to 
shortage of plasma, ACTH levels of animals infused with 100 ng IL-1/day could 
not be measured. Intracerebroventricular infusion of IL-1 induced a dose-
dependent increase (p<0.0005) in plasma В levels (AUC) and a dose-dependent 
103 
Mechanisms of chronic ΗΡΑ axis activation by IL-1 
increase (p<0.0005) in total adrenal weight (saline: 44.8 ± 0.7 mg; 100 ng IL-1: 
46.7 ± 1.3 mg; 500 ng IL-1: 57.3 ± 2.2 mg; mean ±SEM of 10-11 rats). Dunnett's 
Fig. 1. Effects of 3 days continuous intracerebroventricular (¡cv) infusion of rats with saline (·) or 
increasing doses of recombinant human IL-1 [100 ng/day ( A ) or 500 ng/day (•)] on plasma ACTH 
(left upper panel) and В (left lower panel) levels, on rectal temperature (middle upper panel), body 
weight change (middle lower panel), and on food (right upper panel) and fluid (right lower panel) 
intake. The icv cannula was implanted stereotactically 10-11 days before implantation of the 
osmotic minipumps. Subcutaneous implantation of the pumps and subsequent connection to the 
icv cannula was performed between 1430-1630 h on day 0 (arrow). Data are expressed as 
means + SEM of 10-14 rats. Inset: corrected areas under the curves (AUC) for days 1-3 of icv 
infusion of saline (орел bars), 100 ng IL-1/day (hatched bars) or 500 ng IL-1/day (closed bars). 
ACTH levels of rats infused with 100 ng IL-1/day are missing due to plasma shortage. *: p<0.05 
vs. saline. 
t-test revealed that the adrenal weight of rats infused with the highest dose of IL-
1 was significantly higher than that of saline-infused rats (p<0.05). Rectal 
temperature increased dose-dependently (p<0.0005) in response to chronic icv 
infusion of IL-1 (AUC). Continuous icv infusion of IL-1 induced a dose-dependent 
decrease in body weight gain and also in food and fluid intake (AUC; all three: 
p<0.0005). 
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Effects of pretreatment with anti-CRH antiserum in rats infused ip with IL-1 or 
saline 
The effects of pretreatment of rats with anti-CRH antiserum on the earlier 
mentioned parameters in rats infused ip with IL-1 (4.0 //g/day) or saline are 
shown in Fig. 2. Pretreatment of rats with the anti-CRH antibody induced a small, 
though not significant decrease in plasma В levels compared with NRI pretreat­
ment. Continuous infusion of 4.0 //g IL-1/day induced a significant increase in 
plasma ACTH and В levels compared with infusion of saline. The IL-1-induced in­
crease in plasma ACTH levels was significantly reduced by pretreatment of the 
rats with anti-CRH antiserum (p<0.05), whereas the IL-1-induced plasma В res­
ponse was slightly, but not significantly diminished. The IL-1-induced increase in 
total adrenal weight was not significantly decreased by pretreatment of the rats 
Fig. 2. Effects of 3 days chronic intraperitoneal (ip) infusion of saline or 4.0 //g IL-1/day following 
pretreatment of rats with an anti-CRH antiserum or normal rat IgG [NRI/saline (o), NRI/IL-1 (·), 
anti-CRH/saline (•), anti-CRH/IL-1 (•)] on plasma ACTH (/eft upper panel) and В (left lower 
panel) levels, on rectal temperature (middle upper panel), body weight change (middle lower 
panel), and on food (right upper panel) and fluid (right lower panel) intake. The anti-CRH 
antiserum and NRI (100 nmol/rat) were injected intravenously via the jugular cannula on day 0, 
2.5-3 h before ip implantation of the osmotic minipumps (arrow). Each point represents the mean 
+ SEM of 8 rats. 
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with the anti-CRH antibody (55.3 ± 5.4 mg vs. 52.7 ± 4.4 mg, NRI/IL-1 vs. anti-
CRH/IL-1, NS). Rectal temperature was significantly increased by IL-1 compared 
with saline infusion (p<0.05). Treatment with anti-CRH antiserum prior to saline 
infusion had no significant effect on rectal temperature nor did treatment with 
anti-CRH antiserum significantly affect the IL-1-induced increase in rectal 
temperature. Continuous infusion of 4.0 μ^ IL-1/day for 3 days significantly 
decreased body weight gain, and food and fluid intake compared with values in 
saline-infused animals. Treatment of rats with anti-CRH antiserum prior to saline 
infusion had no effect on these three parameters nor did it significantly affect the 
IL-1-induced decreases in body weight gain and food intake. The IL-1-induced 
decrease in fluid intake, however, was significantly larger in the group of animals 
pretreated with anti-CRH antiserum compared with that of animals pretreated 
with NRI (p<0.05). 
Effects of macrophage-depletion or hypophysectomy (HPX) in rats infused ip with 
IL-1 or saline 
The effects of macrophage-depletion by pretreatment of rats with liposomes 
containing CI2MDP on the earlier mentioned parameters in rats infused ip with IL-
1 (4.0 //g/day) or saline are shown in Fig. 3. Pretreatment of rats with CI2MDP-
liposomes had no significant effect on plasma ACTH and В levels and on total 
adrenal weight compared with values of control rats. Continuous ip infusion of 4.0 
//g IL-1/day induced a significant increase in plasma ACTH and В levels 
compared with saline infusion. Pretreatment of rats with CI2MDP-liposomes 
significantly raised the IL-1-induced increase in plasma ACTH and В levels (both 
p<0.05). Pretreatment of the rats with CI2MDP-liposomes induced a slight, 
although not significant, increase of the IL-1-induced increase in total adrenal 
weight (55.8 ± 1.3 mg vs. 63.4 ± 2.7 mg, saline/IL-1 vs. CI2MDP-liposomes/IL-1, 
NS). IL-1 infusion induced a significant increase in rectal temperature. 
Pretreatment with CI2MDP-liposomes slightly, though not significantly, increased 
rectal temperature of saline-infused rats, and it had no significant effect on the IL-
1-induced increase in rectal temperature. Continuous infusion of 4.0 //g IL-1/day 
significantly decreased body weight gain, and food and fluid intake as compared 
to control values. Treatment of rats with CI2MDP-liposomes prior to saline 
infusion slightly, though not significantly, decreased these three parameters, and 
it also did not significantly affect the IL-1-induced decrease in body weight gain, 
food and fluid intake. 
All of the HPX rats infused with 0.5 //g IL-1/day had died within 18 h after 
pump implantation, whereas sham-operated rats did not die during IL-1 infusion. 
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Fig. 3. Effects of continuous intraperitoneal (ip) administration of saline or 4 0 //g IL-1/day for 3 
days in rats which were treated with saline or with liposomes containing CI2MDP, to induce 
depletion of macrophages [saline/saline (o), saline/IL-1 (·), CI2MDP-liposomes/salme (o), CI2MDP-
liposomes/IL-1 (•)], on plasma ACTH (left upper panel) and В {left lower panet) levels, on rectal 
temperature [middle upper panel), body weight change (middle lower panel), and on food (right 
upper panel) and fluid [right lower panel) intake CI2MDP-liposome suspension or saline was 
administered intravenously (0 8 ml via the tail vein) and intraperitoneal^ (0 2 ml) twice (between 
0900-1000 h and between 1130-1230 h), 2 days prior to ip implantation of the osmotic mimpumps 
(day 0, arrow) Data are expressed as means + SEM of 5-8 rats 
Effects of dexamethasone or adrenalectomy (ADX) in rats infused ip with IL-1 or 
saline 
Figure 4 shows the effects of treatment of rats with DEX on the earlier 
mentioned parameters in rats infused with IL-1 (2.0 //g/day) or saline. Daily 
treatment of rats with DEX completely abolished the effects of IL-1 on plasma 
ACTH and В levels (ACTH p<0.001, B: p<0.0005) and on total adrenal weight 
(57.5 ± 1 5 mg vs. 25.1 ± 0.6 mg, salme/IL-1 vs. DEX/IL-1, p<0.0005). The IL-1-
induced decrease in food and fluid intake were significantly reduced by daily DEX 
treatment (food: p<0.01, fluid: p<0 05). 
All of the ADX rats infused with 0.5 μ§ IL-1/day had died within 18 h after 
pump implantation, whereas none of the sham-operated rats died during IL-1 
infusion. 
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F/g. 4. Effects of chronic intraperitoneal (ip) infusion of 2.0 μα. IL-1/day in rats receiving saline or 
dexamethasone (DEX) [saline/IL-1 (o), DEX/IL-1 (·)] on plasma ACTH (ten upper pane!) and В 
(/eft lower pane!) levels, on rectal temperature (middle upper panel), body weight change (middle 
lower panel), and on food (nght upper panel) and fluid (right lower pane!) intake. Saline or DEX 
(600 //g/injection/rat) was administered subcutaneously twice a day (between 1300-1430 h and 
between 2230-2330 h) from day -1 up to and including day 2 The osmotic minipumps were 
implanted on day 0 (arrow). Each point represents the mean + SEM of 7-8 rats. 
DISCUSSION 
The present study shows that continuous icv infusion of low doses of IL-1 in 
rats stimulates the activity of the ΗΡΑ axis, increases rectal temperature and 
decreases food and fluid intake. Our results are complementary to those in other 
recent studies, showing that continuous icv infusion of IL-1, in doses as used in 
our study, decreases the activity of the hypothalamus-pituitary-gonadal axis 
(15,16) and decreases thyrotropin-releasing hormone gene expression (17). It is 
of interest that the doses of IL-1 which were effective in the present study (100 
and 500 ng IL-1/day, icv) were considerably lower than the dose of IL-1 which 
was needed for stimulation of the pituitary-adrenal axis in our previous study 
(2000 ng IL-1/day), in which the cytokine was given by continuous ip infusion (6). 
These observations suggest that the site of action of IL-1 during chronic icv 
infusion is located in the central nervous system. 
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Pretreatment of animals with the anti-CRH antibody significantly reduced the 
plasma ACTH response to IL-1 infusion, indicating that the CRH system plays an 
intermediate role in the stimulation of the ΗΡΑ axis by chronic ip IL-1 
administration. This agrees with data of other researchers who did demonstrate 
such a role for CRH in the IL-1-induced stimulation of the ΗΡΑ axis in short-term 
experiments (18-20). It has to be noted, however, that the plasma ACTH 
response to chronic IL-1 administration was not completely abolished by 
pretreatment with the anti-CRH antiserum. There are a number of possible 
explanations for this observation. First, it may be that the amount of the anti-CRH 
antibody we used was insufficient to fully neutralize all of the secreted CRH. 
Secondly, factors structurally distinct from CRH might be involved in the 
activation of the ΗΡΑ axis by chronic IL-1 infusion. Chronic stress has been 
shown to increase vasopressin immunoreactivity in CRH axon terminals in the 
external zone of the median eminence (21,22) and acute administration of IL-1 in 
vivo has also been shown to induce the release of vasopressin in addition to that 
of CRH (23,24). Thus besides CRH, other factors might be involved in the 
activation of the ΗΡΑ axis following continuous IL-1 infusion. Thirdly, longtenm IL-
1 administration might directly stimulate the pituitary and/or adrenal gland to 
release ACTH and В respectively. Indeed, in vitro IL-1 has been shown to induce 
ACTH release from mouse anterior pituitary tumor cells (25,26) and В release 
from isolated rat adrenal cells (27,28) after a prolonged incubation period (24 h). 
To investigate whether IL-1 during chronic administration is also capable of 
directly stimulating В secretion by the adrenal gland, we infused IL-1 in 
hypophysectomized rats. However, IL-1 infusion in doses as low as 0.5 //g/day in 
these rats was lethal within 18 h, most probably because these rats cannot 
augment pituitary-adrenal activity during IL-1 infusion. This observation 
underscores that in hypophysectomized rats IL-1, at least in the first day of 
infusion, cannot stimulate the adrenal gland directly to a degree sufficient to cope 
with the stress of chronic IL-1 administration. 
It is known that endotoxin and IL-1 can induce the production of IL-1 and tumor 
necrosis factor-σ (TNF) (29,30) and that macrophages are the main source of 
endogenous production of these cytokines (31). Therefore, exogenously 
administered endotoxin or IL-1 might stimulate macrophages to release IL-1 and 
TNF, which in turn could further stimulate the activity of the ΗΡΑ axis. Derijk and 
co-workers (32) have indeed demonstrated that in rats pretreated with CI2MDP-
containing liposomes the plasma ACTH and В response to subpyrogenic doses 
of endotoxin was completely prevented. Treatment with CI2MDP-containing 
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liposomes eliminates macrophages as the CI2MDP-containing liposomes are 
selectively ingested by macrophages resulting in the death of the macrophages 
by the toxic effect of CI2MDP (13). 
Surprisingly, the effect of IL-1 on the activity of the ΗΡΑ axis was significantly 
enhanced instead of decreased in macrophage-depleted rats compared with 
control rats. It is known that macrophages can also produce cytokines which 
inhibit the ΗΡΑ axis, such as p-interferon (33), or which can antagonize IL-1 
activity, such as IL-1 receptor antagonist (34). We speculate that decreased 
production of these peptides accounts for the observed enhancement of the 
stimulation of the ΗΡΑ axis by IL-1 in macrophage-depleted rats in our study. In 
contrast with the additive effect on IL-1-induced activation of the ΗΡΑ axis, 
macrophage depletion had no effect on the increase in rectal temperature and on 
the anorexia induced by IL-1, implying that macrophage-derived products are 
probably not involved in these effects. A similar discrepancy was observed in the 
study using the anti-CRH antiserum: immunoneutralization of CRH decreased the 
IL-1-induced activation of the ΗΡΑ axis whereas it did not significantly alter the 
effect of ip infused IL-1 on rectal temperature and food intake. 
We investigated whether high or low concentrations of circulating 
glucocorticoids are capable of modulating the effects induced by chronic ip IL-1 
infusion. The present study shows that continuous IL-1 infusion, in a dose as low 
as 0.5 //g/day, in adrenalectomized rats was lethal within 18 h. This observation 
suggests that an intact function of the adrenal glands is needed to survive the 
stress induced by IL-1 infusion. The present study also shows that daily 
administration of high doses of dexamethasone completely abolished the 
activation of the ΗΡΑ axis by ip infusion of 2.0 //g IL-1/day. This observation fits 
well in the concept of immunoregulatory feedback between IL-1 and 
glucocorticoid hormones, in which glucocorticoids block the production and action 
of IL-1 thereby protecting the animal from a harmful overshoot of defense 
reactions (3,35). 
Infection and inflammation are often accompanied by a sustained activation of 
the ΗΡΑ axis and by fever and anorexia. There is compelling evidence that IL-1 
is an important trigger for the activation of the ΗΡΑ axis under these conditions. 
Our study demonstrates that lower doses of IL-1 were able to activate the ΗΡΑ 
axis when infused icv compared with ip. Furthermore, the present study provides 
evidence that the CRH system is involved in the activation of the ΗΡΑ axis by 
continuous ip infusion of IL-1. However, other mediators structurally distinct from 
CRH, such as vasopressin, might also be involved. Our study provides no 
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evidence for a direct stimulatory effect of IL-1 on the release of corticosterone by 
the adrenal gland which is of sufficient magnitude to resist the stress of chronic ip 
IL-1 administration. It seems that endogenous macrophage-derived mediators, 
induced by ip IL-1 administration, express an inhibitory rather than a stimulatory 
effect on the activity of the ΗΡΑ axis. Finally, exogenous administration of 
glucocorticosteroids block the effect of IL-1 on the ΗΡΑ axis. Thus, both 
macrophage-derived products as well as glucocorticoids exert an inhibitory effect 
on the IL-1 induced activation of the ΗΡΑ axis, thereby preventing excessive 
stimulation of this axis by IL-1, which would result in a dangerous state of 
suppression of the immune system. 
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ABSTRACT 
We investigated the effects of separate and combined intraperitoneal admini-
stration for 3 days of recombinant human ¡nterleukin-1ß (IL-1) and recombinant 
human tumor necrosis factor-σ (TNF) on plasma adrenocorticotropic hormone 
(ACTH) and corticosterone (В) levels, adrenal weight, food intake and rectal 
temperature. Rats were equipped with a jugular cannula for daily blood sampling 
and with an intraperitoneally implanted Alzet osmotic minipump loaded with either 
saline, IL-1 (2.0 //g/day), TNF (0.2, 2.0 or 10.0 //g/day) or with IL-1 in com­
bination with TNF. Plasma ACTH and В levels and adrenal weight were signifi­
cantly increased, in a dose-dependent way, by simultaneous infusion of IL-1 and 
TNF but not by administration of either cytokine alone. Chronic administration of 
IL-1 alone induced a significant decrease in food intake and a significant 
elevation of rectal temperature, whereas infusion of only the highest dose of TNF 
significantly elevated rectal temperature. Coinfusion of IL-1 and TNF induced 
both effects in a dose-dependent and synergistic way. Our data show that 
simultaneous infusion of IL-1 and TNF in rats has a synergistic effect on the 
activity of the pituitary-adrenal axis as well as on food intake and rectal 
temperature. The existence of two pathways, which act synergistically, may in­
crease the sensitivity of the host to respond to subtle inflammatory stimuli. 
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INTRODUCTION 
Activation of the immune system during bacterial infections is accompanied by 
stimulation of the hypothalamic-pituitary-adrenal axis (ΗΡΑ axis), and there is 
increasing evidence that bacterial endotoxin is responsible for the stimulation of 
both the immune system and the ΗΡΑ axis during such conditions (1, 20). The 
activation of the ΗΡΑ axis by endotoxin is probably mediated by proinflammatory 
cytokines, especially interleukin-1 (IL-1; see Ref. 21) and tumor necrosis factor 
(TNF; see Ref. 19). It is thought that these cytokines are also important 
mediators of other biological effects of endotoxin including the induction of 
anorexia, fever and the acute phase response. Despite these similarities, IL-1 
and TNF share no structural homology and recognize different cellular receptors. 
However, both cytokines are capable of inducing each other's synthesis (6, 12), 
and many cells express both IL-1 and TNF receptors, which may contribute to 
their overlapping biological activities (3). 
It has been shown that acute administration of IL-1 (10, 22, 30) or TNF (2, 24, 
30) activates the ΗΡΑ axis in mice and rats, as manifested by increased levels of 
adrenocorticotropic hormone (ACTH) and corticosterone (В). Del Rey and 
Besedovsky (4) demonstrated that IL-1 is more potent than TNF in increasing 
plasma levels of ACTH and В in rats when administered acutely. There are only 
a few studies on the effects of chronic administration of IL-1 and TNF on the 
activity of the ΗΡΑ axis (8, 16). In the studies from our laboratory it was shown 
that continuous infusion of IL-1 (2 and 4 /yg/day, for 7 days) induced a sustained 
and dose-dependent stimulation of the ΗΡΑ axis throughout the infusion period 
(28), whereas continuous administration of TNF in a dose of 4 //g/day for 7 days 
did not affect plasma В levels (30). 
Many types of cells express receptors for IL-1 and TNF, but both types of 
receptors have different mechanisms for signal transduction. Therefore the 
effects of these two cytokines may be additive or synergistic (3). Waage and 
Espevik (32) demonstrated that IL-1 potentiates the lethal effect of TNF in mice, 
and synergistic effects of IL-1 and TNF on muscle proteolysis (7) and on plasma 
ACTH levels (19) were found after coadministration of these cytokines to rats. 
Okusawa et al. (17) demonstrated in rabbits that the combination of IL-1 and TNF 
was more potent in inducing hemodynamic ind hematological changes typical of 
septic shock than either agent alone. In co trast, Gelin et al. (9) failed to show 
synergism between IL-1 and TNF in stimulating the ΗΡΑ axis. Moreover, Long et 
al. (13) found that, although both IL-1 and TNF are capable of causing fever 
when injected into rats, administration of TNF attenuates fever due to injection of 
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IL-1, suggesting antagonism between IL-1 and TNF. Very recently, Mehta et al. 
(15) showed that low doses of IL-1 and TNF individually stimulate insulin release 
but in combination cause suppression of insulin release by rat pancreatic ß-cells 
in vitro. 
In the light of these controversial data, we investigated in the present study the 
effects of 3 days continuous infusion of IL-1 and TNF, separately or in 
combination, on the activity of the ΗΡΑ axis. Plasma ACTH and В levels were 
measured daily. In addition, we investigated the effects of the treatments on 
adrenal weight, daily body weight change, food and fluid intake, and rectal 
temperature. We show that IL-1 and TNF, when infused simultaneously into rats, 
synergize to stimulate the ΗΡΑ axis and to induce dose-dependent changes in 
body weight, food consumption, and rectal temperature. 
MATERIALS AND METHODS 
Materials 
Recombinant human (rh) IL-1B was kindly provided by Dr. R.C. Newton (Du 
Pont Pharmaceuticals, Wilmington, DE). The preparation was supplied in sterile 
Dulbecco's phosphate buffered saline and endotoxin contamination was 
negligible (<1 endotoxin unit lipopolysaccharides/mg IL-1). 
Human TNF-σ produced by recombinant DNA technology in Escherichia coli 
was obtained from Genentech (San Francisco, CA), through the courtesy of Dr. 
G. Adolf, Ernst-Boehringer-lnstitut für Arzneimittelforschung (Vienna, Austria). The 
specific activity of the preparation was 6x107 U/mg protein on murine L-M cells. 
The preparation (lot К 9011AX) was supplied in 10 mM sodium phosphate and 
200 mM sodium chloride (pH 7). According to the specifications of the suppliers, 
endotoxin contamination was negligible (<1.2 ng/mg protein, as detected in the 
limulus amoebocyte lysate assay). 
Both IL-1 and TNF were diluted to the desired concentration in sterile pyrogen-
free saline just before use. All chemicals used were of analytical grade. 
Animals 
Male albino Wistar rats (Cpb:WU, 10-12 wk old, 200-220 g) were obtained 
from the local breeding facility. The animals were individually housed in Plexi­
glass cages in an artificially lighted room (lights on at 0700; lights off at 1900). 
Rats were provided commercial rat chow (RMH-TM; Hope Farms, Woerden, The 
Netherlands) and tap water ad libitum. Room temperature was 23.1 + 0.2 eC. 
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Experimental procedures 
To diminish the stress by the experimental procedures, the animals were 
handled daily by the experimentator, starting 1 wk before cannulation. Blood was 
collected from freely moving rats by means of a chronic cannula. Rats were 
cannulated according to the method described by Steffens (26), with some minor 
modifications, as described earlier (29). Briefly, under Hypnorm (0.5 ml/kg body 
wt im; 10 mg/ml fluanisone and 0.315 mg/ml phentanyl citrate; Janssen 
Pharmaceutica, Tilburg, The Netherlands)-Dormicum (1.0 ml/kg body wt ip; 5.0 
mg/ml midazolam hydrochloride; Hoffmann-La Roche, Mijdrecht, The Nether-
lands)-atropine (0.025 mg/rat sc; Pharmachemie, Haarlem, The Netherlands) 
anesthesia, a Silastic cannula (ID 0.5 mm; OD 0.94 mm; Dow Corning, Midland, 
Ml) was inserted into the right external jugular vein and passed down to the 
atrium. The distal end of the cannula was tunneled subcutaneously and 
exteriorized through a stab wound on the skin of the head, where it was 
connected to a hooked stainless steel tube. This assembly was anchored to the 
skull with three stainless steel screws and acrylic cement. During cannulation, 
rats were continuously exposed to a gas flow of 02-N20 (each 500 ml/min). To 
keep the cannula patent, it was filled with a 0.9% NaCI solution containing 
heparin (500 lU/ml; Organon Teknika, Boxtel, The Netherlands) and polyvinyl­
pyrrolidone (1 g/ml; Merck, Darmstadt, Germany). 
Seven or eight days after cannulation, rats were equipped with intraperitoneally 
implanted osmotic minipumps (1//l/h for 3 days, model 1003D; Alzet, Palo Alto, 
CA), which were loaded with either sterile pyrogen-free physiological saline or 
saline containing IL-1, TNF or IL-1 in combination with TNF. After loading, the 
pumps were equilibrated, immersed in saline at 37°C for 3-4 h according to the 
instructions of the manufacturer. The pumps were implanted intraperitoneally 
under halothane (ICI Pharmaceuticals, Macclesfield, UK)-02-N20 anesthesia 
between 1430 and 1630. The indwelling cannula and the osmotic minipumps 
were tolerated well by the animals, with no signs of discomfort or infection. 
Protocol 
A total of eight groups of rats was continuously infused with saline, IL-1, TNF, 
or with a combination of IL-1 and TNF. One group of rats was infused with 2.0 μα, 
IL-1/day (1 //g IL-1 * 57 pmol IL-1). TNF was infused at a rate of 0.2, 2.0, or 
10.0 //g/day. Three other groups were infused with IL-1 (2.0 //g/day) in 
combination with TNF at a dose of 0.2, 2.0, or 10.0 //g/day (1 //g TNF » 57 pmol 
TNF). A control group of rats received osmotic pumps filled with 0.9% (wt/vol) 
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NaCI solution. Each group consisted of 6-9 rats. 
Food and water intake was estimated daily between 0815 and 0900 by 
weighing the residual food pellets and water for individual cages. Body weight 
was measured daily at about the same time (0815-0900), and daily body weight 
changes were calculated by subtracting the values measured on subsequent 
days. Body temperature was measured two times a day between 0815 and 0900 
and between 1230-1430 in conscious hand-held rats by insertion of a thermal 
probe into the rectum. The probe was connected to a digital temperature monitor 
(Digital DT100, Elbatron, Kerkdriel, The Netherlands). The mean daily rectal 
temperature for each rat was determined by averaging the morning and afternoon 
rectal temperatures. At the end of the experiment (day 3) rats were killed by 
decapitation, and the adrenals were removed, freed of fat, and weighed. 
Blood sampling 
Blood was collected once a day from freely moving rats for 5 days starting 1 
day before implantation of the minipumps (day -1 up to and including day 3). 
Because of the circadian rhythm in hormone release, blood was withdrawn from 
the animals every day at about the same time (between 1000 and 1200). Blood 
samples (1.8 ml) for measurement of plasma levels of ACTH and В were col­
lected on ice in prechilled tubes containing EDTA [45 μ\ of a 10% (wt/vol) EDTA 
solution in saline]. The samples were gently shaken and spun for 10 min at 1,500 
g (4°C). Plasma was separated, and red blood cells were resuspended in sterile 
physiological saline (1.3 ml) and returned to each rat. Plasma samples were 
stored at -20°C, in aliquots of 250 μ\ to which 60 kallikrein inhibitory units 
aprotinin (Bayer, Leverkusen, Germany) was added. 
Hormone measurements 
Plasma ACTH and В values were measured by radioimmunoassay, as 
described by Sweep et al. (28). In the group of rats infused with saline alone and 
in the group infused with IL-1 in combination with 0.2 //g TNF/day, one rat had to 
be excluded with respect to hormone measurements because of blood clotting in 
the jugular cannula. 
Statistical analysis 
All data are presented as the mean ± SE of 6-9 rats/group. The effect of 
infusion of IL-1 in combination with TNF is considered to be synergistic if the 
effect of combined IL-1 and TNF infusion is significantly larger than the sum of 
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the effects of IL-1 and TNF infusion separately. In the statistical analysis, first the 
areas under the curves (AUC) were calculated. These were corrected for pre-
treatment values (day -1 and/or 0) by subtracting the mean of the pretreatment 
values from treatment values on each day (days 1-3). As it appears that the 
effect of TNF on the various parameters is directly proportional to the logarithm of 
the dose, we used the following linear regression model: 
AUC= σ0 + ^(IL-1) + a2 (log TNF) + a3 (IL-1) χ log TNF 
Here a0 is an estimate of the effect of chronic administration of saline, σ, is an 
estimate of the effect of continuous infusion of IL-1 alone, a2 and a2 + a3 are 
estimates of the dose-response relationship for the effects of chronic infusion of 
TNF alone (a2) or TNF in combination with IL-1 (a2 + σ3). So, the coefficient a3 of 
the interaction term is an estimate for the synergism between IL-1 and TNF. Thus 
testing for a significant dose-response relationship and/or synergism implies 
testing whether the corresponding o's are equal to zero. In case a significant 
dose-response relationship was found, Dunnett's f-test was performed in order to 
identify which dose of TNF induced a significant change in response compared 
with the TNF-free treatment group. Differences are considered as statistically 
significant if Ρ was less than 0.05. 
RESULTS 
Effects on plasma ACTH, В and adrenal weight 
Figure 1 shows the effects of 3 days of continuous infusion in rats with saline, 
IL-1 alone (2.0 //g/day), TNF alone (0.2, 2.0, or 10.0 //g/day), or 2.0 pg IL-1 in 
combination with 0.2, 2.0 or 10.0 pg TNF/day on plasma levels of ACTH and B. 
The present experimental conditions (implantation of the minipump, infusion and 
blood collection procedures), as such, virtually did not alter pituitary-adrenal 
activity, as demonstrated by stable plasma В levels in animals implanted with 
saline-filled osmotic pumps. 
Preinfusion levels of ACTH and В showed no marked differences between the 
various groups. ACTH preinfusion values varied between 89 and 137 pg/ml, and 
preinfusion values of В varied between 24 and 64 nmol/l. Infusion of 2.0 μ$ IL-
1/day caused a small increase in plasma ACTH levels on the 1st day of infusion 
(+33 ± 14 pg/ml vs. day 0). Administration of 0.2, 2.0, or 10.0 //g TNF/day did not 
significantly affect plasma ACTH levels. Infusion of IL-1 in combination with 
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Fig. 1. Effects of 3 days continuous infusion in rats with saline, ¡nterleukin-1 (IL-1), or increasing 
doses of tumor necrosis factor (TNF) [/eft saline (o), 2.0 /;g IL-1/day (·), 0.2 //g TNF/day (•), 2.0 
//g TNF/day (Δ), or 10.0 //g TNF/day (v)] or IL-1 either alone or in combination with different 
doses of TNF [right IL-1 (·), IL-1 with 0.2 f/g TNF/day (•), IL-1 with 2.0 //g TNF/day (A), or IL-1 
with 10.0 //g TNF/day (•)] on plasma ACTH (fop) and corticosterone (В; bottom) levels. Blood 
samples were taken daily between 1000 and 1200. Osmotic minipumps were implanted between 
1430 and 1630 on day 0 (arrow). Data are expressed as the mean + SE of 6-9 rats. Inset 
corrected areas under curves (AUC) for days 1-3. Left (separate IL-1 and TNF infusion): saline 
(a), 2.0 fiq ILI/day (b), 0.2 μg TNF/day (c), 2.0 ^ TNF/day (d), or 10.0 //g TNF/day (e). Right 
(combined IL-1 and TNF infusion): IL-1 (b), IL-1 and 0.2 j/g TNF/day (f), IL-1 and 2.0 j/g TNF/day 
(g), or IL-1 and 10.0 //g TNF/day (h). ACTH levels (including AUC) of saline-infused animals are 
missing due to plasma shortage. *P<0.05 vs. IL-1 alone. 
increasing doses of TNF (0.2, 2.0, or 10.0 //g/day) induced a dose-dependent 
increase in plasma ACTH levels compared with ACTH levels in animals infused 
with IL-1 alone, and a significant dose-response relationship was found with 
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respect to the responses of plasma ACTH (AUC) in the four groups (P<0.005). 
The effect of combined IL-1 and TNF infusion was synergistic (P<0.05) compared 
with the effects of separate IL-1 and TNF infusions. The highest ACTH levels 
were found on day 1 of infusion (IL-1: 132 ± 2 1 pg/ml; IL-1 and 0.2 //g TNF/day: 
187 ± 12 pg/ml; IL-1 and 2.0 //g TNF/day: 202 ± 29 pg/ml; IL-1 and 10.0 //g 
TNF/day: 204 ± 21 pg/ml). Plasma ACTH levels declined over days 2 and 3. Due 
to plasma shortage, plasma ACTH levels of the saline-treated animals could not 
be measured. 
Plasma В levels were not significantly affected in rats continuously infused with 
either IL-1 alone or TNF alone (AUC, days 1-3) compared with levels in saline-
treated rats. Only a small increase in plasma В levels on day 1 of treatment with 
2.0 //g IL-1/day or with 10.0 //g TNF/day, compared with saline-treated animals, 
was observed (IL-1: 130 ± 52 nmol/l; TNF: 104 ± 49 nmol/l; saline: 31 ± 5 
nmol/l). Infusion of IL-1 in combination with 0.2, 2.0, or 10.0 //g TNF/day induced 
a dose-dependent increase in plasma В levels compared with the levels in 
animals infused with IL-1 alone; a significant dose-response relationship was 
found with respect to the responses of plasma В (AUC) in the four groups 
(P<0.0005). The effect of combined IL-1 and TNF infusion was synergistic 
(P<0.0005) compared with the effects of separate IL-1 and TNF infusions. The 
highest В levels were measured on day 1 of infusion (IL-1: 130 ± 52 nmol/l; IL-1 
and 0.2 //g TNF/day: 262 ± 52 nmol/l; IL-1 and 2.0 /#g TNF/day: 355 ± 48 птоІЛ; 
IL-1 and 10.0 //g TNF/day: 415 ± 48 nmol/l). Like the plasma ACTH levels, 
plasma В levels decreased over days 2 and 3. 
Total adrenal weight (summed weight of both adrenal glands) of rats treated 
for 3 days with 2.0 μ^ IL-1 /day or with increasing doses of TNF alone did not 
significantly differ from total adrenal weight of rats infused with saline (40.1 ±1.5 
mg). Chronic infusion of rats with IL-1 in combination with 0.2, 2.0, or 10 //g 
TNF/day induced a dose-dependent increase in total adrenal weight compared 
with that of rats treated with IL-1 alone. A significant dose-response relationship 
(P<0.0005) was found with respect to the effects on total adrenal weight in the 
four groups (IL-1: 39.1 ± 1 . 2 mg; IL-1 and 0.2 /ig TNF/day: 44.9 ± 1 . 4 mg, 
P<0.05 vs. IL-1; IL-1 and 2.0 /yg TNF/day: 45.2 ± 1.1 mg, P<0.05 vs. IL-1; IL-1 
and 10.0 μg TNF/day: 50.8 ± 1.9 mg, P<0.05 vs. IL-1). The effect of combined 
IL-1 and TNF infusion was synergistic (P<0.0005) compared with the effects of 
separate IL-1 and TNF infusions. 
123 
Synergism between IL-1 and TNF 
0 
•-10 
20 
MUC 
^ C u 
І^  
day 
day day 
day 
Fig. 2. The effects of 3 days continuous administration of saline, IL-1, or different doses of TNF 
[teff· saline (о), 2 0 /ig IL-1/day (·), 0 2 //g TNF/day (•), 2 0 //g TNF/day (Δ), or 10 0 //g 
TNF/day (v)] or IL-1 either alone or in combination with increasing doses of TNF [right IL-1 (·), 
IL-1 with 0 2 //g TNF/day (•), IL-1 with 2 0 //g TNF/day (A), or IL-1 with 10 0 μς TNF/day (τ)] on 
food and fluid intake (top and middle) and on daily body weight change {bottom) Food and fluid 
intake was estimated by weighing the residual food pellets and water for individual cages Daily 
body weight change for each rat was calculated by subtraction of the daily measured body 
weights (between 0815 and 0900) on subsequent days Data are expressed as the mean + SE of 
6-9 rats Inset corrected AUC for days 1-3 Left (separate IL-1 and TNF infusion) saline (a), 2 0 
pg IL-1/day (b), 0 2 /;g TNF/day (c), 2 0 j/g TNF/day (d), or 10 0 //g TNF/day (e) Right (combined 
IL-1 and TNF infusion) IL-1 (b), IL-1 and 0 2 //g TNF/day (f), IL-1 and 2 0 //g TNF/day (g), or IL-1 
and 10 0 //g TNF/day (h) *P<0 05 vs saline (left) and IL-1 (right) 
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Effects on food and fluid intake and on body weight change 
The effects of chronic administration of saline, IL-1 alone, TNF alone and of IL-
1 in combination with different doses of TNF on food and fluid intake and on 
body weight change are shown in Fig. 2. In saline-infused control rats, there was 
a slight reduction in both food (-4.6 ± 1.3 g) and fluid (-4.8 ± 1.4 ml) intake 1 day 
after implantation of the pumps compared with day 0. This decrease is probably 
due to the anesthesia on the day of implantation of the pumps. Chronic infusion 
of rats for 3 days with 2.0 μ^ IL-1/day significantly reduced food intake (AUC, 
P<0.05), whereas infusion of rats with increasing doses of TNF did not 
significantly affect food intake during the infusion period compared with saline 
treatment. Continuous administration of IL-1 in combination with 0.2, 2.0, or 10.0 
//g TNF/day induced a pronounced and dose-dependent decrease in food intake 
compared with food intake by rats infused with IL-1 alone, and a significant dose-
response relationship was found with respect to the effects on food intake (AUC) 
in the four groups (P<0.0005). The effect of combined IL-1 and TNF infusion was 
synergistic (P<0.0005) compared with the effects of separate IL-1 and TNF 
infusions. Effects on food intake were maximal on days 1-2 and were only 
partially restored on day 3. 
Fluid intake was not significantly affected by continuous infusion of rats with 
2.0 ^g IL-1/day or with increasing doses of TNF (0.2, 2.0, or 10.0 //g/day) 
compared with fluid intake by saline-infused rats. Infusion of IL-1 in combination 
with increasing doses of TNF also did not significantly affect fluid intake of the 
animals compared with that of rats infused with IL-1 alone. 
There was a small decrease in body weight on the 1st day of infusion of rats 
with 2.0 //g IL-1/day or with 2.0 or 10.0 //g TNF/day compared with saline-infused 
rats. Combined infusion of IL-1 and TNF induced a dose-dependent weight loss 
of the animals compared with infusion of rats with IL-1 alone, and a significant 
dose-response relationship was found with respect to the effects on body weight 
change (AUC) in the four groups (P<0.0005). The effect of combined IL-1 and 
TNF infusion was synergistic (P<0.0005) compared with the effects of separate 
IL-1 and TNF infusions. 
Effects on rectal temperature 
Figure 3 shows the effects of continuous infusion of saline, IL-1 alone, 
increasing doses of TNF alone, or of IL-1 in combination with TNF on rectal 
temperature. Saline-infused rats showed a small decrease in daily rectal 
temperature compared with preinfusion values. Chronic administration of IL-1 
induced a significant increase (P<0.0005) in rectal temperature compared with 
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saline infusion. Continuous infusion of increasing doses of TNF (0.2, 2.0, or 10.0 
//g/day) induced a dose-dependent amelioration of the decrease in rectal 
temperature, as seen during saline infusion. A significant dose-response 
relationship was found with respect to the effects of TNF on rectal temperature 
(AUC) in the four groups (P<0.005). Infusion of rats with IL-1 in combination with 
TNF induced a dose-dependent increase in rectal temperature compared with the 
increase in rectal temperature induced by infusion of IL-1 alone, and a significant 
dose-response relationship was found with respect to the effects on rectal 
temperature (AUC) in the four groups (P<0.0005). The effect of combined IL-1 
and TNF infusion was synergistic (P<0.0005) compared with the effects of 
separate IL-1 and TNF infusions. Rectal temperature returned to preinfusion 
values over days 2-3. 
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Fig. 3. Effects of 3 days chronic administration of saline, IL-1, or different doses of TNF [left 
saline (o), 2 0 /rç IL-1/day (·), 0 2 /;g TNF day (D), 2 0 //g TNF/day (Δ), or 10 0 /^ TNF/day (v)] 
or IL-1 either alone or in combination with increasing doses of TNF [right IL-1 (·), IL-1 with 0 2 
/#g TNF/day (•), IL-1 with 2 0 //g TNF/day (A), or IL-1 with 10 0 //g TNF/day (•)] on rectal 
temperature Rectal temperature was calculated by averaging morning and afternoon rectal 
temperature Each point represents the mean + SE of 6-9 rats Inset corrected AUC for days 1-3 
Left (separate IL-1 and TNF infusion) saline (a), 2 0 //g IL-1/day (b), 0 2 //g TNF/day (c), 2 0 //g 
TNF/day (d), or 10 0 //g TNF/day (e) Right (combined IL-1 and TNF infusion) IL-1 (b), IL-1 and 
0 2 i#g TNF/day (f), IL-1 and 2 0 //g TNF/day (g), or IL-1 and 10 0 //g TNF/day (h) *P<0 05 vs 
saline {left) and IL-1 (nght) **P<0 0005 vs saline 
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DISCUSSION 
In the present study, it is demonstrated that continuous intraperitoneal infusion 
of 0.2, 2.0 or 10.0 //g TNF/day had no significant effect on plasma ACTH and В 
levels and on adrenal weight and that chronic administration of 2.0 μ^ IL-1/day 
induced only a slight increase in plasma levels of ACTH and В on the 1st day of 
infusion. However, continuous infusion of IL-1 in combination with increasing 
doses of TNF dose dependently induced an increase in plasma levels of ACTH 
and В and total adrenal weight. Our results demonstrate that IL-1 (2.0 //g/day) 
and TNF (0.2, 2.0, or 10.0 //g/day) act synergistically to increase plasma levels of 
ACTH and В and total adrenal weight in rats. 
In line with our results, Perlstein et al. (19) recently showed that simultaneous 
intraperitoneal bolus injections of rhlL-Ισ (10 ng) and rhTNFo (1 //g) in mice 
induced a response of plasma ACTH levels significantly greater than the sum of 
the ACTH responses to each cytokine injected alone. These workers also 
demonstrated that the synergistic effect of coinjection of rhlL-1a and rhTNFo on 
plasma ACTH levels was completely blocked by pretreatment of the mice with an 
anti-IL-6 antibody, suggesting that these cytokines synergistically induced IL-6 to 
produce the ACTH response. Indeed, Shalaby et al. (23) have shown that IL-1 
and TNF act synergistically to stimulate IL-6 production in vivo. IL-1 and IL-6 also 
synergize to stimulate ACTH production; Perlstein et al. (18) showed that rhlL-1o 
and rhlL-6, when administered in suboptimal doses to mice, synergize to induce 
an early (30-60 min) response of ACTH, whereas a later (2-3 h) response was 
similar to that observed after IL-1 administration alone. In contrast, synergism 
between IL-1 and TNF could not be demonstrated by Gelin et al. (9), who 
showed in mice that the effect of intraperitoneal injections of rhlL-Ισ in 
combination with rhTNFo on plasma В levels and on urinary В excretion was as 
great as the effect of twice daily injections of rhlL-Ισ alone. 
A common problem during infectious diseases is a decrease in appetite. This 
anorexia is probably a major cause of the body weight loss that occurs with 
infection. IL-1 (11, 14, 28) and TNF (14, 25, 31) are peptides capable of inducing 
anorexia when administered in sufficient amounts. There is little known about the 
effects of combined IL-1 and TNF infusion on food intake and body weight. The 
present study shows that chronic infusion of rats with IL-1 (2.0 //g/day) 
significantly decreased food intake, whereas daily body weight change was not 
significantly affected. Chronic administration of TNF in the doses used in our 
study (0.2, 2.0, or 10.0 //g/day) had no significant effect on food consumption and 
on daily body weight change. Continuous infusion of IL-1 in combination with 
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TNF, however, induced a very pronounced and dose-dependent suppression of 
food intake and of body weight gain during the infusion period. These results are 
in line with observations by Gelin et al. (9), who demonstrated that twice daily 
combined injections (40 ng rhlL-1o/day + 45 ng rhTNFo/day) of mice resulted in 
a significant decrease in food intake, whereas separate injections of rhlL-1o (40 
ng/day) or rhTNFa (450 ng/day, a dose ten times higher than in the combined 
injection) had no effect on food intake. 
Another activity of the cytokines IL-1 and TNF is their ability to elevate body 
temperature. The effects of acute administration of these cytokines on body 
temperature are well documented (5). We confirm here that chronic infusion of 
2.0 //g IL-1/day or 10.0 //g TNF/day for 3 days induces an increase in rectal 
temperature compared with saline-infused rats, whereas administration of the 
lower doses of TNF (0.2 or 2.0 //g/day) had no significant effect on rectal 
temperature. This is in line with previous studies from our laboratory in which it 
was demonstrated that continuous infusion of 2.0 or 4.0 //g IL-1/day for 1 wk 
significantly increased rectal temperature (28), whereas chronic infusion of 4.0 or 
8.0 //g TNF/day had no effect on rectal temperature (27, 29). In the present 
study, we show that simultaneous infusion of rats for 3 days with IL-1 combined 
with increasing doses of TNF induced a dose-dependent increase in rectal 
temperature, an effect which was clearly synergistic. In this respect it is of 
interest that Waage et al. (32) found that injection of mice with 0.375 //g 
recombinant murine TNF-σ resulted in hypothermia, whereas injection with 0.5 //g 
rhlL-1o caused a small increase in body temperature. Combined injection of IL-1 
and TNF caused a lowering of body temperature which was of greater magnitude 
than when TNF was injected alone. Recently, Long et al. (13) reported that the 
elevation of body temperature in rats induced by an intraperitoneal bolus injection 
of 10 //g/kg rhlL-1ß was significantly decreased by simultaneous injection of 1 
//g/kg rhTNF-σ, whereas administration of higher doses of TNF (up to 50 //g/kg) 
slightly, although not significantly, lowered the febrile response to IL-1. TNF itself 
did not affect body temperature. However, it is difficult to compare our study with 
the study of Long et al. because we studied rather long-term (1-3 days) effects of 
continuous infusion of IL-1 and TNF on rectal temperature while Long et al. 
studied short-term (2-7 h) effects of acute coinjection of IL-1 and TNF on body 
core temperature. 
In summary, we demonstrated that continuous intraperitoneal infusion of rats 
with 0.2, 2.0, or 10.0 //g TNF/day for 3 days had no significant effect on plasma 
ACTH and В levels, whereas continuous infusion of 2.0 //g IL-1/day induced only 
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a slight increase in plasma ACTH and В levels on the 1st day of infusion. 
However, simultaneous infusion of IL-1 with increasing doses of TNF stimulated 
the ΗΡΑ axis in a dose-dependent and synergistic way. Infusion of IL-1 alone 
significantly increased rectal temperature and decreased food intake, and infusion 
of the highest dose of TNF significantly increased rectal temperature compared 
with saline infusion. However, simultaneous infusion of IL-1 and TNF induced 
much greater changes in rectal temperature, food consumption, and body weight 
change compared with the effects of infusion of each cytokine alone. Although it 
is not fully established in what ways the apparent redundancy of the IL-1 and 
TNF systems benefit the organism, the existence of two pathways, which act 
synergistically, as clearly demonstrated in the present study, may indicate 
increased sensitivity of the host to respond to subtle inflammatory stimuli (3). 
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SUMMARY AND CONCLUSIONS 
There is ample evidence that endotoxin is responsible for the stimulation of the 
immune system during bacterial infections. Stimulation of the immune system by 
endotoxin results in an increased production of cytokines by cells of the immune 
system. It is well known that administration of endotoxin to rodents induces an 
increase in plasma levels of adrenocorticotropic hormone (ACTH) and cortico­
sterone (В), which indicates that the ΗΡΑ axis is activated. It has been postulated 
that the cytokines interleukin-1 (IL-1), tumor necrosis factor (TNF) and interleukin-
6 (IL-6) are important mediators in this respect. These cytokines are also thought 
to be important mediators of other biological effects of endotoxin including 
induction of fever and anorexia. 
We studied whether these cytokines, in particular IL-1, can indeed activate the 
ΗΡΑ axis in rats and by which mechanism. As it is unknown whether during 
(bacterial) infections plasma levels of these cytokines are only transiently 
increased or elevated for a prolonged period, we decided to study the effects of 
cytokines on the ΗΡΑ axis both during short-term and long-term cytokine admini­
stration. Chapters 2, 3 and 4 deal with the effects of acute administration of IL-1, 
TNF or IL-6 on the activity of the ΗΡΑ axis in rats. To study the mechanism by 
which these cytokines activate this axis, both in vivo and in vitro studies were 
performed. Chapters 5, 6 and 7 focus on the effects of chronic infusion of IL-1B 
for 3 or 7 days on the activity of the ΗΡΑ axis in rats and on the mechanism by 
which chronically infused IL-1 activates the ΗΡΑ axis. Furthermore, the effects of 
continuously infused IL-1 on body weight, rectal temperature, and on food and 
fluid intake were investigated. 
Although a number of studies have been published regarding the effect of 
acute administration of IL-1 on the activity of the ΗΡΑ axis, only a few have been 
reported concerning the effects of acute administration of TNF and IL-6. 
Moreover, a study systematically comparing the effects of a single peripheral or 
central bolus injection of each of the three cytokines on the activity of the ΗΡΑ 
axis is lacking. Therefore the experiments described in chapter 2 were designed 
to systematically compare the effects of a single intravenous (i.v.) or 
intracerebroventricular (i.c.v.) bolus injection of recombinant human interleukin-1 β 
(IL-1 ß), recombinant human tumor necrosis factora (TNFo) or recombinant 
human interleukin-6 (IL-6) on the activity of the ΗΡΑ axis in rats (dose-response 
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and time-course study). Furthermore, the role of endogenous corticotropin-
releasing hormone (CRH) in the activation of the ΗΡΑ axis by i.v. administration 
of these cytokines was investigated using a neutralizing monoclonal antibody 
directed against rat CRH. Finally, it was studied, using an recombinant human IL-
1 receptor antagonist (IL-1ra), whether stimulation of the ΗΡΑ axis by i.v. 
administration of TNF and IL-6 is mediated by endogenous IL-1. Rats were 
equipped with a jugular cannula for repeated blood sampling and a subgroup of 
rats also received an i.c.v. implanted cannula. IL-1 ß, TNFa or IL-6 was 
administered i.v. or i.c.v. in increasing doses. Intravenous administration of IL-1 ß, 
TNFa or IL-6 and i.c.v. administration of IL-1B or IL-6 induced a significant dose-
dependent increase in plasma В levels, whereas i.c.v. injection of TNFa in doses 
up till 1000 ng/rat was not effective. Intravenous pretreatment of rats with anti-
CRH antiserum had no significant overall effect on the plasma В response to i.v. 
administered IL-1B (500 and 3000 ng/rat), whereas the plasma В responses to 
i.v. TNFa or IL-6 administration (3000 ng/rat) were significantly reduced. 
Intravenous pretreatment of the animals with IL-1 га significantly blocked the 
plasma В response to i.v. treatment with IL-1 β, whereas the TNFa- and IL-6-
induced increase in plasma В levels were not affected. The experiments 
described in this chapter show that: i] i.v. administered IL-1ß, TNFa or IL-6 and 
i.c.v. administered IL-1ß or IL-6 dose-dependently stimulate the ΗΡΑ axis; ii] 
when given i.v. or i.c.v., IL-1B is more powerful than TNFa and IL-6 in activating 
the ΗΡΑ axis; iii] endogenous CRH is involved in the activation of the ΗΡΑ axis 
by acute i.v. administration of TNFa and IL-6. It is most likely that in case of i.v. 
treatment with IL-1ß a CRH-independent mechanism is involved. This study 
provides no arguments for the involvement of IL-1 in TNFa- or IL-6-induced 
activation of the ΗΡΑ axis. 
It is not fully understood at which level (hypothalamus, pituitary gland or 
adrenal gland) IL-1 activates the ΗΡΑ axis. In chapter 3 the question is 
addressed whether acute administration of IL-1 can induce activation of the ΗΡΑ 
axis at the level of the hypothalamus. The effects of a single i.v. bolus injection of 
IL-1 ß on the ΗΡΑ axis were evaluated by double immunocytochemical staining of 
the paraventricular hypothalamic nucleus (PVH) for Fos-like-immunoreactivity 
(Fos-LI), a marker for activated neurons, and for CRH-like-immunoreactivity. One, 
2 and 4 h after IL-1 ß or physiological saline injections, rats were killed and 
perfused, and the brain processed for Fos-immunohistochemistry. Dense popu-
lations of neurons containing Fos-LI-positive nuclei were found in the PVH of IL-
1ß-treated rats. In particular, the dorsal medial parvocellular part, but also some 
134 
Summary and conclusions 
of the other parvocellular subdivisions contained many Fos-LI-positive neurons. 
Maximal induction of staining was found at a dose of 5 //g IL-1ß/rat after 1 or 2 h 
survival, while immunostaining had decreased to almost control levels after 4 h. 
No Fos-LI was found in the PVH of control animals. Double immunocytochemical 
staining for Fos and CRH revealed that Fos-LI was predominantly present in 
parvocellular CRH-containing neurons of the PVH. The finding that peripherally 
injected IL-1B induces Fos-LI in hypothalamic CRH neurons strengthens the 
hypothesis that these neurons are part of the circuitry mediating IL-1ß-induced 
activation of the ΗΡΑ axis. 
In addition to the experiments described in chapter 3, which showed a possible 
central site of action of IL-1ß, chapter 4 describes experiments investigating a 
possible peripheral site of action (pituitary gland or adrenal gland) of cytokines in 
activating the ΗΡΑ axis. The in vitro secretion of ß-endorphin-like-immuno-
reactivity (ßE-IR) by the anterior and neurointermediate lobes (AL and NIL, 
respectively) of the rat pituitary gland and the release of В by the rat adrenal 
gland after exposure of freshly isolated cell preparations and tissue fragments to 
recombinant human interleukin-1a (IL-Ισ), IL-1ß, IL-6 and TNFa were studied. 
Besides these cytokines, interleukin-2 has also been reported to activate the ΗΡΑ 
axis. Therefore we also studied the effects of recombinant human interleukin-2 
(IL-2) on the pituitary and adrenal gland in vitro. Isolated AL and NIL cells were 
incubated for 2 h with cytokines (1 pg/ml - 1 //g/ml), CRH (5-10"10 M) or with 
cytokines in combination with CRH (AL cells). Isolated adrenal cells were 
incubated for 2 h with cytokines (1 pg/ml - 1 //g/ml), ACTH (25 pg/ml) or with 
cytokines in combination with ACTH. Furthermore, AL, NIL and adrenal tissue 
fragments were superfused for 30 or 60 min with cytokines (10 and/or 100 
ng/ml). Incubation of AL, NIL and adrenal cells and superfusion of the 
corresponding tissue fragments with cytokines had no significant effect on ßE-IR 
and В release respectively. However, there were some exceptions: i] incubation 
of AL cells with IL-2 increased CRH-induced ßE-IR release; ii] incubation of NIL 
cells with IL-2 induced an increase of basal ßE-IR release; in] ACTH-induced В 
release was reduced after co-incubation of adrenal cells with TNFo and after 
prolonged (6 h) superfusion of adrenal tissue with TNFa; iv] prolonged (6 h) 
superfusion of adrenal fragments with IL-1 ß increased basal В release. The data 
presented in this chapter suggest that the acute activation of the ΗΡΑ axis of rats 
by peripheral administration of the cytokines IL-1ß, TNFo and IL-6 in vivo is not 
mediated by a direct action of these cytokines at the level of the pituitary and/or 
adrenal gland. 
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Chapter 5 describes in vivo as well as in vitro experiments dealing with the 
question whether continuous intraperitoneal (i.p.) infusion of IL-1ß can induce a 
long-term activation of the ΗΡΑ axis. Rats were equipped with a jugular cannula 
for repeated blood sampling and with i.p. implanted osmotic minipumps loaded 
with either IL-1 ß (delivery rate 0.5, 2.0 or 4.0 //g/24 h for 7 days) or with saline. 
At the end of the treatment the rats were decapitated, the adrenals weighed, and 
the in vitro release of ßE-IR by the anterior lobe of the pituitary and that of В by 
the adrenal gland was measured. Continuous administration of 2.0 and 4.0 //g IL-
1ß/24 h resulted in a persistent increase in plasma ACTH and В concentrations 
compared to the levels in saline-infused rats, with peak levels on the first day of 
administration. In addition, adrenal weights of IL-1 ß rats were significantly higher 
than those of saline rats. In vivo treatment with 4.0 //g IL-1B/24 h induced an 
increase in spontaneous in vitro release of ßE-IR and В from superfused anterior 
pituitary and adrenal tissue respectively, whereas the in vitro response of the 
pituitary (to CRH) and of the adrenal (to ACTH) of animals chronically treated in 
vivo with IL-1 ß were significantly diminished. IL-1ß at a dose of 0.5 μ^ failed to 
affect plasma ACTH and В values, adrenal weight and in vitro ßE-IR and В 
release. Chronic infusion of rats with 4.0 μg IL-lß/24 h induced prolonged fever, 
whereas at lower doses of IL-1 ß (2.0 and 0.5 //g), temperatures were elevated 
only during the first 2 days of infusion. IL-1 ß at a dose of 2.0 and 4.0 //g/24 h 
induced a loss of body weight during the first 2 days of the treatment period 
compared to saline treatment and daily body weight gain reached initial levels by 
the third day. Plasma norepinephrine and/or epinephrine concentrations were 
raised only on day 1 of the 2.0- and 4.0-//g IL-1 ß experiments. Thus, it is unlikely 
that the observed prolonged effects of IL-1ß on the activity of the ΗΡΑ axis do 
result from general stress effects induced by IL-1 treatment. The experiments 
described in this chapter show the potential of IL-1 ß to induce a dose-dependent 
and long-term activation of the ΗΡΑ axis. 
Chapter 6 describes experiments dealing with mechanisms by which chronical­
ly (3 days) infused IL-1 β activates the ΗΡΑ axis in rats. First, it was investigated 
whether chronic i.c.v. infusion of IL-1, like continuous i.p. infusion of IL-1, is 
capable of inducing a sustained activation of the ΗΡΑ axis. Secondly, the 
involvement of the central CRH system in the activation of the ΗΡΑ axis during 
continuous i.p. infusion of IL-1 was examined by pretreatment of the rats with a 
monoclonal anti-CRH antibody. Thirdly, it was investigated whether peripheral 
mechanisms, such as release of mediators from IL-1-activated macrophages 
(experiments in macrophage-depleted rats) or a direct effect of IL-1 on В 
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production by the adrenal glands (experiments in hypophysectomized (HPX) 
rats), are involved in the activation of the ΗΡΑ axis during continuous i.p. infusion 
of IL-1. Finally, it was studied whether high (experiments in rats receiving daily 
dexamethasone (DEX) injections) or low (experiments in adrenalectomized (ADX) 
rats) concentrations of circulating glucocorticoids are capable of modulating the 
effect of chronically infused IL-1 on the activity of the ΗΡΑ axis. Intracerebro-
ventricular infusion of IL-1 β, even in doses as low as 0.1 //g/24 h, significantly 
increased plasma В levels. HPX- and ADX-rats died within 18 h after starting the 
IL-1 ß infusion (0.5 //g/24 h). Immunoneutralization of CRH significant-ly 
decreased and macrophage depletion, by pretreatment of the rats with CI2MDP-
containing liposomes, significantly increased the stimulation of the ΗΡΑ axis by 
IL-1 ß in a dose of 4.0 //g/24 h. Administration of high doses of DEX completely 
abolished the stimulation of the ΗΡΑ axis by IL-1ß (2.0 //g/24 h). The 
experiments described in this chapter demonstrate that lower doses of IL-1 ß 
were able to activate the ΗΡΑ axis when infused i.c.v. than when infused i.p.. 
With respect to stimulation of the ΗΡΑ axis by chronic i.p. infusion of IL-1ß the 
data i] provide evidence that the CRH system is involved; ii] provide no evidence 
for a direct stimulatory effect of IL-1 ß on the release of В by the adrenal gland 
which is of sufficient magnitude to resist the stress of chronic IL-1 ß infusion; 
¡ii] show that endogenous macrophage-derived mediators, induced by IL-1 β 
infusion, express an inhibitory rather than a stimulatory effect on the activity of 
the ΗΡΑ axis; iv] demonstrate that exogenous administration of DEX blocks the 
effect of IL-1 ß, which fits well in the concept of an immunoregulatory feedback 
system between IL-1 and glucocorticoids; v] show that an intact function of the 
adrenal gland is needed to survive the stress induced by IL-1 infusion. 
IL-1 and TNF share many of their biological activities. So, the effects of 
simultaneous administration of these cytokines may be additive or synergistic. 
However, antagonistic effects of co-administration of IL-1 and TNF have also 
been reported. The experiments described in chapter 7 focus on the effects of 
separate and combined i.p. infusion for 3 days of IL-1 β and TNFCT on the activity 
of the ΗΡΑ axis. Rats were equipped with an i.p. implanted osmotic minipump 
loaded with either saline, IL-1B (2.0 //g/24 h), TNFCT (0.2, 2.0 or 10.0 //g/24 h) or 
with IL-1 ß in combination with each of the three doses of TNFo. Plasma ACTH 
and В levels and adrenal weight were significantly increased, in a dose-
dependent way, by simultaneous infusion of IL-1ß and TNFo, but not by admini-
stration of either cytokine alone. Chronic administration of IL-1 ß alone induced a 
significant decrease in food intake and a significant elevation of rectal 
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temperature, whereas only infusion of the highest dose of TNFa significantly 
elevated rectal temperature but had no effect on food intake. Continuous infusion 
of IL-1 ß in combination with increasing doses of TNFo induced both effects in a 
dose-dependent and synergistic way. These data show that simultaneous 
infusion of IL-1 ß and TN Fa in rats has a synergistic effect on the activity of the 
ΗΡΑ axis as well as on food intake and rectal temperature. The existence of two 
pathways, which act synergistically, may increase the sensitivity of the host to 
respond to subtle inflammatory stimuli. 
CONCLUSIONS 
We have clearly shown that acute peripheral (i.v.) administration of IL-1 
induces a dose-dependent activation of the ΗΡΑ axis. However, at which level 
(hypothalamus, pituitary gland and/or adrenal gland) this cytokine stimulates the 
ΗΡΑ axis is not fully comprehended. The observation that i.v. administration of 
IL-1 induces an increase in Fos-like-immunoreactivity (Fos-LI) in the 
hypothalamus strongly indicates the involvement of the hypothalamus in the 
action of IL-1. The finding that lower doses of IL-1 are needed to activate the 
ΗΡΑ axis when administered i.c.v. than when administered i.v. further 
substantiates a central site of action of IL-1 in activating the ΗΡΑ axis. IL-1-
induced Fos-LI is predominantly present in CRH-containing neurons of the PVH 
which suggests the involvement of the central CRH system in IL-1-induced 
activation of the ΗΡΑ axis. Pretreatment of rats with a neutralizing anti-CRH 
antiserum induces an early and short-term blockade of the activation of the ΗΡΑ 
axis after i.v. administration of IL-1, which indeed suggests the involvement of 
endogenous CRH. However, the anti-CRH antiserum does not induce a complete 
blockade which suggests the involvement of (a) CRH-independent mechanism(s). 
Neither short-term incubation of anterior pituitary or adrenal cells nor short-term 
superfusion of the corresponding tissue fragments with IL-1 does induce an 
increased hormone release from these tissues in vitro. These findings suggest 
that a direct action of IL-1 on the pituitary and/or adrenal gland in vivo is not 
likely. 
Chronic peripheral (i.p.) infusion of IL-1 induces a dose-dependent and long-
term activation of the ΗΡΑ axis. This prolonged activation of the ΗΡΑ axis seems 
to be rather specific as plasma ACTH and В levels are chronically increased 
throughout the infusion period, whereas the plasma levels of other stress 
hormones such as (nor)epinephrine and prolactin are not affected by IL-1 
infusion. Chronic IL-1 administration induces fever and anorexia. As these IL-1 
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effects occur only during the first days of infusion, they cannot account for the 
sustained increase in plasma ACTH and В levels during IL-1 treatment. This 
temporariness could be due to development of tolerance to the pyrogenic and 
anorectic effects of chronic IL-1 infusion possibly related to the IL-1-induced 
activation of the ΗΡΑ axis. Pretreatment of rats with an anti-CRH antiserum 
inhibits the IL-1-induced increase in plasma ACTH levels, indicating a central site 
of action of chronically applied IL-1 involving the CRH system. As the plasma 
ACTH response to IL-1 infusion is reduced but not fully blocked, other mediators 
structurally distinct from CRH may also be involved in long-term activation of the 
ΗΡΑ axis by continuous IL-1 infusion. A central site of action of chronically 
infused IL-1 is also supported by the observation that lower doses of IL-1 are 
needed to activate the ΗΡΑ axis when infused i.c.v. than when infused ¡.p.. 
Interestingly, in our experiments the IL-1-induced increase in plasma В levels is 
not significantly affected by immunoneutralization of CRH suggesting a possible 
direct action of chronically infused IL-1 on the adrenal glands. This is supported 
by in vitro experiments, as long-term (6 h) superfusion of adrenal gland 
fragments with IL-1 induces increased В release. In order to study a possible 
direct action of IL-1 on adrenal В release in vivo, hypophysectomized-rats were 
chronically infused with IL-1. However, this treatment was without exception 
lethal to these rats and therefore no conclusion could be drawn from these 
experiments with respect to a possible direct action of IL-1 in vivo on the adrenal 
glands. To study the role of plasma levels of glucocorticoids during chronic IL-1 
infusion, IL-1 was infused to dexamethasone-treated rats and to 
adrenalectomized(ADX)-rats. Daily dexamethasone administration abolished the 
effect of chronic IL-1 infusion on the ΗΡΑ axis, whereas ADX-rats died during 
chronic IL-1 infusion. Macrophage depletion increased the effect of chronic IL-1 
infusion on the activity of the ΗΡΑ axis. So, glucocorticoids as well as 
macrophage-derived products exert an inhibitory effect on the IL-1-induced 
activation of the ΗΡΑ axis, thereby preventing excessive stimulation of this axis 
by IL-1, which would result in a dangerous state of suppression of the immune 
system. 
Simultaneous infusion of IL-1 and TNF increased the activity of the ΗΡΑ axis 
synergistics Ну. Rectal temperature and food intake were both synergistically 
affected by continuous infusion of IL-1 in combination with TNF. The existence of 
two pathways, which act synergistically, may result in increased sensitivity of the 
host to respond to subtle inflammatory stimuli. 
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Administration of a single, peripheral (i.v.) bolus injection of TNF or IL-6 
activates the ΗΡΑ axis dose-dependently. However, both cytokines are less 
potent than IL-1 as higher doses are needed to elevate the activity of the ΗΡΑ 
axis. Pretreatment of rats with an anti-CRH antiserum did induce an overall 
reduction of the TNF- or IL-6-induced activation of the ΗΡΑ axis which suggests 
a central site of action of TNF and IL-6 involving the CRH system. Acute i.c.v. 
administration of TNF, however, did not activate the ΗΡΑ axis, possibly because 
i.c.v. administered TNF is not capable of reaching the (hypothalamic) centers 
responsible for activation of the ΗΡΑ axis. Pretreatment of the rats with an IL-1 
receptor antagonist did not modulate the effect of TNF or IL-6 on the ΗΡΑ axis. 
Neither short-term incubation of anterior pituitary or adrenal cells nor short-term 
superfusion of the corresponding tissue fragments with TNF or IL-6 in vitro 
induced increased hormone release from these tissues. These findings suggest 
that a direct action of TNF or IL-6 on the pituitary and/or adrenal gland in vivo is 
highly unlikely. 
Taken together, our data show that IL-1 and, to a minor degree, TNF and IL-6 
are capable of activating the ΗΡΑ axis involving at least the central CRH system. 
Whether these cytokines are indeed mediators of the increased activity of the 
ΗΡΑ axis during bacterial infections and inflammatory diseases remains to be 
elucidated. In this respect, the availability of cytokine knock-out animals and 
neutralizing anti-cytokine antibodies provide new tools for further research on this 
subject. 
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Er zijn sterke aanwijzingen dat endotoxinen verantwoordelijk zijn voor de 
stimulatie van het immuunsysteem tijdens bacteriële infecties. Stimulatie van het 
immuunsysteem door endotoxinen leidt tot een verhoogde produktie van cytokines 
door cellen van het immuunsysteem. Ook is aangetoond dat toediening van 
endotoxinen aan ratten of muizen leidt tot verhoogde plasmaspiegels van 
adrenocorticotroop hormoon (ACTH) en corticosteron (B), hetgeen kenmerkend is 
voor een geactiveerde hypothalamus-hypofyse-bijnieras (HHB-as). Gepostuleerd is 
dat de cytokines interleukine-1 (IL-1), tumor necrosis factor (TNF) en interleukine-6 
(IL-6) belangrijke mediatoren zijn in dit opzicht. Deze cytokines worden ook 
verantwoordelijk gehouden voor andere biologische effecten van endotoxinen, zoals 
inductie van koorts en anorexie. 
Wij hebben onderzocht of de genoemde cytokines, met name IL-1, inderdaad in 
staat zijn de HHB-as te activeren en via welke mechanismen zij dat dan doen. Daar 
het niet goed bekend is of tijdens (bacteriële) infecties de plasmaspiegels van deze 
cytokines slechts kortdurend dan wel voor een langere periode verhoogd zijn, werd 
besloten de effecten van zowel acute als van langdurige toediening van cytokines 
op de HHB-as te bestuderen. De hoofdstukken 2, 3 en 4 handelen over de effecten 
van acute toediening van IL-1, TNF of IL-6 op de activiteit van de HHB-as in de rat. 
Zowel in vivo als in vitro experimenten zijn uitgevoerd om het mechanisme waardoor 
deze cytokines de HHB-as activeren te bestuderen. De hoofdstukken 5, 6 en 7 
handelen over de effecten van continue infusie van IL-1 gedurende 3 of 7 dagen op 
de activiteit van de HHB-as in de rat en over het achterliggende mechanisme. Ook 
worden in deze studies de effecten van chronische infusie van IL-1 op het 
lichaamsgewicht, de rectale temperatuur en op de voedsel- en vochtopname van de 
ratten gevolgd. 
Hoewel er nogal wat studies gepubliceerd zijn met betrekking tot het effect van 
acute toediening van IL-1 op de activiteit van de HHB-as, is het aantal studies met 
betrekking tot het effect van acute toediening van TNF of IL-6 op de activiteit van 
de HHB-as zeer beperkt. Bovendien ontbreekt een studie waarin de effecten van 
één, perifere of centrale, bolus-injectie van ieder van de drie cytokines afzonderlijk 
op de activiteit van de HHB-as worden vergeleken. In hoofdstuk 2 worden 
dosisafhankelijkheid en tijdsverloop van de effecten van één intraveneuze (i.v.) of 
intracerebroventriculaire (i.c.v.) bolus-injectie van recombinant humaan interleukine-
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1ß (IL-1ß) op de activiteit van de HHB-as van de rat vergeleken met die van 
recombinant humaan tumor necrosis factor? (TNFo) en van recombinant humaan 
interleukine-6 (IL-6) toediening. Verder werd de rol van endogeen "corticotropin-
releasing" hormoon (CRH) bij de activering van de HHB-as na i.v. toediening van 
ieder van deze cytokines bestudeerd, gebruikmakend van een neutralizerend 
monoclonaal antilichaam gericht tegen ratte-CRH. Tenslotte werd nagegaan of 
stimulatie van de HHB-as na i.v. toediening van TNFo of IL-6 gemedieerd zou 
kunnen worden door endogeen IL-1. Hierbij werd gebruik gemaakt van een IL-1 
receptor-antagonist (IL-1 ra). De ratten werden voorzien van een canule in een vena 
jugularis voor herhaalde bloedafname en bij een deel van deze groep ratten werd 
ook een canule in een laterale hersenventrikel geïmplanteerd. IL-1B, TNFo of IL-6 
werd i.v. of i.c.v. toegediend in oplopende doseringen. Intaveneuze toediening van 
IL-1 ß, TNF? of IL-6 en i.c.v. toediening van IL-Ш of IL-6 induceerden een 
significante dosis-afhankelijke stijging van de plasmaspiegels van B, terwijl i.c.v. 
injecties van TNFo (in doseringen oplopend tot 1000 ng/rat) niet effectief bleken. 
Voorbehandeling (i.v.) van de ratten met een anti-CRH-antiserum had geen 
significant effect op de stijging van de plasmaspiegels van В na i.v. toediening van 
IL-1 ß (500 en 3000 ng/rat), terwijl de stijgingen van de plasmaspiegels van В na i.v. 
toediening van TNFo en IL-6 (3000 ng/rat) wel significant minder waren. 
Voorbehandeling (i.v.) van de ratten met IL-1 ra blokkeerde de stijging van de 
plasmaspiegels van В na i.v. toediening van IL-1 (i, terwijl de door TNFo en IL-6 
geïnduceerde stijging van de plasmaspiegels van В niet beïnvloed werd. De 
experimenten die in dit hoofdstuk beschreven worden tonen aan dat: i] i.v. 
toediening van IL-1ß, TNFo of IL-6 en i.c.v. toediening van IL-1 β of IL-6 de HHB-as 
dosis-afhankelijk stimuleren; ii] IL-1 fi, i.v. of i.c.v. toegediend, de HHB-as krachtiger 
stimuleert dan TNFo en IL-6; iii] endogeen CRH betrokken is bij de activering van 
de HHB-as na i.v. toediening van TNFo of IL-6. In het geval van IL-1 β is er 
waarschijnlijk een CRH-onafhankelijk mechanisme in het spel. Deze studie verschaft 
geen argumenten voor betrokkenheid van endogeen IL-1 bij de activering van de 
HHB-as door TNFo of IL-6. 
Het is niet duidelijk op welk niveau (hypothalamus, hypofyse of bijnieren) IL-1 de 
HHB-as activeert. Hoofdstuk 3 heeft betrekking op de vraag of acute toediening 
van IL-1 de HHB-as kan activeren op het niveau van de hypothalamus. De effecten 
van een i.v. bolus-injectie van IL-1ß op de activiteit van de HHB-as werden 
bestudeerd met behulp van ¡mmunocytochemische dubbelkleuring van de nucleus 
paraventricularis van de hypothalamus (PVH) voor "Fos-like"-immunoreactiviteit 
(Fos-LI), een "marker" voor geactiveerde neuronen, en voor "CRH-like"-
142 
Nederiandse samenvatting 
immunoreactiviteit (CRH-LI). Eén, 2 of 4 uur na i.v. toediening van IL-1B of een 
fysiologische zoutoplossing werden de ratten transcardiaal geperfundeerd met 
paraformaldehyde en de uitgenomen hersenen vervolgens bewerkt voor Fos-
immunocytochemie. In de PVH van met IL-1 β behandelde ratten werden dichte 
populaties van voor Fos-LI positieve neuronen aangetoond. Met name het medio­
dorsale parvocellulaire gedeelte alsmede sommige van de andere parvocellulaire 
delen bevatten veel neuronen met voor Fos-LI positieve kernen. Maximale kleuring 
werd gevonden 1 of 2 uur na i.v. toediening van 5 //g IL-1ß per rat. Vier uur na de 
injectie was de positieve immunokleuring reeds gereduceerd tot nabij het 
controleniveau. Fos-LI werd niet aangetoond in de PVH van controledieren. 
Immunocytochemische dubbelkleuring voor Fos-LI en CRH-LI liet zien dat Fos-LI 
vooral aanwezig was in parvocellulaire CRH-bevattende neuronen van de PVH. De 
bevinding dat perifeer toegediend IL-Ш Fos-LI induceert in hypothalame CRH-
neuronen steunt de hypothese dat CRH-neuronen van de PVH onderdeel zijn van 
een circuit dat de activering van de HHB-as door IL-1ß medieert. 
In hoofdstuk 4 worden experimenten beschreven ter beantwoording van de 
vraag of, naast de hypothalamus, ook de hypofyse en/of de bijnieren van ratten 
organen zijn waarop IL-1 direct effect heeft. Hiertoe werd in vitro de afgifte van ß-
endorfme-immunoreactiviteit (ßE-IR) door de vóór-, respectievelijk de achter-
middenkwab van de hypofyse (AL en NIL, respectievelijk) en van В door de bijnier 
na blootstelling van vers geïsoleerde cellen en weefselfragmenten aan recombinant 
humaan ¡nterleukine-1o (IL-1 α), IL-1ß, IL-6 of TNFo bestudeerd. Ook van 
interleukine-2 is beschreven dat het de HHB-as kan activeren. Vandaar dat we in 
vitro ook de effecten van recombinant humaan interleukine-2 (IL-2) op de hypofyse 
en de bijnier hebben bestudeerd. Geïsoleerde AL en NIL cellen werden gedurende 
2 uur geïncubeerd met cytokines (1 pg/ml - 1 //g/ml), CRH (5-10"10 M) of met 
cytokines in combinatie met CRH (alleen de AL-cellen). Geïsoleerde bijniercellen 
werden gedurende 2 uur geïncubeerd met cytokines (1 pg/ml -1 //g/ml), ACTH (25 
pg/ml) of met cytokines in combinatie met ACTH. Verder werd het effect nagegaan 
van superfusie gedurende 30 of 60 minuten van weefselfragmenten van de hypofyse 
(AL en NIL) respectievelijk de bijnier met dezelfde cytokines (10 en/of 100 ng/ml). 
Bijnierfragmenten werden ook langdurig gesuperfuseerd met IL-1 u, IL-2 of TNFa(6 
uur; 100 ng/ml). Incubatie van cytokines met cellen afkomstig van AL, NIL of bijnier 
en superfusie van de overeenkomstige weefselfragmenten met cytokines 
beïnvloedden de afgifte van ßE-IR respectievelijk В niet. Er waren echter een aantal 
uitzonderingen: i] incubatie van AL cellen met IL-2 verhoogde de door CRH 
geïnduceerde ßE-IR-afgifte; ii] incubatie van NIL cellen met IL-2 induceerde een 
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verhoging van de basale ßE-IR-afgifte, ni] de door ACTH-ge induceerde afgifte van 
В was verminderd na gelijktijdige incubatie van bijniercellen met TNFa en na 
langdurige (6 uur) superfusie van bijnierweefsel met TNFo, iv] langdurige superfusie 
(6 uur) van bijnierfragmenten met IL-1B verhoogde de basale afgifte van В Deze 
gegevens suggereren dat activering van de HHB-as van ratten na acute toediening 
van cytokines (in ieder geval IL-1ß, TNFo en IL-6) in vivo niet het gevolg is van een 
direct effect van deze cytokines op de hypofyse en/of de bijnier 
Hoofdstuk 5 beschrijft zowel in vivo als in vitro experimenten die betrekking 
hebben op de vraag of continue, intraperitoneale (ι ρ ) infusie van IL-1 in staat is om 
de HHB-as langdurig te activeren Ratten werden uitgerust met een canule in een 
venajugulans voor herhaalde bloedafname en meteen ι ρ geïmplanteerd osmotisch 
minipompje gevuld met IL-1 ß (dosering 0,5, 2,0 of 4,0 //g/24 uur gedurende 7 
dagen) of met een fysiologische zoutoplossing Aan het einde van de behandeling 
werden de ratten gedecapiteerd, de bijnieren gewogen en in vitro de afgifte van ßE-
IR door de hypofyse-voorkwab en van В door de bijnier gemeten Continue infusie 
van 2,0 en 4,0 //g IL-lß/24 uur induceerde een langdurige verhoging van de 
plasmaspiegels van ACTH en В in vergelijking met die bij de controleratten De 
hoogste spiegels werden gemeten op de eerste dag van de infusie De bijnieren van 
de met IL-1 β behandelde dieren waren significant zwaarder dan die van de met 
fysiologisch zout behandelde dieren Infusie van ratten met 4,0 //g IL-lß/24 uur 
verhoogde de spontane afgifte van ßE-IR en В in vitro, terwijl de reacties van de 
hypofyse (op CRH, in vitro) en van de bijnieren (op ACTH, in vitro) van ratten, die 
in vivo met IL-1 β waren behandeld, significant verminderd waren IL-1ß in een 
dosering van 0,5 //g/24 uur had geen effect op de plasmaspiegels van ACTH en B, 
het bijniergewicht en op de afgifte van ßE-IR en В in vitro Chronische infusie van 
ratten met 4,0 //g IL-lß/24 uur induceerde koorts gedurende de gehele 7-daagse 
infusieperiode, terwijl de lagere doseringen van IL-1ß (2,0 en 0,5 //g/24 uur) de 
rectale temperatuur alleen gedurende de eerste 2 dagen van de infusie verhoogden 
IL-1 ß in een dosering van 2,0 en 4,0 //g/24 uur leidde tot een verlies aan 
lichaamsgewicht in de eerste 2 dagen van de behandeling Vanaf dag 3 nam het 
lichaamsgewicht weer toe De plasmaspiegels van adrenaline en/of noradrenaline 
waren alleen verhoogd op dag 1 van de experimenten met 2,0 en 4,0 //g IL-1ß/24 
uur Hieruit werd afgeleid dat het onwaarschijnlijk is dat de waargenomen effecten 
van continue infusie van IL-1ß op de activiteit van de HHB-as het gevolg zijn van 
algemene stress als gevolg van de behandeling De experimenten, die in dit 
hoofdstuk beschreven worden, tonen aan dat IL-1ß in staat is de HHB-as dosis-
afhankelijk en langdurig te activeren 
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Hoofdstuk 6 beschrijft een aantal experimenten die betrekking hebben op het 
mechanisme waardoor chronisch (3 dagen) geïnfundeerd IL-1ß de HHB-as van 
ratten activeert. Als eerste werd nagegaan of chronische centrale (i.c.v.) infusie van 
IL-1 ß in staat is, evenals chronische i.p. infusie van IL-1B, de HHB-as langdurig te 
activeren. Vervolgens werd de betrokkenheid van het CRH systeem bij de activering 
van de HHB-as tijdens continue i.p. infusie van IL-1 β onderzocht. Hiertoe werden 
de ratten voorbehandeld (i.v.) met een anti-CRH-antiserum. Op de derde plaats 
werd bestudeerd of perifere mechanismen, zoals het vrijkomen van mediatoren uit 
door IL-1 ß geactiveerde macrofagen (experimenten met ratten waaruit de macro-
fagen geëlimineerd waren door voorbehandeling (i.v. en i.p) met CI2MDP-bevattende 
liposomen) of een direct effect van IL-1 β op de produktie van В door de bijnieren 
(experimenten met gehypofysectomeerde (HPX) ratten), betrokken zijn bij de 
activering van de HHB-as van ratten tijdens chronische i.p. infusie van IL-1 β. 
Tenslotte werd nagegaan in hoeverre hoge (experimenten met ratten die dagelijks 
dexamethason toegediend kregen) of lage (experimenten met ratten waarbij de 
bijnieren verwijderd waren (ADX)) concentraties circulerende glucocorticoïden het 
effect van chronische IL-1 ß infusie op de HHB-as kunnen moduleren. I.c.v. infusie 
van IL-1 ß, zelfs in de lage dosering van 0,1 //g/24 uur, had een significante 
verhoging van de plasmaspiegels van В tot gevolg. Immunoneutralisatie van CRH 
verlaagde en macrofaag-depletie verhoogde de stimulatie van de HHB-as door i.p. 
infusie van IL-1 ß (4,0 //g/24 uur). HPX- en ADX-ratten stierven binnen 18 uur na de 
start van de infusie met IL-1 ß (0,5 //g/24 uur). Toediening van een hoge dosering 
dexamethason onderdrukte de stimulatie van de HHB-as door infusie met IL-1 ß (2,0 
//g/24 uur) volledig. De in dit hoofdstuk beschreven experimenten tonen aan dat 
lagere doseringen IL-1 ß in staat zijn de HHB-as te stimuleren wanneer het cytokine 
i.c.v. in plaats van i.p. geïnfundeerd wordt. Met betrekking tot stimulatie van de 
HHB-as door chronische i.p. infusie van IL-1ß: i] bewijzen de resultaten de 
betrokkenheid van het CRH systeem; ii] leveren zij geen bewijs voor een direct 
stimulerend effect van IL-1 ß op de afgifte van В door de bijnieren van voldoende 
sterkte om de algemene stress, die chronische i.p. infusie van IL-1 ß veroorzaakt, te 
weerstaan; ¡ii] laten zij zien dat endogene, uit macrofagen afkomstige, mediatoren 
geïnduceerd door chronische i.p. infusie van IL-1ß, een meer remmend dan 
stimulerend effect hebben op de activering van de HHB-as door IL-1ß; iv] tonen zij 
aan dat exogene toediening van dexamethason het effect van IL-1 β blokkeert, 
hetgeen aansluit bij het concept van een immunoregulatoir terugkoppelingssysteem 
tussen IL-1 ß en glucocorticoïden; v] tonen zij aan dat een intacte functie van de 
hypofyse en de bijnieren nodig is om de algemene stress die de infusie van IL-1ß 
veroorzaakt te overleven. 
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De biologische activiteiten van IL-1 en TNF vertonen een grote "overlap". De 
effecten van gelijktijdige toediening van deze cytokines kunnen dan ook een additief 
of zelfs een synergistisch karakter hebben. Antagonisme tussen IL-1 en TNF is 
echter ook beschreven. Daarom concentreren de experimenten, die beschreven 
worden in hoofdstuk 7, zich op de effecten van gescheiden en gelijktijdige i.p. 
infusie van IL-1 en TNF, gedurende 3 dagen, op de activiteit van de HHB-as. Ratten 
werden voorzien van een i.p. geplaatst osmotisch minipompje gevuld met een 
fysiologische zoutoplossing, IL-1ß (2,0//g/24 uur), TNFo (0,2, 2,0 of 10,0//g/24 uur) 
of met IL-1 ß in combinatie met TNFo. Plasmaspiegels van ACTH en В en de 
bijniergewichten waren significant hoger (dosis-afhankelijk) na gelijktijdige infusie 
van IL-1 ß en TNFa, terwijl toediening van IL-1 ß of TN Fa alleen deze parameters 
niet significant beïnvloedde. Chronische toediening van IL-1 β alleen induceerde een 
significante daling van de voedselopname en een significante stijging van de rectale 
temperatuur, terwijl alleen infusie van de hoogste dosis TNFo de rectale temperatuur 
significant verhoogde. Gelijktijdige infusie van IL-1 β en TNFo induceerde beide 
effecten op een dosis-afhankelijke en synergistische manier. Samengevat laten de 
in dit hoofdstuk beschreven experimenten zien dat gelijktijdige infusie van IL-1ß en 
TNFcr bij ratten een synergistisch effect heeft op de activiteit van de HHB-as 
alsmede op de voedselopname en de rectale temperatuur. Het bestaan van twee 
routes welke synergistisch werken zou de gevoeligheid van het organisme om te 
reageren op ontstekingsprikkels kunnen verhogen. 
CONCLUSIES 
We hebben aangetoond dat acute, perifere (i.v.) toediening van IL-1 de HHB-as 
dosis-afhankelijk activeert. Op welk niveau (hypothalamus, hypofyse en/of bijnieren) 
dit cytokine de HHB-as stimuleert, is nog niet helemaal duidelijk. De waarneming dat 
i.v. toediening van IL-1 een verhoging induceert van "Fos-like"-immunoreactiviteit 
(Fos-LI) in de hypothalamus is een sterke aanwijzing dat de hypothalamus 
betrokken is bij het mechanisme waarmee IL-1 de HHB-as activeert. De bevinding 
dat de HHB-as geactiveerd wordt door lagere doseringen IL-1, wanneer het cytokine 
i.c.v. toegediend wordt in vergelijking met i.v. toediening, ondersteunt een centraal 
aangrijpingspunt van IL-1. Fos-LI, geïnduceerd door IL-1, is vooral aanwezig in 
CRH-neuronen van de PVH hetgeen betrokkenheid van het centrale CRH-systeem 
bij de activering van de HHB-as door IL-1 suggereert. Voorbehandeling van ratten 
met een neutralizerend anti-CRH-antiserum induceert een vroeg optredende maar 
kortdurende blokkade van de activering van de HHB-as na i.v. toediening van IL-1. 
Ook deze waarneming suggereert betrokkenheid van endogeen CRH. Hetanti-CRH-
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antiserum veroorzaakt echter geen volledige blokkade wat een aanwijzing is voor 
(een) CRH-onafhankelijk(e) mechanisme(n) bij de activering van de HHB-as door 
IL-1. Noch kortdurende incubatie van hypofysevoorkwab- of bijniercellen noch 
kortdurende superfusie van de overeenkomstige weefselfragmenten met IL-1 leidt 
tot een verhoogde hormoonafgifte van deze weefsels in vitro. Deze bevindingen 
suggereren dat een direct effect van IL-1 op de hypofyse en/of bijnier na acute 
toediening in vivo niet waarschijnlijk is. 
Chronische, perifere (i.p.) infusie van IL-1 activeert de HHB-as dosis-afhankelijk 
en langdurig. Dit effect lijkt specifiek omdat de plasmaspiegels van ACTH en В 
chronisch verhoogd zijn gedurende de infusieperiode, terwijl de plasmaspiegels van 
andere stresshormonen, zoals (nor)adrenaline en prolactine, niet beïnvloed worden 
door infusie van IL-1. Chronische IL-1 toediening leidt ook tot koorts en anorexie. 
Deze effecten van IL-1 worden echter alleen gedurende de eerste 2-3 dagen van 
infusie waargenomen en kunnen dus niet verantwoordelijk zijn voor de langdurig 
verhoogde plasmaspiegels van ACTH en В gedurende de infusie van IL-1. Het feit 
dat de koorts en de verminderde voedselopname slechts van tijdelijke aard zijn wijst 
op de ontwikkeling van tolerantie ten aanzien van de pyrogene en anorectische 
effecten van chronische infusie van IL-1, mogelijk als gevolg van de activering van 
de HHB-as door de IL-1 infusie. Voorbehandeling van ratten met een anti-CRH-
antiserum remt de verhoging van de plasmaspiegels van ACTH ten gevolge van de 
infusie van IL-1, hetgeen een aanwijzing is voor een centraal aangrijpingspunt van 
chronisch toegediend IL-1, waarbij het CRH-systeem betrokken is. De stijging van 
de plasmaspiegels van ACTH wordt echter niet volledig geblokkeerd. Dit suggereert 
de betrokkenheid van (een) mediator(en) die structureel verschillend is (zijn) van 
CRH. Een centraal aangrijpingspunt van chronisch toegediend IL-1 wordt ook 
ondersteund door de waarneming dat wanneer het cytokine i.c.v. geïnfundeerd wordt 
lagere doseringen IL-1 voldoende zijn om de HHB-as te activeren in vergelijking met 
i.p. infusie. Opmerkelijk is dat in onze experimenten de verhoging van de 
plasmaspiegels van В door infusie van IL-1 niet significant beïnvloed wordt door 
immunoneutralisatie van CRH hetgeen een mogelijk direct effect van chronisch 
toegediend IL-1 op de bijnieren suggereert. De suggestie van een dergelijk direct 
effect wordt enigermate ondersteund door in vitro experimenten waarin langdurige 
(6 uur) superfusie van bijnierfragmenten met IL-1 verhoogde afgifte van В 
bewerkstelligt. Om een mogelijk direct effect van IL-1 op de afgifte van В door de 
bijnieren in vivo te bestuderen, werden gehypofysectomeerde ratten (HPX-ratten) 
chronisch geïnfundeerd met IL-1. Deze behandeling blijkt zonder uitzondering letaal 
voor HPX-ratten en daarom kunnen naar aanleiding van deze experimenten ook 
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geen conclusies getrokken worden met betrekking tot een mogelijk direct effect van 
IL-1 op de bijnieren in vivo. Om de rol van plasmaspiegels van glucocorticoïden 
tijdens chronische infusie van IL-1 te bestuderen, werden met dexamethason 
behandelde ratten en dieren waarvan de bijnieren verwijderd waren (ADX-ratten), 
chronisch geïnfundeerd met IL-1. Dagelijkse toediening van dexamethason 
onderdrukt het effect van chronische infusie van IL-1 op de HHB-as, terwijl alle 
ADX-ratten dood gaan tijdens chronische infusie van IL-1. Afwezigheid van de 
macrofagen versterkt het effect van chronische infusie van IL-1 op de activiteit van 
de HHB-as. Geconcludeerd wordt dat zowel glucocorticoïden als uit macrofagen 
afkomstige mediatoren het effect van IL-1 op de HHB-as remmen. 
Gelijktijdige infusie van IL-1 en TNF verhoogt de activiteit van de HHB-as 
synergistisch. Ook blijkt synergisme tussen IL-1 en TNF uit de effecten op de rectale 
temperatuur en het eetgedrag. Het bestaan van tenminste twee routes met synergie 
kan er op wijzen dat het organisme op verschillende wijzen en gevoelig op 
ontstekingsprikkels kan reageren. 
Toediening van een perifere (i.v.) bolus injectie van TNF of IL-6 activeert de HHB-
as dosis-afhankelijk. Beide cytokines zijn echter minder krachtig dan IL-1: in 
vergelijking met IL-1 zijn hogere doseringen TNF en IL-6 nodig om de HHB-as te 
stimuleren. Voorbehandeling van ratten met een anti-CRH antiserum reduceert de 
activering van de HHB-as na i.v. toediening van TNF of IL-6. Dit suggereert een 
centraal aangrijpingspunt van TNF en IL-6 waarbij het CRH-systeem betrokken is. 
Acute i.c.v. toediening van TNF echter veroorzaakt geen activering van de HHB-as, 
mogelijk omdat i.c.v. toegediend TNF niet in staat is om de (hypothalame) centra, 
die verantwoordelijk zijn voor de activering van de HHB-as, te bereiken. 
Voorbehandeling van ratten met een IL-1 receptor-antagonist moduleert het effect 
van TNF of IL-6 op de HHB-as niet. Noch kortdurende incubatie van 
hypofysevoorkwab- of bijniercellen noch kortdurende superfusie van de 
overeenkomstige weefselfragmenten met TNF of IL-6 induceert een verhoogde 
hormoonafgifte van deze weefsels in vitro. Deze bevindingen suggereren dat een 
direct effect van TNF of IL-6 op de hypofyse en/of bijnier na acute toediening in vivo 
hoogst onwaarschijnlijk is. 
Samenvattend laten onze gegevens zien dat IL-1 en, in mindere mate, ook TNF 
en IL-6 in staat zijn de HHB-as van ratten te activeren waarbij tenminste het centrale 
CRH-systeem betrokken is. Of deze cytokines daadwerkelijk mediatoren zijn van de 
verhoogde activiteit van de HHB-as tijdens bacterie Ie infecties moet nog opgehelderd 
worden. In dit opzicht verschaffen de beschikbaarheid van cytokine-"knock-out" 
dieren en neutralizerende antilichamen gericht tegen cytokines nieuwe 
mogelijkheden voor onderzoek naar dit fenomeen. 
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